N-heterocyclic derivatives as NOS inhibitors

ABSTRACT

N-Heterocyclic derivatives of the formula (I):                    
     are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

This application is a divisional of application Ser. No. 09/383,813,filed Aug. 26, 1999, now U.S. Pat. No. 6,432,947, which is acontinuation-in-part of application Ser. No. 09/025,124, filed Feb. 17,1998, now abandoned which is a continuation-in-part of application Ser.No. 08/808,975, filed Feb. 19, 1997, now abandoned. The disclosures ofthese applications are incorporated by reference in full herein.

FIELD OF THE INVENTION

The invention relates to a series of N-heterocyclic compounds andderivatives useful as inhibitors of nitric oxide synthase (NOS) and tomethods of therapy for various diseases employing those compounds.

BACKGROUND OF THE INVENTION

Nitrogen monoxide (NO) has been implicated in a number of diversephysiological processes, including smooth muscle relaxation, plateletinhibition, nerve transmission, immune regulation and penile erection.Nitric oxide is produced under various conditions by virtually allnucleated mammalian cells. A number of pathologies are ascribed toabnormalities in NO production including stroke, insulin dependentdiabetes, septic shock-induced hypotension, rheumatoid arthritis andmultiple sclerosis. Nitric oxide is synthesized in biological tissues byan enzyme called nitric oxide synthase (NOS) which uses NADPH andmolecular oxygen to oxidize L-arginine to citrulline and nitric oxide.

Nitric oxide synthase (NOS) exists in at least three isoforms, whichfall into two primary categories: constitutive and inducible. Twoconstitutive isoforms, which are calcium and calmodulin dependent, havebeen identified, and one inducible isoform has been identified. Theconstitutive isoforms are (1) a neuronal isoform, NOS-1 or nNOS, whichis found in the brain and skeletal muscles and (2) an endothelialisoform, NOS-3 or eNOS, which is expressed in the endothelium of bloodvessels, the epithelium of the bronchial tree and in the brain. Theseconstitutive isoforms are not the target of the NOS inhibitors of thepresent invention.

The inducible isoform (NOS2 or iNOS) is expressed in virtually allnucleated mammalian cells following exposure to inflammatory cytokinesor lipopolysaccharide. Its presence in macrophages and lung epithelialcells is particularly noteworthy. The inducible isoform is neitherstimulated by calcium nor blocked by calmodulin antagonists. It containsseveral tightly bound co-factors, including FMN, FAD andtetrahydrobiopterin.

Nitric oxide generated by the inducible form of NOS has been implicatedin the pathogenesis of inflammatory diseases. In experimental animals,hypotension induced by lipopolysaccharide or tumor necrosis factor a canbe reversed by NOS inhibitors. Conditions which lead to cytokine-inducedhypotension include septic shock, hemodialysis and interleukin therapyin cancer patients. It is expected that an iNOS inhibitor would beeffective in treating cytokine-induced hypotension. In addition, recentstudies have suggested a role for NO in the pathogenesis ofinflammation, and NOS inhibitors would therefore have beneficial effectson inflammatory bowel disease, cerebral ischemia and arthritis.Inhibitors of NOS may also be useful in treating adult respiratorydistress syndrome (ARDS) and myocarditis, and they may be useful asadjuvants to short term immunosuppression in transplant therapy.

The diversity and ubiquity of NO function in physiology make thespecific therapeutic targeting of NO-related phenomena an importantconsideration. Since endogenous NO production is the result of theactions of related but distinct isozymes, the differential inhibition ofNOS isozymes allows more selective therapy with fewer side effects.

SUMMARY OF THE INVENTION

In one aspect, the invention is directed compounds of formula (I):

wherein:

A is —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹,—SO₂NHC(O)R¹, —N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹;

each X, Y and Z are independently N or C(R¹⁹);

each U is N or G(R⁵), provided that U is N only when X is N and Z and Yare CR¹⁹;

V is N(R⁴), S, O or C(R⁴)H;

each W is N or CH;

Q is chosen from the group consisting of a direct bond, —C(O)—, —O—,—C(═N—R¹)—, —S(O)_(t), and —N(R⁶)—;

m is zero or an integer from 1 to 4;

n is zero or an integer from 1 to 3;

q is zero or one;

r is zero or one, provided that when Q and V are heteroatoms, m, q, andr cannot all be zero; when A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR²,—N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (where t is zero), or—N(R¹)SO₂R²², n, q, and r cannot all be zero; and when Q is a heteroatomand A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR², —N(R¹)R²¹,—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (when t is zero) or —N(R¹)SO₂R²², m andn cannot both be zero;

t is zero, one or two;

each R¹ and R² are independently chosen from the group consisting ofhydrogen, optionally substituted C₁-C₂₀ alkyl, optionally substitutedcycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹,—[C₂-C₈ alkyl]—R¹⁰ (optionally substituted by hydroxy), —[C₁-C₈]—R¹¹(optionally substituted by hydroxy), and optionally substitutedheterocyclyl;

or R¹ and R² together with the nitrogen atom to which they are attachedis an optionally substituted N-heterocyclyl;

R³ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,optionally substituted aryl, haloalkyl, —[C₁-C₈ alkyl]—C(O)N(R¹)R²,—[C₁-C₈ alkyl]—N(R¹)R², —[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈alkyl]—R¹¹, and heterocyclyl (optionally substituted by one or moresubstituents selected from the group consisting of halo, alkyl, alkoxyand imidazolyl);

or when Q is —N(R⁶)— or a direct bond to R³, R³ may additionally beaminocarbonyl, alkoxycarbonyl, alkylsulfonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl and —C(═NR¹⁸)—NH₂;

or —Q—R³ taken together represents —C(O)OH, —C(O)N(R¹)R²,—C(═NH)—N(R¹)R² or

R⁴ is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyland cycloalkyl, provided that when A is —R¹ or —OR¹, R⁴ cannot behydrogen, and when V is CH, R⁴ may additionally be hydroxy;

R⁵ is chosen from the group consisting of hydrogen, halo, alkyl,haloalkyl, optionally substituted aralkyl, optionally substituted aryl,—OR¹⁶, —S(O)_(t)R¹⁶, —N(R¹⁶)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —N(R¹⁶)C(O)OR¹⁶,—N(R¹⁶)C(O)R¹⁶, —[C₀-C₈ alkyl]—C(O)OR¹⁶, —[C₀-C₈ alkyl]—C(H)[C(O)OR¹⁶]₂,and —[C₀-C₈ alkyl]—C(O)N(R¹)R¹⁶;

R⁶ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,—[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈ alkyl]—R¹¹, acyl,—C(O)R⁸, —C(O)—[C₁-C₈ alkyl]—R⁸, alkoxycarbonyl, optionally substitutedaryloxycarbonyl, optionally substituted aralkoxycarbonyl, alkylsulfonyl,optionally substituted aryl, optionally substituted heterocyclyl,alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl,aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionallysubstituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl,dialkylaminosulfonyl, arylaminosulfonyl, arylsulfonylaminocarbonyl,optionally substituted N-heterocyclyl, —C(═NH)—N(CN)R¹,—C(O)—R²³—N(R¹)R², —C(O)—R²³—N(R¹)C(O)—R²³—N(R¹)R², and—C(O)—N(R¹)—R²³—C(O)OR¹;

each R⁸ and R⁹ are independently chosen from the group consisting ofhaloalkyl, cycloalkyl (optionally substituted with halo, cyano, alkyl oralkoxy), carbocyclyl (optionally substituted with one or moresubstituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)—R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, andalkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, and R²⁰ is independently hydrogen oralkyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

R¹⁸ is hydrogen, NO₂, or toluenesulfonyl;

each R¹⁹ is independently hydrogen, alkyl (optionally substituted withhydroxy), cyclopropyl, halo or haloalkyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl; and

R²³ is an amino acid residue;

as a single stereoisomer or mixture thereof, or a pharmaceuticallyacceptable salt thereof.

In another aspect, the invention is directed to compounds of formula(II):

wherein:

A is —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹,—SO₂NHC(O)R¹, —N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R², or —CH═NOR¹;

each X, Y and Z are independently N or C(R¹⁹);

each U is N or C(R⁵), provided that U is N only when X is N and Z and Yare CR¹⁹;

each W is N or CH;

n is zero or an integer from 1 to 3;

t is zero, one or two;

 is an optionally substituted N-heterocyclyl;

each R¹ and R² are independently chosen from the group consisting ofhydrogen, optionally substituted C₁-C₂₀ alkyl, optionally substitutedcycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹,—[C₂-C₈ alkyl]—R¹⁰ (optionally substituted by hydroxy), —[C₁-C₈]—R¹¹(optionally substituted by hydroxy), optionally substitutedheterocyclyl;

or R¹ and R² together with the nitrogen atom to which they are attachedis an optionally substituted N-heterocyclyl;

R⁵ is chosen from the group consisting of hydrogen, halo, alkyl,haloalkyl, optionally substituted aralkyl, optionally substituted aryl,—OR¹⁶, —S(O)_(t)—R¹⁶, —N(R¹⁶)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —N(R¹⁶)C(O)OR¹⁶,—N(R¹⁶)C(O)R¹⁶, —[C₀-C₈ alkyl]—C(O)OR¹⁶, —[C₀-C₈ alkyl]—C(H)[C(O)OR¹⁶]₂,and —[C₀-C₈ alkyl]—C(O)N(R¹)R¹⁶;

each R⁹ is independently chosen from the group consisting of haloalkyl,cycloalkyl (optionally substituted with halo, cyano, alkyl or alkoxy),carbocyclyl (optionally substituted with one or more substituentsselected from the group consisting of halo, alkyl and alkoxy), andheterocyclyl (optionally substituted with alkyl, aralkyl or alkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)—R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto,alkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹⁴ and R²⁰ are independently hydrogen or alkyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

each R¹⁹ is independently hydrogen, alkyl (optionally substituted withhydroxy), cyclopropyl, halo or haloalkyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl; and

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl; as a single stereoisomer or mixturethereof, or a pharmaceutically acceptable salt thereof.

In another aspect, the invention is directed to compounds of formula(III):

wherein:

A is —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹)R²¹—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹, —SO₂NHC(O)R¹,—N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹;

each X, Y and Z are independently N or C(R¹⁹);

each U is N or C(R⁵), provided that U is N only when X is N and Z and Yare CR¹⁹;

V is N(R⁴), S, O or C(R⁴)H;

each W is N or CH;

n is zero or an integer from 1 to 3;

q is zero or one;

r is zero or one;

t is zero, one or two;

 is an optionally substituted carbocyclyl or optionally substitutedN-heterocyclyl;

each R¹ and R² are independently chosen from the group consisting ofhydrogen, optionally substituted C₁-C₂₀ alkyl, optionally substitutedcycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹,—[C₂-C₈ alkyl]—R¹⁰ (optionally substituted by hydroxy), —[C₁-C₈]—R¹¹(optionally substituted by hydroxy), optionally substitutedheterocyclyl;

or R¹ and R² together with the nitrogen atom to which they are attachedis an optionally substituted N-heterocyclyl;

R⁴ is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyland cycloalkyl; provided that when A is —R¹ or —OR¹, R⁴ cannot behydrogen, and when V is CH, R⁴ may additionally be hydroxy;

R⁵ is chosen from the group consisting of hydrogen, halo, alkyl,haloalkyl, optionally substituted aralkyl, optionally substituted aryl,—OR¹⁶, —S(O)_(t)R¹⁶, —N(R¹⁶)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —N(R¹⁶)C(O)OR¹⁶,—N(R¹⁶)C(O)R¹⁶, —[C₀-C₈ alkyl]—C(O)OR¹⁶, —[C₀-C₈ alkyl]—C(H)[C(O)OR¹⁶]₂,and —[C₀-C₈ alkyl]—C(O)N(R¹)R¹⁶;

each R⁹ is independently chosen from the group consisting of haloalkyl,cycloalkyl (optionally substituted with halo, cyano, alkyl or alkoxy),carbocyclyl (optionally substituted with one or more substituentsselected from the group consisting of halo, alkyl and alkoxy), andheterocyclyl (optionally substituted with alkyl, aralkyl or alkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)—R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto,alkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹², R¹³, R¹⁴ and R²⁰ are independently hydrogen or alkyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

each R¹⁹ is independently hydrogen, alkyl (optionally substituted withhydroxy), cyclopropyl, halo or haloalkyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl; and

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl;

as a single stereoisomer or mixture thereof, or a pharmaceuticallyacceptable salt thereof.

In another aspect, the invention is directed to compounds of formula(Ya), formula (Yb) and formula (Yc):

wherein:

n and m are each independently an integer from 1 to 4;

A is —C(O)OR¹ or —C(O)N(R¹)R²;

each W is N or CH;

each R¹ is independently hydrogen, alkyl, aryl or aralkyl;

each R² is independently hydrogen, C₀-C₂₀ alkyl, —(CH₂)_(n)—N(R¹)₂,heterocyclylalkyl (optionally substituted by alkyl, halo, haloalkyl oralkoxy), aralkyl (optionally substituted by halo, alkyl, alkoxy, or—N(R¹)₂);

R⁴ is hydroxy, cyano, heterocyclyl, —N(R¹)R², —N(R¹)—C(O)—R¹,—N(R¹)—C(O)OR¹, —N(R¹)—S(O)_(t)—R¹, or —N(R¹)—C(O)—N(R¹)₂;

R⁵ is hydrogen, halo, alkyl, aryl, aralkyl, or haloalkyl;

as a single stereoisomer or mixture thereto, or a pharmaceuticallyacceptable salt thereof.

In another aspect, the invention is directed to compounds of formula(IV):

wherein:

AA is an amino acid;

X, Y and Z are independently N or C(R¹⁹);

U is N or C(R⁵), provided that U is N only when X is N and Z and Y areCR¹⁹;

W is N or CH;

R¹ and R² are independently chosen from the group consisting ofhydrogen, optionally substituted C₁-C₂₀ alkyl, optionally substitutedcycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹,—[C₂-C₈ alkyl]—R¹⁰ (optionally substituted by hydroxy), —[C₁-C₈]—R¹¹(optionally substituted by hydroxy), and optionally substitutedheterocyclyl;

or R¹ and R² together with the nitrogen atom to which they are attachedis an optionally substituted N-heterocyclyl;

R⁵ is chosen from the group consisting of hydrogen, halo, alkylhaloalkyl, optionally substituted aralkyl, optionally substituted aryl,—OR¹⁶, —S(O)_(t)—R¹⁶, —N(R¹⁶)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —N(R¹⁶)C(O)OR¹⁶,—N(R¹⁶)C(O)R¹⁶, —[C₀-C₈ alkyl]—C(O)OR¹⁶, —[C₀-C₈ alkyl]—C(H)[C(O)OR¹⁶]₂,and —[C₀-C₈ alkyl]—C(O)N(R¹)R¹⁶;

each R⁹ is independently chosen from the group consisting of haloalkyl,cycloalkyl (optionally substituted with halo, cyano, alkyl or alkoxy),carbocyclyl (optionally substituted with one or more substituentsselected from the group consisting of halo, alkyl and alkoxy), andheterocyclyl (optionally substituted with alkyl, aralkyl or alkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)—R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, andalkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

R¹⁹ is hydrogen, alkyl (optionally substituted with hydroxy),cyclopropyl, halo or haloalkyl;

each R²¹ is hydrogen, alkyl, cycloalkyl, optionally substituted aryl,optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

or R²¹ taken together with R¹⁶ and the nitrogen to which they ateattached is an optionally substituted N-heterocyclyl;

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl; and

t is zero, one or two;

as a single isomer or mixture thereof, or a pharmaceutically acceptablesalt thereof.

In another aspect, the invention is directed to compounds of formula(Va), formula (Vb) and formula (Vc):

wherein B is a fused 5- or 6-membered optionally substituted carbocyclylor heterocyclyl; and

wherein:

A is —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR²,—N(R¹)R²—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹, —SO₂NHC(O)R¹,—N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹;

each X and Y are independently N or C(R¹⁹);

V is N(R⁴), S, O or C(R⁴)H;

each W is N or CH;

Q is chosen from the group consisting of a direct bond, —C(O)—, —O—,—C(═N—R¹)—, —S(O)_(t), and —N(R⁶)—;

m is zero or an integer from 1 to 4;

n is zero or an integer from 1 to 3;

q is zero or one;

r is zero or one, provided that when Q and V are heteroatoms, m, q, andr cannot all be zero; when A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR²,—N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (where t is zero), or—N(R¹)SO₂R²², n, q, and r cannot all be zero; and when Q is a heteroatomand A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR², —N(R¹)R²¹,—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (when t is zero) or —N(R¹)SO₂R²², m andn cannot both be zero;

t is zero, one or two;

 is an optionally substituted N-heterocyclyl;

 is an optionally substituted carbocyclyl or optionally substitutedN-heterocyclyl;

each R¹ and R² are independently chosen from the group consisting ofhydrogen, optionally substituted C₁-C₂₀ alkyl, optionally substitutedcycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹,—[C₂-C₈ alkyl]—R¹⁰ (optionally substituted by hydroxy), —[C₁-C₈]—R¹¹(optionally substituted by hydroxy), and optionally substitutedheterocyclyl;

or R¹ and R² together with the nitrogen atom to which they are attachedis an optionally substituted N-heterocyclyl;

R³ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,optionally substituted aryl, haloalkyl, —[C₁-C₈ alkyl]—C(O)N(R¹)R²,—[C₁-C₈ alkyl]—N(R¹)R², —[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈alkyl]—R¹¹, and heterocyclyl (optionally substituted by one or moresubstituents selected from the group consisting of halo, alkyl, alkoxyand imidazolyl);

or when Q is —N(R⁶)— or a direct bond to R³, R³ may additionally beaminocarbonyl, alkoxycarbonyl, alkylsulfonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl and —C(═NR¹⁸)—NH₂; or —Q—R³ taken togetherrepresents —C(O)OH, —C(O)N(R¹)R², —C(═NH)—N(R¹)R² or

R⁴ is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyland cycloalkyl;

provided that when A is —R¹ or —OR¹, R⁴ cannot be hydrogen, and when Vis CH, R⁴ may additionally be hydroxy;

R⁶ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,—[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈ alkyl]—R¹¹, acyl,—C(O)R⁸, —C(O)—[C₁-C₈ alkyl]—R⁸, alkoxycarbonyl, optionally substitutedaryloxycarbonyl, optionally substituted aralkoxycarbonyl, alkylsulfonyl,optionally substituted aryl, optionally substituted heterocyclyl,alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl,aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionallysubstituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl,dialkylaminosulfonyl, arylaminosulfonyl, arylsulfonylaminocarbonyl,optionally substituted N-heterocyclyl, —C(═NH)—N(CN)R¹,—C(O)—R²³—N(R¹)R², —C(O)—R²³—N(R¹)C(O)—R²³—N(R¹)R², and—C(O)—N(R¹)—R²³—C(O)OR¹;

each R⁸ and R⁹ are independently chosen from the group consisting ofhaloalkyl, cycloalkyl (optionally substituted with halo, cyano, alkyl oralkoxy), carbocyclyl (optionally substituted with one or moresubstituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, andalkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, and R²⁰ are independently hydrogen oralkyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

R¹⁸ is hydrogen, NO₂, or toluenesulfonyl;

each R¹⁹ is independently hydrogen, alkyl (optionally substituted withhydroxy), cyclopropyl, halo or haloalkyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl; and

R²³ is an amino acid residue;

as a single stereoisomer or mixture thereof, or a pharmaceuticallyacceptable salt thereof.

In another aspect, the invention is directed to compounds of formula(VIa), formula (VIb) or formula (VIc):

wherein B is a fused 5- or 6-membered optionally substituted carbocyclylor heterocyclyl; and

wherein:

A is —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹,—SO₂NHC(O)R¹, —N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹;

each X and Z are independently N or C(R¹⁹);

V is N(R⁴, S, O or C(R⁴)H;

each W is N or CH;

Q is chosen from the group consisting of a direct bond, —C(O)—, —O—,—C(═N—R¹)—, —S(O)_(t), and —N(R⁶)—;

m is zero or an integer from 1 to 4;

n is zero or an integer from 1 to 3;

q is zero or one;

r is zero or one, provided that when Q and V are heteroatoms, m, q, andr cannot all be zero; when A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR²,—N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (where t is zero), or—N(R¹)SO₂R, n, q, and r cannot all be zero; and when Q is a heteroatomand A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR², —N(R¹)R²¹,—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (when t is zero) or —N(R¹)SO₂R²², m andn cannot both be zero;

t is zero, one or two;

 is an optionally substituted N-heterocyclyl;

 is an optionally substituted carbocyclyl or optionally substitutedN-heterocyclyl;

each R¹ and R² are independently chosen from the group consisting ofhydrogen, optionally substituted C₁-C₂₀ alkyl, optionally substitutedcycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹,—[C₂-C₈ alkyl]—R¹⁰ (optionally substituted by hydroxy), —[C₁-C₈]—R¹¹(optionally substituted by hydroxy), and optionally substitutedheterocyclyl;

or R¹ and R² together with the nitrogen atom to which they are attachedis an optionally substituted N-heterocyclyl;

R³ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,optionally substituted aryl, haloalkyl, —[C₁-C₈ alkyl]—C(O)N(R¹)R²,—[C₁-C₈ alkyl]—N(R¹)R², —[C₁-C₃ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈alkyl]—R¹¹, and heterocyclyl (optionally substituted by one or moresubstituents selected from the group consisting of halo, alkyl, alkoxyand imidazolyl);

or when Q is —N(R⁶)— or a direct bond to R³, R³ may additionally beaminocarbonyl, alkoxycarbonyl, alkylsulfonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl and —C(═NR¹⁸)—NH₂;

or —Q—R³ taken together represents —C(O)OH, —C(O)N(R¹)R²,—C(═NH)—N(R¹)R² or

R⁴ is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyland cycloalkyl;

provided that when A is —R¹ or —OR¹, R⁴ cannot be hydrogen, and when Vis CH, R⁴ may additionally be hydroxy;

R⁶ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,—[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈ alkyl]—R¹¹, acyl,—C(O)R⁸, —C(O)—[CG-C₈ alkyl]—R⁸, alkoxycarbonyl, optionally substitutedaryloxycarbonyl, optionally substituted aralkoxycarbonyl, alkylsulfonyl,optionally substituted aryl, optionally substituted heterocyclyl,alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl,aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionallysubstituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl,dialkylaminosulfonyl, arylaminosulfonyl, arylsulfonylaminocarbonyl,optionally substituted N-heterocyclyl, —C(═NH)—N(CN)R¹,—C(O)—R²³—N(R¹)R², —C(O)—R²³—N(R¹)C(O)—R²³—N(R¹)R²,—C(O)—N(R¹)—R²³—C(O)OR¹;

each R⁸ and R⁹ are independently chosen from the group consisting ofhaloalkyl, cycloalkyl (optionally substituted with halo, cyano, alkyl oralkoxy), carbocyclyl (optionally substituted with one or moresubstituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)—R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, andalkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, and R²⁰ are independently hydrogen oralkyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

R¹⁸ is hydrogen, NO₂, or toluenesulfonyl;

each R¹⁹ is independently hydrogen, alkyl (optionally substituted withhydroxy), cyclopropyl, halo or haloalkyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl; and

R²³ is an amino acid residue;

as a single stereoisomer or mixture thereof, or a pharmaceuticallyacceptable salt thereof.

In another aspect, the invention is directed to compounds of formula(VIIa), formula (VIIb), or formula (VIIc):

wherein:

A is —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹,—SO₂NHC(O)R¹, —N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹;

each X, Y and Z are independently N or C(R¹⁹);

each U is N or C(R⁵), provided that U is N only when X is N and Z and Yare CR¹⁹;

V is N(R⁴), S, O or C(R⁴)H;

each W is N or CH;

Q is chosen from the group consisting of a direct bond, —C(O)—, —O—,—C(═N—R¹)—, —S(O)_(t), and —N(R⁶)—;

m is zero or an integer from 1 to 4;

n is zero or an integer from 1 to 3;

q is zero or one;

r is zero or one, provided that when Q and V are heteroatoms, m, q, andr cannot all be zero; when A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR²,—N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (where t is zero), or—N(R¹)SO₂R²², n, q, and r cannot all be zero; and when Q is a heteroatomand A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR², —N(R¹)R²¹,—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (when t is zero) or —N(R¹)SO₂R²², m andn cannot both be zero;

t is zero, one or two;

 is an optionally substituted N-heterocyclyl;

 is an optionally substituted carbocyclyl or optionally substitutedN-heterocyclyl;

each R¹ and R² are independently chosen from the group consisting ofhydrogen, optionally substituted C₁-C₂₀ alkyl, optionally substitutedcycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹,—[C₂-C₈ alkyl]—R¹⁰ (optionally substituted by hydroxy), —[C₁-C₈]—R¹¹(optionally substituted by hydroxy), and optionally substitutedheterocyclyl;

or R¹ and R² together with the nitrogen atom to which they are attachedis an optionally substituted N-heterocyclyl;

R³ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,optionally substituted aryl, haloalkyl, —[C₁-C₈ alkyl]—C(O)N(R¹)R²,—[C₁-C₈ alkyl]—N(R¹)R², —[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈alkyl]—R¹¹, and heterocyclyl (optionally substituted by one or moresubstituents selected from the group consisting of halo, alkyl, alkoxyand imidazolyl);

or when Q is —N(R⁶)— or a direct bond to R³, R³ may additionally beaminocarbonyl, alkoxycarbonyl, alkylsulfonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl and —C(═NR¹⁸)—NH₂;

or —Q—R³ taken together represents —C(O)OH, —C(O)N(R¹)R²,—C(═NH)—N(R¹)R² or

R⁴ is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyland cycloalkyl;

provided that when A is —R¹ or —OR¹, R⁴ cannot be hydrogen, and when Vis CH, R⁴ may additionally be hydroxy;

R⁵ is chosen from the group consisting of hydrogen, halo, alkyl,haloalkyl, optionally substituted aralkyl, optionally substituted aryl,—OR¹⁶, —S(O)_(t)—R¹⁶, —N(R¹⁶)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —N(R¹⁶)C(O)OR¹⁶,—N(R¹⁶)C(O)R¹⁶, —[C₀-C₈ alkyl]—C(O)OR¹⁶, —[C₀-C₈ alkyl]—C(H)[C(O)OR¹⁶]₂,and —[C₀-C₈ alkyl]—C(O)N(R¹)R¹⁶;

R⁶ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,—[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈ alkyl]—R¹¹, acyl,—C(O)R⁸, —C(O)—[C₁-C₈ alkyl]—R⁸, alkoxycarbonyl, optionally substitutedaryloxycarbonyl, optionally substituted aralkoxycarbonyl, alkylsulfonyl,optionally substituted aryl, optionally substituted heterocyclyl,alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl,aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionallysubstituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl,dialkylaminosulfonyl, arylaminosulfonyl, arylsulfonylaminocarbonyl,optionally substituted N-heterocyclyl, —C(═NH)—N(CN)R¹,—C(O)—R²³—N(R¹)R², —C(O)—R²³—N(R¹)C(O)—R²³—N(R¹)R², and—C(O)—N(R¹)—R²³—C(O)OR¹;

each R⁸ and R⁹ are independently chosen from the group consisting ofhaloalkyl, cycloalkyl (optionally substituted with halo, cyano, alkyl oralkoxy), carbocyclyl (optionally substituted with one or moresubstituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, andalkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, and R²⁰ are independently hydrogen oralkyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

R¹⁸ is hydrogen, NO₂, or toluenesulfonyl;

each R¹⁹ is independently hydrogen, alkyl (optionally substituted withhydroxy), cyclopropyl, halo or haloalkyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl; and

R²³ is an amino acid residue;

as a single stereoisomer or mixture thereof, or a pharmaceuticallyacceptable salt thereof.

In another aspect, the invention is directed to compounds of formula(VIII):

wherein two of X, Y and Z are nitrogen and the third is CH.

In another aspect, the invention provides compounds of formula (IXa),formula (IXb), or formula (IXc):

wherein:

 is a solid support;

L is a linker residue;

each X, Y and Z are independently N or C(R¹⁹);

each U is N or C(R⁵), provided that U is N only when X is N and Z and Yare CR¹⁹;

V is N(R⁴), S, O or C(R⁴)H;

each W is N or CH;

Q is chosen from the group consisting of a direct bond, —C(O)—, —O—,—C(═N—R¹)—, —S(O)_(t), and —N(R⁶)—;

m is zero or an integer from 1 to 4;

n is zero or an integer from 1 to 3;

q is zero or one;

r is zero or one, provided that when Q and V are heteroatoms, m, q, andr cannot all be zero;

t is zero, one or two;

 is an optionally substituted N-heterocyclyl;

 is an optionally substituted carbocyclyl or optionally substitutedN-heterocyclyl;

each R² is independently chosen from the group consisting of hydrogen,optionally substituted C₁-C₂₀ alkyl, optionally substituted cycloalkyl,—[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹, —[C₂-C₈alkyl]—R¹⁰ (optionally substituted by hydroxy), —[C₁-C₈]—R¹¹ (optionallysubstituted by hydroxy), and optionally substituted heterocyclyl;

R³ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,optionally substituted aryl, haloalkyl, —[C₁-C₈ alkyl]—C(O)N(R¹)R²,—[C₁-C₈ alkyl]—N(R¹)R², —[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈alkyl]—R¹¹, and heterocyclyl (optionally substituted by one or moresubstituents selected from the group consisting of halo, alkyl, alkoxyand imidazolyl);

or when Q is —N(R⁶)— or a direct bond to R³, R³ may additionally beaminocarbonyl, alkoxycarbonyl, alkylsulfonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl and —C(═NR¹⁸)—NH₂;

or —Q—R³ taken together represents —C(O)OH, —C(O)N(R¹)R²,—C(═NH)—N(R¹)R² or

R⁴ is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyland cycloalkyl;

provided that when A is —R¹ or —OR¹, R⁴ cannot be hydrogen, and when Vis CH, R⁴ may additionally be hydroxy;

R⁵ is chosen from the group consisting of hydrogen, halo, alkyl,haloalkyl, optionally substituted aralkyl, optionally substituted aryl,—OR¹⁶, —S(O)_(t)—R¹⁶, —N(R¹⁶)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —N(R¹⁶)C(O)OR¹⁶,—N(R¹⁶)C(O)R¹⁶, —[C₀-C₈ alkyl]—C(O)OR¹⁶, —[C₀-C₈ alkyl]—C(H)[C(O)OR¹⁶]₂,and —[C₀-C₈ alkyl]—C(O)N(R¹)R¹⁶;

R⁶ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,—[C₁-CB alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈ alkyl]—R¹¹, acyl,—C(O)R⁸, —C(O)—[C₁-C₈ alkyl]—R⁸, alkoxycarbonyl, optionally substitutedaryloxycarbonyl, optionally substituted aralkoxycarbonyl, alkylsulfonyl,optionally substituted aryl, optionally substituted heterocyclyl,alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl,aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionallysubstituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl,dialkylaminosulfonyl, arylaminosulfonyl, arylsulfonylaminocarbonyl,optionally substituted N-heterocyclyl, —C(═NH)—N(CN)R¹,—C(O)—R²³—N(R¹)R², —C(O)—R²³—N(R¹)C(O)—R²³—N(R¹)R², and—C(O)—N(R¹)—R²³—C(O)OR¹;

each R⁸ and R⁹ are independently chosen from the group consisting ofhaloalkyl, cycloalkyl (optionally substituted with halo, cyano, alkyl oralkoxy), carbocyclyl (optionally substituted with one or moresubstituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)—R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, andalkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, and R²⁰ are independently hydrogen oralkyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

R¹⁸ is hydrogen, NO₂, or toluenesulfonyl;

each R¹⁹ is independently hydrogen, alkyl (optionally substituted withhydroxy), cyclopropyl, halo or haloalkyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl; and

R²³ is an amino acid residue;

as a single stereoisomer or mixture thereof, or a pharmaceuticallyacceptable salt thereof.

In another aspect, the invention is directed to pharmaceuticalcompositions comprising a compound of formula (I), formula (II), formula(III), formula (IV), formula (Ya), formula (Yb), formula (Yc), formula(Va), formula (Vb), formula (Vc), formula (VIa), formula (VIb), formula(VIc), formula (VIIa), formula (VIIb), or formula (VIIc) as describedabove, and a pharmaceutically acceptable carrier.

In another aspect, the invention is directed to processes forsynthesizing compounds of formula (I), formula (II) and formula (III) asdescribed above: comprising the sequential steps of:

(a) reacting one equivalent of a compound of formula (XI):

where W is N or CH;

with about one equivalent of an chloro-substituted compound of formula(XII):

where X, Y and Z are independently N or C(R¹⁹);

U is N or C(R⁵), provided that U is N only when X is N and Z and Y areCR¹⁹, and provided that X, Y and Z can not all be C(R¹⁹) when U isC(R⁵);

R⁵ is chosen from the group consisting of hydrogen, halo, alkyl,haloalkyl, optionally substituted aralkyl, optionally substituted aryl,—OR¹⁶, —S(O)_(t)—R¹⁶, —N(R¹⁶)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —N(R¹⁶)C(O)OR¹⁶,—N(R¹⁶)C(O)R¹⁶, —[C₀-C₈ alkyl]—C(O)OR¹⁶, —[C₀-C₈alkyl]—C(H)[C(O)OR^(16]) ₂, and —[C₀-C₈ alkyl]—C(O)N(R¹)R¹⁶;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

each R¹⁹ is independently hydrogen, alkyl (optionally substituted withhydroxy), cyclopropyl, halo or haloalkyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl; and

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl;

to produce a compound of formula (XII):

(b) reacting said compound of formula (XIII) with a compound of formula(XIVa), formula (XIVb), or formula (XIVc):

wherein:

A is —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂,—N(R¹)C(O)R²,—N(R¹⁶)C(O)OR²,—N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹,—SO₂NHC(O)R¹, —N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹;

V is N(R⁴), S, or O;

Q is chosen from the group consisting of a direct bond, —C(O)—, —O—,—C(═N—R¹)—, —S(O)_(t), and —N(R⁶)—;

m is zero or an integer from 1 to 4;

n is zero or an integer from 1 to 3;

q is zero or one;

r is zero or one, provided that when Q and V are heteroatoms, m, q, andr cannot all be zero; when A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR²,—N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (where t is zero), or—N(R¹)SO₂R²², n, q, and r cannot all be zero; and when Q is a heteroatomand A is —OR¹, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR², —N(R¹)R²¹,—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (when t is zero) or —N(R¹)SO₂R²², m andn cannot both be zero;

t is zero, one or two;

 is an optionally substituted N-heterocyclyl;

 is an optionally substituted carbocyclyl or optionally substitutedN-heterocyclyl; each R¹ and R² are independently chosen from the groupconsisting of hydrogen, optionally substituted C₁-C₂₀ alkyl, optionallysubstituted cycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈alkynyl]—R⁹, —[C₂-C₃ alkyl]—R¹⁰ (optionally substituted by hydroxy),—[C₁-C₈]—R¹¹ (optionally substituted by hydroxy), and optionallysubstituted heterocyclyl;

or R¹ and R² together with the nitrogen atom to which they are attachedis an optionally substituted N-heterocyclyl;

R³ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,optionally substituted aryl, haloalkyl, —[C₁-C₈ alkyl]—C(O)N(R¹)R²,—[C₁-C₈ alkyl]—N(R¹)R², —[C₁-C₈ alkyl]—R⁸, —[C₂-CB alkyl]—R¹⁰, —[C₁-C₈alkyl]—R¹¹, and heterocyclyl (optionally substituted by one or moresubstituents selected from the group consisting of halo, alkyl, alkoxyand imidazolyl);

or when Q is —N(R⁶)— or a direct bond to R³, R³ may additionally beaminocarbonyl, alkoxycarbonyl, alkylsulfonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl and —C(═NR¹⁸)—NH₂;

or —Q—R³ taken together represents —C(O)OH, —C(O)N(R¹)R²,—C(═NH)—N(R¹)R² or

R⁴ is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyland cycloalkyl;

provided that when A is —R¹ or —OR¹, R⁴ cannot be hydrogen, and when Vis CH, R⁴ may additionally be hydroxy;

R⁴ is chosen from the group consisting of hydrogen, alkyl, cycloalkyl,—[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈ alkyl]—R¹¹, acyl,—C(O)R⁸, —C(O)—[C₁-C₈ alkyl]—R⁸, alkoxycarbonyl, optionally substitutedaryloxycarbonyl, optionally substituted aralkoxycarbonyl, alkylsulfonyl,optionally substituted aryl, optionally substituted heterocyclyl,alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl,aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionallysubstituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl,dialkylaminosulfonyl, and arylaminosulfonyl, arylsulfonylaminocarbonyl,optionally substituted N-heterocyclyl, —C(═NH)—N(CN)R¹,—C(O)—R²³—N(R¹)R², —C(O)—R²³—N(R¹)C(O)—R²³—N(R¹)R²,—C(O)—N(R¹)—R²³—C(O)OR¹;

each R⁸ and R⁹ are independently chosen from the group consisting ofhaloalkyl, cycloalkyl (optionally substituted with halo, cyano, alkyl oralkoxy), carbocyclyl (optionally substituted with one or moresubstituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy);

each R¹⁰ is independently chosen from the group consisting of halo,alkoxy, optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)—R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, andalkylsulfonamido;

each R¹¹ is independently chosen from the group consisting of cyano,di(alkoxy)alkyl, carboxy, alkoxycarbonyl, aminocarbonyl,monoalkylaminocarbonyl and dialkylaminocarbonyl;

each R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, and R²⁰ are independently hydrogen oralkyl;

each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl;

R¹⁸ is hydrogen, NO₂, or toluenesulfonyl;

each R²¹ is independently hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, optionally substituted aralkyl, —C(O)R²² or —SO₂R²²;

or R²¹ taken together with R¹ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

or R²¹ taken together with R¹⁶ and the nitrogen to which they areattached is an optionally substituted N-heterocyclyl;

each R²² is independently alkyl, cycloalkyl, optionally substituted arylor optionally substituted aralkyl; and

R²³ is an amino acid residue;

to produce a compound of formula (I), formula (II) or formula (III) asdescribed above.

In another aspect, the invention is directed to processes forsynthesizing a compound of formula (I), formula (II) and formula (III)as described above; comprising photolytically cleaving the compound offormula (IXa), formula (IXb) or formula (IXc):

wherein:

U, V, W, X, Y, Z, R², R³, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷ and R²⁰ are as definedabove for compounds of formula (I), formula (II) or formula (III);

 is a solid support;

 and L is a linker residue of formula (IX):

wherein the unsatisfied valence on the right of the formula representsthe point of attachment to the solid substrate and the unsatisfiedvalence on the left of the formula represents the point of attachment tothe ligand;

to form the compound of formula (I), formula (II) and formula (III) asdefined above.

In another aspect, the invention is directed to methods of treating acondition resulting from an abnormality in nitric oxide production whichcomprises administering to a mammal having a condition resulting from anabnormality in nitric oxide production a therapeutically effectiveamount of compound of formula (I), formula (II), formula (III), formula(IV), formula (Ya), formula (Yb), formula (Yc), formula (Va), formula(Vb), formula (Vc), formula (VIa), formula (VIb), formula (VIc), formula(VIIa), formula (VIIb), or formula (VIIc) as described above.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used in this specification and appended claims, unless specified tothe contrary, the following terms have the meaning indicated:

“Alkyl” refers to a straight or branched hydrocarbon chain radicalconsisting solely of carbon and hydrogen atoms, containing nounsaturation, having from one to eight carbon atoms, and which isattached to the rest of the molecule by a single bond, e.g., methyl,ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl,1,1-dimethylethyl (t-butyl), and the like. Alkyl radicals having morethan eight carbon atoms are indicated herein by the notation“[C_(x)-C_(y) alkyl]” where x and y indicate the number of carbonspresent. Alkyl radicals may be optionally substituted by one or moresubstituents independently selected from the group consisting of halo,hydroxy, alkoxy, carboxy, cyano, carbonyl, alkoxycarbonyl, cyano, amino,monoalkylamino, dialkylamino, nitro, alkylthio, amidino, aryl,heterocyclyl, aryloxy, aralkoxy, acylamino, aminocarbonyl,monoalkylaminocarbonyl, and dialkylaminocarbonyl.

“Alkenyl” refers to a straight or branched chain monovalent or divalentradical consisting solely of carbon and hydrogen, containing at leastone double bond and having from one to eight carbon atoms, e.g.,ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and thelike.

“Alkynyl” refers to a straight or branched chain monovalent or divalentradical consisting solely of carbon and hydrogen, containing at leastone triple bond and having from one to eight carbon atoms, e.g.,ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-3-ynyl, and thelike.

“Alkoxy” refers to a radical of the formula —OR_(a) where R_(a) is analkyl radical as defined above, e.g., methoxy, ethoxy, propoxy, and thelike.

“Alkoxycarbonyl” refers to a radical of the formula —C(O)OR_(a) whereR_(a) is an alkyl radical as defined above, e.g., methoxycarbonyl,ethoxycarbonyl, n-propoxycarbonyl, and the like.

“Alkoxycarbonylalkyl” refers to a radical of the formula—R_(a)—C(O)OR_(a) where each R_(a) is independently an alkyl radical asdefined above, e.g., 2-(methoxycarbonyl)ethyl, 3-(ethoxycarbonyl)propyl,4-(n-propoxycarbonyl)butyl, and the like.

“Alkylsulfonylamino” refers to a radical of the formula —N(H)S(O)₂—R_(a)where R_(a) is an alkyl radical as defined above, e.g.,methylsulfonylamino, ethylsulfonylamino, and the like.

“Alkylsulfonyl” refers to a radical of the formula —S(O)₂—R_(a) whereR_(a) is an alkyl radical as defined above, e.g., methylsulfonyl,ethylsulfonyl, and the like.

“Alkylthio” refers to a radical of the formula —S—R_(a) where R_(a) isan alkyl radical as defined above, e.g., methylthio, ethylthio,n-propylthio, and the like.

“Amidino” refers to a radical of the formula —C(NH)—NH₂.

“Amino” refers to a radical of the formula —NH₂.

“Aminocarbonyl” refers to a radical of the formula —C(O)NH₂.

“Aminosulfonyl” refers to a radical of the formula —S(O)₂NH₂.

“Aryl” refers to a phenyl or naphthyl radical. The aryl radical may beoptionally substituted by one or more substituents selected from thegroup consisting of hydroxy, mercapto, halo, alkyl, alkenyl, alkynyl,phenyl, phenylalkyl, phenylalkenyl, alkoxy, phenoxy, phenylalkoxy,haloalkyl, haloalkoxy, formyl, nitro, cyano, cycloalkyl, hydroxyalkyl,alkoxyalkyl, phenoxyalkyl, phenylalkoxyalkyl, amidino, ureido,alkoxycarbonyamino, amino, monoalkylamino, dialkylamino,monophenylamino, monophenylalkylamino, sulfonylamino, akylsulfonylamino,aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl,monophenylaminoalkyl, monophenylalkylaminoalkyl, acyl, carboxyalkyl,alkoxycarbonylalkyl, aminocarbonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl, aminocarbonylalkyl, monoalkylaminocarbonylalkyl,and dialkylaminocarbonylalkyl, as defined herein.

“Aralkyl” refers to a radical of the formula —R_(a)R_(b) where R_(a) isan alkyl radical as defined above and R_(b) is an aryl radical asdefined above, e.g., benzyl, and the like. The aryl radical may beoptionally substituted as described above.

“Aryloxy” refers to a radical of the formula —OR_(b) where R_(b) is anaryl radical as defined above, e.g., phenoxy and naphthoxy, and thelike. The aryl radical may be optionally substituted as described above.

“Aryloxycarbonyl” refers to a radical of the formula —C(O)OR_(b) whereR_(b) is an aryl radical as defined above, e.g., phenoxycarbonyl.

“Aralkoxy” refers to a radical of the formula —OR_(c) where R_(c) is anaralkyl radical as defined above, e.g., benzyloxy, and the like. Thearalkyl radical may be optionally substituted as described above.

“Aralkoxycarbonyl” refers to a radical of the formula —C(O)OR_(c) whereR_(c) is an aralkyl radical as defined above, e.g., benzyloxycarbonyl,and the like. The aralkyl radical may be optionally substituted asdescribed above.

“Arylaminocarbonyl” refers to a radical of the formula —C(O)N(R_(b))Hwhere R_(b) is an aryl radical as defined above, e.g.,phenylaminocarbonyl, and the like. The aryl radical may be optionallysubstituted as described above.

“Arylaminosulfonyl” refers to a radical of the formula —S(O)₂N(R_(b))Hwhere R_(b) is an aryl radical as defined above, e.g.,phenylaminosulfonyl, and the like. The aryl radical may be optionallysubstituted as described above.

“Arylsulfonyl” refers to a radical of the formula —S(O)₂—R_(b) whereR_(b) is an aryl radical as defined above, e.g., phenylsulfonyl, and thelike. The aryl radical may be optionally substituted as described above.“Arylsulfonylaminocarbonyl” refers to a radical of the formula—C(O)N(H)S(O)₂R_(b) where R_(b) is an aryl radical as defined above,e.g., phenylsulfonylaminocarbonyl, and the like. The aryl radical may beoptionally substituted as described above.

“Acyl” refers to a radical of the formula —C(O)—R_(a) and —C(O)R_(b)where R_(a) is an alkyl radical as defined above and R_(b) is an arylradical as defined above, e.g., acetyl, propionyl, benzoyl, and thelike.

“Acylamino” refers to a radical of the formula —N(H)—C(O)—R_(a) and—N(H)—C(O)—R_(b) where R_(a) is an alkyl radical as defined above andR_(b) is an aryl radical as defined above, e.g., acetylamino,benzoylamino and the like.

“Alkylene” refers to straight or branched chain divalent radicalconsisting solely of carbon and hydrogen, containing no unsaturation andhaving from one to eight carbon atoms, e.g., methylene, ethylene,propylene, n-butylene, and the like. The alkylene radical may beoptionally substituted by one or more substituents selected from thegroup consisting of alkyl, hydroxy, —N(R¹⁶)R²¹ or —C(O)N(R¹)R¹⁶ whereR¹, R¹⁶ and R²¹ are as defined above in the Summary of the Invention.

“Amino acid” refers to a divalent radical of the formula—N(R⁴)—R²³—C(O)— where R⁴ is as described above in the Summary of theInvention for R⁴ and R²³ is an amino acid residue. “Amino acid residue”refers to the alkylene chain between the nitrogen atom and the carboxygroup, which is substituted by the various “side chains” of the knownamino acids. For example, amino acid residues of α-amino acids includethe α-carbon (to which the carboxy group and the nitrogen atom isattached) and the side chain. For example, the amino acid residue ofalanine is —C(CH₃)—; the amino acid residue of serine is —C(CH₂OH)—, andso forth. The term “amino acid” is therefore intended to include α-aminoacids, β-amino acids, γ-amino acids, and so forth, and all opticalisomers thereof. Examples of such amino acids include alanine,asparagine, N-β-trityl-asparagine, aspartic acid, asparticacid-β-t-butyl ester, arginine, N^(g)M-Mtr-arginine, cysteine,S-trityl-cysteine, glutamic acid, glutamic acid-γ-t-butyl ester,glutamine, N-γ-trityl-glutamine, glycine, histidine,N^(im)-trityl-histidine, isoleucine, leucine, lysine, N^(ε)-Boc-lysine,methionine, phenylalanine, proline, serine, O-t-butyl-serine, threonine,tryptophan, N^(in)-Boc-tryptophan, tyrosine, valine, sarcosine,L-alanine, chloro-L-alanine, 2-aminoisobutyric acid,2-(methylamino)isobutyric acid, D,L-3-aminoisobutyric acid,(R)-(−)-2-aminoisobutyric acid, (S)-(+)-2-aminoisobutyric acid,D-leucine, L-leucine, D-norvaline, L-norvaline, L-2-amino-4-pentenoicacid, D-isoleucine, L-isoleucine, D-norleucine, 2,3-diaminopropionicacid, L-norleucine, D,L-2-aminocaprylic acid, β-alanine,D,L-3-aminobutyric acid, 4-aminobutyric acid, 4-(methylamino)butyricacid, 5-aminovaleric acid, 5-aminocaproic acid, 7-aminoheptanoic acid,8-aminocaprylic acid, 11-aminodecanoic acid, 12-aminododecanoic acid,carboxymethoxylamine, D-serine, D-homoserine, L-homoserine,D-allothreonine, L-allothreonine, D-threonine, L-threonine,D,L-4-amino-3-hydroxybutyric acid, D-,L-3-hydroxynorvaline,(3S,4S)-(−)-statine, 5-hydroxy-D,L-lysine,1-amino-1-cyclopropanecarboxylic acid, 1-amino-1-cyclopentanecarboxylicacid, 1-amino-1-cyclohexanecarboxylic acid,5-amino-1,3-cyclohexadiene-1-carboxylic acid,2-amino-2-norbornanecarboxylic acid, (S)-(−)-2-azetidinecarboxylic acid,cis-4-hydroxy-D-proline, cis-4-hydroxy-L-proline,trans-4-hydroxy-L-proline, 3,4-dehydro-D,L-proline,3,4-dehydro-L-proline, D-pipecolinic acid, L-pipecolinic acid, nipecoticacid, isonipecotic acid, mimosine, 2,3-diaminopropionic acid,D,L-2,4-diaminobutyric acid, (S)-(+)-diaminobutyric acid, D-ornithine,L-ornithine, 2-methylornithine, N-ε-methyl-L-lysine, N-methyl-D-asparticacid, D,L-2-methylglutamic acid, D,L-2-aminoadipic acid, D-2-aminoadipicacid, L-2-aminoadipic acid, (+/−)-3-aminoadipic acid, D-cysteine,D-penicillamine, L-penicillamine, D,L-homocysteine, S-methyl-L-cysteine,L-methionine, D-ethionine, L-ethionine, S-carboxymethyl-L-cysteine,(S)-(+)-2-phenylglycine, (R)-(−)-2-phenylglycine, N-phenylglycine,N-(4-hydroxyphenyl)glycine, D-phenylalanine, thienylalanine,(S)-(−)indoline-2-carboxylic acid, α-methyl,D,L-phenylalanine,β-methyl-D,L-phenylalanine, D-homophenylalanine, L-homophenylalanine,D,L-2-fluorophenylglycine, D,L-2-fluorophenylalanine,D,L-3-fluorophenylalanine, D,L-4-fluorophenylalanine,D,L-4-chlorophenylalanine, L4-chlorophenylalanine,4-bromo-D,L-phenylalanine, 4-iodo-D-phenylalanine,3,3′,5-triiodo-L-thyronine, (+)-3,3′,5-triiodo-L-thyronine, D-thyronine,L-thyronine, D,L-m-tyrosine, D-4-hydroxyphenylglycine, D-tyrosine,L-tyrosine, O-methyl-L-tyrosine, 3-fluoro-D,L-tyrosine,3-iodo-L-tyrosine, 3-nitro-L-tyrosine, 3,5-diiodo-L-tyrosine, D,L-dopa,L-dopa, 2,4,5-trihydroxyphenyl-D,L-alanine, 3-amino-L-tyrosine,4-amino-D-phenylalanine, 4-amino-L-phenylalanine,4-amino-D,L-phenylalanine, 4-nitro-L-phenylalanine,4-nitro-D,L-phenylalanine, 3,5-dinitro-L-tyrosine, D,L-α-methyltyrosine,L-α-methyltyrosine, (−)-3-(3,4-dihydroxyphenyl)-2-methyl-L-alanine,D,L-threo-3-phenylserine, trans-4-(aminomethyl)cyclohexane carboxylicacid, 4-(aminomethyl)benzoic acid, D,L-3-aminobutyric acid,3-aminocyclohexane carboxylic acid, cis-2-amino-1-cyclohexane carboxylicacid, γ-amino-β-(p-chlorophenyl)butyric acid (Baclofen),D,L-3-aminophenylpropionic acid, 3-amino-3-(4-chlorophenyl)propionicacid, 3-amino-3-(2-nitrophenyl)propionic acid, and3-amino-4,4,4-trifluorobutyric acid.

“Carbocyclyl” refers to a stable 3- to 15-membered ring radicalconsisting solely of carbon and hydrogen atoms. For purposes of thisinvention, the carbocyclyl radical may be a monocyclic, bicyclic ortricyclic ring system, and may include fused or bridged ring systems,and the ring system may be partially or fully saturated or aromatic, andthe carbon atoms in the ring system may be optionally oxidized. Examplesof such carbocyclyl radicals include, but are not limited to, cycloalkylradicals (as defined herein), norbornane, norbornene, adamantyl,bicyclo[2.2.2]octane, phenyl, naphthalenyl, insanely, indenyl, azulenyl,fluorenyl, anthracenyl, and the like. The carbocyclyl ring may besubstiuted by R⁶ as described above in the Summary of the Invention, orby one or more substituents selected from the group consisting ofhydroxy, mercapto, halo, alkyl, alkenyl, alkynyl, phenyl, phenylalkyl,phenylalkenyl, alkoxy, phenoxy, phenylalkoxy, haloalkyl, haloalkoxy,formyl, nitro, cyano, cycloalkyl, hydroxyalkyl, alkoxyalkyl,phenoxyalkyl, phenylalkoxyalkyl, amidino, ureido, alkoxycarbonyamino,amino, monoalkylamino, dialkylamino, monophenylamino,monophenylalkylamino, sulfonylamino, akylsulfonylamino, aminoalkyl,monoalkylaminoalkyl, dialkylaminoalkyl, monophenylaminoalkyl,monophenylalkylaminoalkyl, acyl, carboxyalkyl, alkoxycarbonylalkyl,aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl,aminocarbonylalkyl, monoalkylaminocarbonylalkyl, anddialkylaminocarbonylalkyl, as defined herein.

“Cycloalkyl” refers to a stable 3- to 10-membered monocyclic or bicyclicradical which is saturated, and which consist solely of carbon andhydrogen atoms, e.g., cyclopropyl, cyclobutyl, cyclobutyl, cyclohexyl,decalinyl and the like. Unless otherwise stated specifically in thespecification, the term “cycloalkyl” is meant to include cycloalkylradicals which are optionally substituted by one or more substituentsindependently selected from the group consisting of alkyl, halo,hydroxy, amino, cyano, nitro, alkoxy, carboxy and alkoxycarbonyl.

“Carboxy” refers to the radical of the formula —C(O)OH.

“Carboxyalkyl” refers to a radical of the formula —R_(a)—C(O)OH whereR_(a) is an alkyl radical as defined above, e.g., carboxymethyl,2-carboxyethyl, 3-carboxypropyl, and the like.

“Di(alkoxy)alkyl” refers to a radical of the formula —R_(a)(—OR_(a))₂where each R_(a) is independently an alkyl radical as defined above andwhere the —OR_(a) groups may be attached to any carbon in the R_(a)group, e.g., 3,3-dimethoxypropyl, 2,3-dimethoxypropyl, and the like.

“Dialkylamino” refers to a radical of the formula —N(R_(a))R_(a) whereeach R_(a) is independently an alkyl radical as defined above, e.g.,dimethylamino, diethylamino, (methyl)(ethyl)amino, and the like.

“Dialkylaminocarbonyl” refers to a radical of the formula—C(O)N(R_(a))R_(a) where each R_(a) is independently an alkyl radical asdefined above, e.g., dimethylaminocarbonyl, methylethylaminocarbonyl,diethylaminocarbonyl, dipropylaminocarbonyl, ethylpropylaminocarbonyl,and the like.

“Dialkylaminosulfonyl” refers to a radical of the formula—S(O)₂N(R_(a))R_(a) where each R_(a) is independently an alkyl radicalas defined above, e.g., dimethylaminosulfonyl, methylethylaminosulfonyl,diethylaminosulfonyl, dipropylaminsulfonyl, ethylpropylaminosulfonyl,and the like.

“Halo” refers to bromo, chloro, iodo or fluoro.

“Haloalkyl” refers to an alkyl radical, as defined above, that issubstituted by one or more halo radicals, as defined above, e.g.,trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl,1-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl,1-bromomethyl-2-bromoethyl, and the like.

“Haloalkoxy” refers to a radical of the formula —OR_(d) where R_(d) isan haloalkyl radical as defined above, e.g., trifluoromethoxy,difluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy,1-fluoromethyl-2-fluoroethoxy, 3-bromo-2-fluoropropoxy,1-bromomethyl-2-bromoethoxy, and the like.

“Heterocyclyl” refers to a stable 3- to 15-membered ring radical whichconsists of carbon atoms and from one to five heteroatoms selected fromthe group consisting of nitrogen, oxygen and sulfur. For purposes ofthis invention, the heterocyclyl radical may be a monocyclic, bicyclicor tricyclic ring system, which may include fused or bridged ringsystems; and the nitrogen, carbon or sulfur atoms in the heterocyclylradical may be optionally oxidized; the nitrogen atom may be optionallyquaternized; and the heterocyclyl radical may be partially or fullysaturated or aromatic. The heterocyclyl radical may be attached to themain structure at any heteroatom or carbon atom which results in thecreation of a stable compound. Examples of such heterocyclyl radicalsinclude, but are not limited to, azepinyl, azetidinyl, acridinyl,benzimidazolyl, benzodioxolyl, benzodioxanyl, benzothiazolyl,benzoxazolyl, benzopyranyl, benzofuranyl, benzothienyl, carbazolyl,cinnolinyl, decahydroisoquinolyl, dioxolanyl, furyl, isothiazolyl,quinuclidinyl, imidazolyl, imidazolinyl, imidazolidinyl,isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl,indolizinyl, isoxazolyl, isoxazolidinyl, morpholinyl, naphthyridinyl,oxadiazolyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl,2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, oxazolyl,oxazolidinyl, perhydroazepinyl, piperidinyl, piperazinyl, 4-piperidonyl,phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl,purinyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, pyridinyl,pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl,quinolinyl, quinuclidinyl, isoquinolinyl, thiazolyl, thiazolidinyl,thiadiazolyl, triazolyl, tetrazolyl, tetrahydrofuryl, tetrahydropyranyl,tetrahydroisoquinolyl, thienyl, thiomorpholinyl, thiomorpholinylsulfoxide, and thiomorpholinyl sulfone. The heterocyclyl radical may beoptionally substituted by R⁶ as defined above in the Summary of theInvention or may be optionally substituted by one or more substituentsselected from the group consisting of hydroxy, mercapto, halo, alkyl,alkenyl, alkynyl, phenyl, phenylalkyl, phenylalkenyl, alkoxy, phenoxy,phenylalkoxy, haloalkyl, haloalkoxy, formyl, nitro, cyano, amidino,cycloalkyl, hydroxyalkyl, alkoxyalkyl, phenoxyalkyl, phenylalkoxyalkyl,amidino, ureido, alkoxycarbonyamino, amino, monoalkylamino,dialkylamino, monophenylamino, monophenylalkylamino, aminoalkyl,monoalkylaminoalkyl, dialkylaminoalkyl, monophenylaminoalkyl,monophenylalkylaminoalkyl, alkylcarbonyl, carboxyalkyl,alkoxycarbonylalkyl, aminocarbonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl, aminocarbonylalkyl, monoalkylaminocarbonylalkyl,dialkylaminocarbonylalkyl, and imidazolyl, as defined herein.

“Heterocyclylalkyl” refers to a radical of the formula —R_(a)—R_(e)where R_(a) is an alkyl radical as defined above and R_(e) is aheterocyclyl radical as defined above, e.g.,2-(1,3-benzodioxol-5-yl)ethyl, and 3-(1,4-benzodioxan-6-yl)propyl, andthe like.

“Linker residue” refers to any component capable of being selectivelycleaved to release the residue of the compound of the invention from thesolid support. See, e.g., Greene and Wuts, Protective Groups in OrganicSynthesis, 2nd ed., Wiley (1991). Specific linker residues and cleavagereagents for them are depicted in Table 7 below.

“Monoalkylamino” refers to, a radical of the formula —N(H)R_(a) whereR_(a) is an alkyl radical as defined above, e.g., methylamino,ethylamino, propylamino, and the like.

“Monoalkylaminocarbonyl” refers to a radical of the formula—C(O)N(H)R_(a) where R_(a) is an alkyl radical as defined above, e.g.,methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, and thelike.

“Monoalkylaminosulfonyl” refers to a radical of the formula—S(O)₂N(H)R_(a) where R_(a) is an alkyl radical as defined above, e.g.,methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, and thelike.

“N-heterocyclyl” refers to a heterocyclyl radical as defined above whichcontains at least one nitrogen atom and which is attached to the mainstructure through the nitrogen atom. The N-heterocyclyl radical maycontain up to three additional hetero atoms. Examples includepiperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl,azetidinyl, indolyl, pyrrolyl, imidazolyl, tetrahydroisoquinolyl,perhydroazepinyl, tetrazolyl, triazolyl, oxazinyl, and the like, and maybe optionally substituted as described above for heterocyclyl radicals.In addition to being optionally substituted by the substituents listedabove for a heterocyclyl radical, the N-heterocyclyl radical may also beoptionally substituted by R⁶ as defined above in the Summary of theInvention.

“Phenylalkyl” refers to an alkyl radical as defined above substituted bya phenyl radical, e.g., benzyl, and the like.

“Optional” or “optionally” means that the subsequently described eventof circumstances may or may not occur, and that the description includesinstances where said event or circumstance occurs and instances in whichit does not. For example, “optionally substituted aryl” means that thearyl radical may or may not be substituted and that the descriptionincludes both substituted aryl radicals and aryl radicals having nosubstitution. The term “—[C₂-C₈ alkyl]—R¹⁰ (optionally substituted byhydroxy)” means that the alkyl has the optional substitution. The samegoes for the term “—[C₁-C₈ alkyl]—R¹¹ (optionally substituted byhydroxy)”. The term “optionally substituted —S(O)_(t)R²²” means that theR²² substituents all have the optional substitution.

“Phenylalkenyl” refers to an alkenyl radical as defined abovesubstituted by a phenyl radical.

The term “pharmaceutically acceptable salt” refers to salts preparedfrom pharmaceutically acceptable non-toxic acids or bases includinginorganic acids and bases and organic acids and bases. When thecompounds of the present invention are basic, salts may be prepared frompharmaceutically acceptable non-toxic acids including inorganic andorganic acids. Suitable pharmaceutically acceptable acid addition saltsfor the compounds of the present invention include acetic,benzenesulfonic (besylate), benzoic, camphorsulfonic, citric,ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric,isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic,nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaricacid, p-toluenesulfonic, and the like. When the compounds contain anacidic side chain, suitable pharmaceutically acceptable base additionsalts for the compounds of the present invention include metallic saltsmade from aluminum, calcium, lithium, magnesium, potassium, sodium andzinc or organic salts made from lysine, N,N′-dibenzylethylenediamine,chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine(N-methylglucamine) and procaine.

“Solid support” refers to the material upon which synthesis of thecompounds of the invention may be performed, and may be also referred toherein as beads or resins. The term “solid support” is intended toinclude beads, pellets, disks, fibers, gels, or particles such ascelluslose beads, pore-glass beads, silica gels, polysteyrene beadsoptionally cross-linked with divinylbenzene and optionally grafted withpolyethylene glycol and optionally functionalized with amino, hydroxy,carboxy, or halo groups, grafted co-poly beads, poly-acrylamide beads,latex beads, dimethylacrylamide beads optionally cross-linked withN,N′-bis-acryloyl ethylene diamine, glass particles coated withhydrophobic polymer, etc., i.e., material having a rigid or semi-rigidsurface; and soluble supports such as low molecular weightnon-cross-linked polystyrene.

“Therapeutically effective amount” refers to that amount of a compoundof the invention which, when administered to a human in need thereof, issufficient to effect treatment, as defined below, for conditionsresulting from an abnormality in nitric oxide production. The amount ofa compound of the invention which constitutes a “therapeuticallyeffective amount” will vary depending on the compound, the condition andits severity, and the age of the human to be treated, but can bedetermined routinely by one of ordinary skill in the art having regardto his own knowledge and to this disclosure.

“Treating” or “treatment” as used herein covers the treatment of acondition in a human, which condition results from an abnormality innitric oxide production, and includes:

(i) preventing the condition from occurring in a human, in particular,when such human is predisposed to the condition but has not yet beendiagnosed as having it

(ii) inhibiting the condition, i.e., arresting its development, or

(iii) relieving the condition, i.e., causing regression of thecondition.

The yield of each of the reactions described herein is expressed as apercentage of the theoretical yield.

Most of the compounds described herein contain one or more asymmetriccenters and may thus give rise to enantiomers, diastereomers, and otherstereoisomeric forms that may be defined, in terms of absolutestereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.The present invention is meant to include all such possible isomers, aswell as, their racemic and optically pure forms. Optically active (R)-and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthonsor chiral reagents, or resolved using conventional techniques. When thecompounds described herein contain olefinic double bonds or othercenters of geometric asymmetry, and unless specified otherwise, it isintended that the compounds include both E and Z geometric isomers.Likewise, all tautomeric forms are also intended to be included.

The nomenclature used herein is a modified form of the I.U.P.A.C.nomenclature system wherein the compounds of the invention are namedherein as amide derivatives. For example, the following compound of theinvention:

is named herein as2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(4-methoxyphenyl)methyl]pentanediamide.Unless otherwise indicated, compound names are intended to include anysingle stereoisomer, enantiomer, racemate or mixtures thereof.

Utility of the Compounds of the Invention

Nitric oxide generated by the inducible form of nitric oxide synthase(i-NOS) has been implicated in the pathogenesis of numerous inflammatoryand autoimmune diseases and also in diseases which are generally notregarded as inflammatory, but nevertheless may involve cytokines whichlocally up-regulate i-NOS. The compounds of the invention, alone or incombination with other pharmaceutical agents, are therefore useful intreating mammals, preferably humans, having a condition resulting froman abnormality in nitric oxide production. Such conditions include, butare not limited to, the following:

Multiple sclerosis (Parkinson, J. F. et al., J. Mol. Med. (1997), Vol.75, pp. 174-186); stroke or cerebral ischemia (Iadecola, C. et al., J.Neurosci. (1997), Vol. 17, pp. 9157-9164); Alzheimer's disease (Smith,M. A. et al., J. Neurosci. (1997), Vol. 17, pp.2653-2657; Wallace, M. N.et al., Exp. Neurol. (1997), Vol. 144, pp. 266-272); HIV dementia(Adamson D. C. et al., Science (1996), Vol. 274, pp. 1917-1921);Parkinson's disease (Hunot, S. et al., Neuroscience (1996), Vol. 72, pp.355-363); meningitis (Koedel, U. et al., Ann. Neurol. (1995), Vol. 37,pp. 313-323); dilated cardiomyopathy and congestive heart failure (SatohM et al., J. Am. Coll. Cardiol. (1997), Vol. 29, pp. 716-724);atherosclerosis (Wilcox, J. N. et al., Arterioscler. Thromb. Vasc. Biol.(1997), Vol. 17, pp. 2479-2488); restenosis or graft stenosis, septicshock and hypotension (Petros, A. et al., Cardiovasc. Res. (1994), Vol.28, pp. 34-39); hemorrhagic shock (Thiemermann, C. et al., Proc. Natl.Acad. Sci. (1993), Vol. 90, pp. 267-271); asthma (Barnes, P. J., Ann.Med. (1995), Vol. 27, pp. 389-393; Flak, T. A. et al., Am. J. Respir.Crit. Care Med. (1996), Vol. 154, pp. S202-S206); adult respiratorydistress syndrome, smoke or particulate-mediated lung injury(Ischiropoulos, H. et al., Am. J. Respir. Crit. Care Med. (1994), Vol.150, pp. 337-341; Van Dyke, K., Agents Actions (1994), Vol. 41, pp.4449); pathogen-mediated pneumonias (Adler, H. et al., J. Exp. Med.(1997), Vol. 185, pp. 1533-1540); trauma of various etiologies (Thomae,K. R. et al., Surgery (1996), Vol. 119, pp. 61-66); rheumatoid arthritisand osteoarthritis (Grabowski, P. S. et al., Br. J. Rheumatol. (1997),Vol. 36, pp. 651-655); glomerulonephritis (Weinberg, J. B. et al., J.Exp. Med. (1994), Vol. 179, pp. 651-660); systemic lupus erythematosus(Belmont, H. M. et al., Arthritis Rheum. (1997), Vol. 40, pp.1810-1816); inflammatory bowel diseases such as ulcerative colitis andCrohn's disease (Godkin, A. J. et al., Eur. J. Clin. Invest. (1996),Vol. 26, pp. 867-872; Singer, I. I. et al., Gastroenterology (1996),Vol. 111, pp. 871-885); insulin dependent diabetes mellitus (McDaniel,M. L., et al., Proc. Soc. Exp. Biol. Med. (1996), Vol. 211, pp. 24-32);diabetic neuropathy or nephropathy (Sugimoto, K. and Yagihashi, S.,Microvasc. Res. (1997), Vol. 53, pp. 105-112; Amore, A. et al., KidneyInt. (1997), Vol. 51, pp. 27-35); acute and chronic organ transplantrejection (Worrall, N. K et al., Transplantation (1997), Vol. 63, pp.1095-1101); transplant vasculopathies (Russell, M. E. et al., (1995),Vol. 92, pp. 457464); graft-versus-host disease (Kichian, K. et al., J.Immunol. (1996), Vol. 157, pp. 2851-2856); psoriasis and otherinflammatory skin diseases (Bruch-Gerharz, D. et al., J. Exp. Med.(1996), Vol. 184, pp. 2007-2012); and cancer (Thomsen, L. L. et al.,Cancer Res. (1997), Vol. 57, pp. 3300-3304).

The compounds of the current invention may also be useful for themanagement of male and female reproductive functions when used alone orcombined with other drugs commonly used for these indications. Examples,without implied limitation, include: inhibition of fertilization,endometrial receptivity and implantation (alone or in combination with aprogesterone antagonist); post-coital contraception (alone or incombination with a progesterone antagonist); induction of abortion (incombination with an antiprogestin and in further combination with aprostaglandin); control and management of labor and delivery; treatmentof cervical incompetence (alone or in combination with progesterone or aprogestin); treatment of endometriosis (alone or in combination withother drugs, including LHRH-agonists/antagonists, antiprogestins orprogestins by either sequential application or by concomitantadministration). See, for example, the following references: Chwalisz, Ket al., J. Soc. Gynecol. Invest. (1997), Vol. 4, No. 1 (Supplement),page 104a, which discusses the inhibition of fertilization, endometrialreceptivity and implantation, or post-coital contraception, alone or incombination with a progesterone antagonist; Chwalisz, K. et al., Prenat.Neonat. Med. (1996), Vol. 1, pp. 292-329, which discusses the inductionof abortion, in combination with an antiprogestin and in furthercombination with a prostaglandin, and the control and management oflabor and delivery; and Chwalisz, K. et al., Hum. Reprod. (1997), vol.12, pp. 101-109, which discusses the treatment of cervial incompetence,alone or in combination with progesterone or a progestin.

Those skilled in the art will also recognize that the compounds of thepresent invention include 1-substituted imidazoles. This class ofcompounds has previously been described as mechanism-based, heme-bindinginhibitors of the cytochrome P450 family of enzymes (Maurice, M. et al.,FASEB J. (1992), Vol. 6, pp. 7528) in addition to nitric oxide synthesis(Chabin, R. N M. et al., Biochemistry (1996), Vol. 35, pp. 9567-9575).The compounds of the present invention may thus be useful as inhibitorsof selected cytochrome P450 family members of therapeutic interestincluding, but not limited to, P450 enzymes involved in steroid andretinoid biosynthesis (Masamura et al., Breast Cancer Res. Treat.(1995), Vol. 33, pp. 19-26; Swart, P. et al., J. Clin. Endocnnol.Metab., Vol. 77, pp. 98-102; Docks, P. et al., Br. J. Dermatol. (1995),Vol. 133, pp. 426-32) and cholesterol biosynthesis (Burton, P. M. etal., Biochem. Pharmacol. (1995), Vol. 50, pp. 529-544; and Swinney, D.C. et al., Biochemistry (1994), Vol. 33, pp. 4702-4713). Imidazole-basedcompounds may also have antifungal activity (Aoyama, Y. et al., Biochem.Pharmacol. (1992), Vol. 44, pp. 1701-1705). The P450 inhibitory activityof the compounds of the present invention can be assessed usingappropriate assay systems specific for the P450 isoform of interest.Such assays are included in the references cited above. One additionalexample of mammalian cytochrome P450 isoform that may be inhibited bythe compounds of the present invention is cytochrome P450 3A4 which canbe assayed in a manner similar to the method described in Yamazaki etal., Carcinogenesis (1995), Vol. 16, pp. 2167-2170.

Testing of the Compounds of the Invention

Nitric oxide synthases are complex enzymes that catalyze the conversionof L-arginine to nitric oxide (NO) and citrulline. Catalysis proceedsthrough two successive oxidations of the guanidinium group ofL-arginine.

A cell-based nitric oxide synthase assay employing the measurement ofnitric oxide oxidation product, nitrite, in the conditioned medium ofcultured cells was employed for the evaluation of the compounds of theinvention. The murine monocytic cell lines RAW 264.7 and J774 are welldocumented as capable of producing >10 μM nitrite in response toimmunostimulation:

Induction of INOS in RAW 264.7 Mouse Monocytes

RAW 264.7 murine macrophage cells were obtained from American TypeCulture Collection (Rockville, Md.) and were maintained in RPMI 1640containing 10% fetal bovine serum (FBS), 5000 units/mL of penicillin andstreptomycin, and 2 mM glutamine (maintenance medium). NOS activity wasmeasured by a fluorescent assay of the nitric oxide oxidation product,nitrite, (Diamani et at., Talanta (1986), Vol. 33, pp. 649652).Induction of iNOS (inducible nitric oxide synthase) is stimulated bytreatment of the cells with lipopolysaccharide and γ-interferon. Themethod of the assay is described below.

Cells are harvested, diluted to 500,000 cells/mL with maintenancemedium, and seeded into 96 well plates at 100 μM/well. The plates areincubated overnight at 37° C, under a 5% CO₂ atmosphere. The medium isthen replaced with 90 μl of BME medium containing 10% FBS, 100 units/mLof penicillin, 100 μl streptomycin, 2 mM glutamine, 100 units/mL ofinterferon-γ and 2 μg/mL of lipopoly-saccharide.N-guanidino-methyl-L-arginine is added to four wells (negative control)at a final concentration of 200 μM using 10 μl of 2 mM stock solution in100 mM Hepes, pH 7.3+0.1% DMSO and four wells receive only the 100 mMHepes/0.1% DMSO buffer (positive control). Compounds for evaluation aredissolved at 10-fold the desired final concentration in Hepes/DMSO and10 μL of these solutions is transferred to the 96-well plate. The platesare incubated for 17 hrs at 37° C., under a 5% CO₂ atmosphere. Nitriteaccumulated in the culture medium is determined as follows: add 15 μL of2,3-diaminonaphthalene (10 μg/mL in 0.75 M HCl) to each well andincubate for 10 minutes at room temperature. Add 15 μl of 1 N NaOH andmeasure the fluorescence emission at 405 nm, using an excitationwavelength of 365 nm. Enzyme activity in experimental wells isnormalized to percent control using the positive and negative controlvalues. The signal to noise ratio is >10 for the assay.

The compounds of the invention, when tested in this assay, demonstratedthe ability to inhibit nitric oxide production.

Various in vivo assays may be employed to determine the efficacy of thecompounds of the invention in treating a condition resulting from anabnormality in nitric oxide production, such as arthritis. The followingis a description of such an assay utilizing rats:

Effects of Compounds of the Invention on Adjuvant-Induced Arthritis inRats

Male Lewis rats were injected intradermally (proximal quarter of thetail) with 0.1 mL of Mycobacterium butyricum in Incomplete Freund'sAdjuvant (10 mg/mL). Either vehicle (acidified saline, 1 mL/kg) or acompound of the invention (3, 10, or 30 mg/kg) were administeredsubcutaneously (b.i.d.), starting on the day following adjuvantimmunization, and continued until the end of the experiment (N=10 ratsper treatment group). Clinical scores (see below) were measured in alllimbs 3 times per week throughout the study. Rats were euthanized 34-35days after immunization. At the time of euthanasia, a radiologicevaluation (see below) of the hind paws was performed, a blood samplewas collected for clinical blood chemistry and drug levels (high dosegroup only; 6 or 12 hours post final dose), a section of liver wasobtained for measurement of potential toxicity, and the hind limbs werepreserved for histopathological determination.

Clinical scoring—each limb was graded according to the following scale:

0 no signs of inflammation

1 moderate redness, first indication of swelling, joint flexible

2 moderate redness, moderate swelling, joint flexible

3 redness, significant swelling and distortion of the paw, jointbeginning to fuse

4 redness, gross swelling and distortion of the paw, joint completelyfused

Radiological scoring—each hind limb was graded on a scale of 0-3 foreach of the following parameters:

soft tissue swelling

cartilage loss

erosion

heterotropic ossification

The compounds of the invention, when tested in this assay, demonstratedthe ability to treat the arthritis present in the rats.

Those skilled in the art will also recognize that numerous assays forthe activity of the NOS isoforms (iNOS, nNOS and eNOS) exist which canbe used to evaluate the biological activity of the compounds of thecurrent invention. These include assays for native NOS isoforms intissues studied ex vivo (Mitchell et al., Br; J. Pharmacol. (1991), Vol.104, pp. 289-291; Szabo et al., Br. J. Pharmacol. (1993), Vol. 108, pp.786-792; Joly et al., Br. J. Pharmacol. (1995), Vol. 115, pp. 491-497)as well as primary cell cultures and cell lines (Forstermann et al.,Eur. J. Pharmacol. (1992), Vol. 225, pp. 161-165; Radmoski et al.,Cardiovasc. Res. (1993), Vol. 27, pp. 1380-1382; Wang et al., J.Pharmacol. Exp. Ther. (1994), Vol. 268, pp. 552-557). Those skilled inthe art will also recognize that recombinant NOS enzymes can beexpressed in heterologous cells by either transient transfection(Karlsen et al., Diabetes, (1995), Vol. 44, pp. 753-758), stabletransfection (McMillan et al., Proc. Natl. Acad. Sci. (1992), Vol. 89,pp. 11141-11145; Sessa et al., J. Biol. Chem. (1995), Vol. 270, pp.17641-17644) or via the use of lytic virus transfection (Busconi &Michel, Mol. Pharmacol. (1995), Vol. 47, pp. 655-659; List et al.,Biochem. J. (1996), Vol. 315, pp. 57-63) using NOS cDNAs. Heterologousexpression can be achieved in mammalian cells (McMillan et al., Proc.Natl. Acad. Sci. (1992), Vol. 89, pp. 11141-11145), insect cells(Busconi & Michel, Mol. Pharmacol. (1995), Vol. 47, pp. 655-459; List etal., Biochem. J. (1996), Vol. 315, pp. 5763), yeast (Sari et al.,Biochemistry (1996), Vol. 35, pp. 7204-7213) or bacteria (Roman et al.,Proc. Natl. Acad. Sci. (1995), Vol. 92, pp. 8428-8432; Martasek et al.,Biochem. Biophys Res. Commun. (1996), Vol. 219, pp. 359-365). Any ofthese heterologous expression systems can be used to establish iNOS,nNOS and eNOS assay systems to evaluate the biological activity of thecompounds of the present invention.

Administration of the Compounds of the Invention

Any suitable route of administration may be employed-for providing apatient with an effective dosage of compounds of the invention. Forexample, oral, rectal, parenteral (subcutaneous, intramuscular,intravenous), transdermal, and like forms of administration may beemployed. Dosage forms include tablets, troches, dispersions,suspensions, solutions, capsules, patches, and the like.

The pharmaceutical compositions of the present invention comprise thecompounds of the invention as the active ingredient, and may alsocontain a pharmaceutically acceptable carrier, and optionally, othertherapeutic ingredients. Carriers such as starches, sugars, andmicrocrystalline cellulose, diluents, granulating agents, lubricants,binders, disintegrating agents, and the like are suitable in the case oforal solid preparations (such as powders, capsules, and tablets), andoral solid preparations are preferred over the oral liquid preparations.Methods for their preparation are well known in the art.

Because of their ease of administration, tablets and capsules representthe most advantageous oral dosage unit forms, in which case solidpharmaceutical carriers are employed. If desired, tablets may be coatedby standard aqueous or nonaqueous techniques. In addition to the commondosage forms set out above, the compounds of the present invention mayalso be administered by controlled or sustained release means anddelivery devices.

Pharmaceutical compositions of the present invention suitable for oraladministration may be presented as discrete units such as capsules,cachets, or tablets, each containing a predetermined v amount of theactive ingredient, as a powder or granules, or as a solution or asuspension in an aqueous liquid, a non-aqueous liquid, an oil-in-wateremulsion, or a water-in-oil liquid emulsion. Such compositions may beprepared by any of the methods of pharmacy, but all methods include thestep of bringing into association the active ingredient with the carrierwhich constitutes one or more necessary ingredients. In general, thecompositions are prepared by uniformly and intimately admixing theactive ingredient with liquid carriers or finely divided solid carriersor both, and then, if necessary, shaping the product into the desiredpresentation.

Preferred Embodiments

Of the compounds of formula (I), as described above in the Summary ofthe Invention, the following group of compounds having the formula (Ia),formula (Ib) or formula (Ic) are preferred:

Of this group of compounds, a preferred subgroup of compounds are thosecompounds wherein A is R¹, —OR¹, —C(O)N(R¹)R², —N(R¹)C(O)N(R¹)R¹⁶,—NR¹C(O)R² or —N(R¹)R²¹; V is N(R⁴); and W is CH.

Of this subgroup of compounds, a preferred class of compounds are thosecompounds wherein A is —C(O)N(R¹)R²; R¹ is hydrogen; and R² is alkyl or—[C₁—C₈]—R⁹; R⁴ is hydrogen or alkyl; R⁵ is hydrogen, halo, alkyl, oralkoxy; and R⁹ is optionally substituted phenyl, tolyl, anisyl,1,4-benzodioxan-6-yl, 1,3-benzodioxol-5-yl, 2-thienyl, pyridinyl ormorpholinyl.

Of this class of compounds, a preferred subclass of compounds are thosecompounds wherein A is —C(O)N(R¹)R²; q, r, n and m are each zero; Q is adirect bond to R³; and R³ is hydrogen.

Of this subclass of compounds, a preferred compound is2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino]-N-[(1,3-benzodioxol-5-yl)ethyl]acetamide.

Of the subclass of compounds, other preferred compounds are selectedfrom the group consisting of:

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[2-3,4-dimethoxyphenyl)ethyl]acetamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl](methyl)amino]-N-[(1,3-benzodioxol-5-yl)methyl]acetamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl](methyl)amino]-N-[(pyridin-4-yl)methyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino]-N-octylacetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](phenylmethyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino]-N-[2-3,4-dimethoxyphenyl)ethyl]-acetamide;

2-[[2-(1H-imidazol-1-yl)pyrimidin-4-yl](methyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methylethyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino]-N-[2-1,3-benzodioxol-5-oxy)ethyl]acetamide;

2-[[4-(1H-imidazol-1-yl)-(methylethyl)pyrimidin-2-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[4-(1H-imidazol-1-yl)-6-methylpyrimidin-2-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(3-chloro-4-methoxyphenyl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino)-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]acetamide; and

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(1,4-benzodioxan-6-yl)methyl]acetamide.

Of the compounds of formula (II) as described above in the Summary ofthe Invention, a preferred group of compounds are those compounds havingthe formula (IIa), formula (IIb) or formula (IIc):

Of this group of compounds, a preferred subgroup of compounds are thosecompounds wherein the N-heterocyclyl is selected from the groupconsisting of imidazolyl, piperidinyl, piperazinyl, pyrrolidinyl,morpholinyl, thiomorpholinyl, azetidinyl, indolyl, pyrrolyl, imidazolyl,tetrahydroisoquinolyl, and perhydroazepinyl.

Of this subgroup of comounds, a preferred class of compounds are thosecompounds wherein the N-heterocyclyl is piperazinyl substituted by R⁶,i.e., the compound of formula (IId), formula.(IIe) or formula

where R⁶ is chosen from the group consisting of hydrogen, alkyl,cycloalkyl, —[C₁-C₈ alkyl]—R⁸, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈ alkyl]—R¹¹,acyl, —C(O)R⁸, —C(O)—[C₁-C₈ alkyl]—R⁸, alkoxycarbonyl, optionallysubstituted aryloxycarbonyl, optionally substituted aralkoxycarbonyl,alkylsulfonyl, optionally substituted aryl, optionally substitutedheterocyclyl, alkoxycarbonylalkyl, carboxyalkyl, optionally substitutedarylsulfonyl, aminocarbonyl, monoalkylaminocarbonyl,dialkylaminocarbonyl, optionally substituted arylaminocarbonyl,aminosulfonyl, monoalkylaminosulfonyl, dialkylaminosulfonyl,arylaminosulfonyl, arylsulfonylaminocarbonyl, optionally substitutedN-heterocyclyl, —C(═NH)—N(CN)R¹, —C(O)—R²³—N(R¹)R²,—C(O)—R²³—N(R¹)C(O)—R²³—N(R¹)R², and —C(O)—N(R¹)—R²³—C(O)OR¹; each R⁸ isindependently selected from the group consisting of haloalkyl,cycloalkyl (optionally substituted with halo, cyano, alkyl or alkoxy),carbocyclyl (optionally substituted with one or more substituentsselected from the group consisting of halo, alkyl and alkoxy), andheterocyclyl (optionally substituted with alkyl, aralkyl or alkoxy); andeach R²³ is an amino acid residue.

Of this class of compounds, a preferred subclass of compounds are thosecompounds where A is —OR¹, —C(O)N(R¹)R², —N(R¹⁶)C(O)N(R¹)R¹⁶, —NR¹C(O)R²or —N(R¹)R²¹; and W is CH.

Of this subclass of compounds, a preferred set of compounds are thosecompounds where A is —C(O)N(R¹)R²; R¹ is hydrogen; R² is lower alkyl,—[C₁-C₈ alkyl]—R⁹, or —[C₁-C₈]—R¹⁰; R⁶ is hydrogen, acetyl,t-butoxycarbonyl, 4-methoxyphenylaminocarbonyl, 4-methoxyphenyl-methyl,methoxycarbonyl, methyl or benzyl; R⁵ is hydrogen, halo, alkyl, oralkoxy; and n is 0 or 1.

Of this set of compounds, a preferred subset of compounds are thosecompounds where R² is —CH₂—R⁹ or —[C₁-C₈]—R¹⁰; R⁹ is optionallysubstituted carbocyclyl or optionally substituted heterocyclyl; and R¹⁰is methylthio.

Of this preferred subset of compounds, preferred compounds are thosecompounds where R² is —CH₂—R⁹; R⁶ is hydrogen, acetyl ort-butoxycarbonyl; and R⁹ is optionally substituted phenyl, tolyl,anisyl, 1,4-benzodioxan-6-yl, 1,3-benzodioxol-5-yl, or 2-thienyl.

Even more preferred are those compounds where R⁵ is chloro, R⁶ is acetyland R⁹ is p-tolyl.

Also preferred are those compounds where R⁵ is chloro, R⁶ is hydrogenand R⁹ is p-tolyl.

Also preferred are those compounds where R⁵ is chloro, R⁶ is hydrogenand R⁹ is 1,4-benzodioxan-6-yl or 1,3-benzodioxol-5-yl.

Also preferred are those compounds where R⁵ is chloro, R⁶ ist-butoxycarbonyl and R⁹ is 1,4-benzodioxan-6-yl or 1,3-benzodioxol-5-yl.

Of this class of compounds, the most preferred compounds are thosecompounds selected from the group consisting of:

N-[(1,3-benzodioxol-5-yl)ethyl]-4-[2-(1H-imidazol-1-yl)-methylpyrimidin-4-yl]-1-(2-methyl-1-oxopropyl)piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl-4-(methoxycarbonyl)piperazine-2-acetamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-[2-(1H-triazol-1-yl)pyrimidin-4-yl]-4-[(dimethylethoxy)carbonyl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methoxypyrimidin-4-yl]-1-(methoxycarbonyl)piperazine-2-acetamide;

1-(acetyl)-N-[(1,3-benzodioxol-5-yl)methyl]-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3chlorophenyl)methyl-4-(methylsulfonyl)piperazine-2-acetamide;and

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(pyridin-3-yl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-carboxamide.

Of the preferred subgroup of compounds of formula (II), anotherpreferred class of compounds are those compounds wherein theN-heterocyclyl is optionally substituted piperidinyl, i.e., the compoundof formula (IIg), formula (IIh) or formula (IIi):

Of this class of compounds, a preferred subclass of compounds are thosecompounds wherein A is —OR¹, —C(O)N(R¹)R², —N(R¹⁶)C(O)N(R¹)R¹⁶,—NR¹C(O)R² or —N(R¹)R²¹; and W is CH.

Of this subclass of compounds, a preferred set of compounds are thosecompounds wherein A is —C(O)N(R¹)R²; R¹ is hydrogen; R² is lower alkylor —[C₁-C₈ alkyl]—R⁹; R⁵ is hydrogen, halo, alkyl, or alkoxy; and

n is zero or one.

Of this set of compounds, a preferred subset of compounds are thosecompounds wherein R² is lower alkyl or —CH₂—R⁹ and R⁹ is4-methoxyphenyl, 1,4-benzodioxan-6-yl, 1,3-benzodioxol-5-yl or3,4-dimethoxyphenyl.

Of this class of compounds, preferred compounds are those compoundsselected from the group consisting of:

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanamine;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[2-(morpholin-4-yl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1-methylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylsulfonylphenyl)methyl]piperidine-2-acetamide;

N-[(4-chlorophenyl)methyl]-1-[2,6-bis(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetamide;

1-(4-fluorophenyl)-4-[1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetyl]piperazine;

1-[(1,3-benzodioxol-5-yl)methyl]-4-[1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetyl]piperazine;

1-(phenylmethyl)-4-[1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetyl]piperazine;

4-[1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetyl]piperazine-1-carboxylicacid, ethyl ester;

1-(4-chlorophenyl)-4-[1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetyl-]-4-hydroxypiperidine;

4-[[1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetyl]amino]piperidine-1-carboxylicacid, ethyl ester;

4-[[1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]piperidine-2-acetyl]amino]piperidine-1-carboxylicacid, ethyl ester;

4-[[1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-acetyl]amino]piperidine-1-carboxylicacid, ethyl ester;

4-[2-[[(1,3-benzodioxol-5-yl)methoxy]ethyl]piperidin-1-yl]-2-(1H-imidazol-1-yl)pyrimidine;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanol;

4-chloro-2-(1H-imidazol-1-yl)-6-piperidin-1-yl)pyrimidine;

4-chloro-2-(1H-imidazol-1-yl)-6-(2-ethylpiperidin-1-yl)pyrimidine;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-methylpiperidine-2-ethanamine;

N-acetyl-N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanamine;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(methylsulfonyl)piperidine-2-ethanamine;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-[2-(4-methoxyphenyl)ethyl]piperidine-2-acetamide;and

N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methoxypyrimidin-4-yl]piperidine-2-acetamide.

Of the preferred subgroup of compounds of formula (II), anotherpreferred class of compounds are those compounds wherein theN-heterocyclyl is optionally substituted pyrrolidinyl, i.e., thecompound of formula (IIj), formula (IIk) or formula (IIm):

Of this class of compounds, a preferred subclass of compounds are thosecompounds wherein A is —OR¹, —C(O)N(R¹)R², —N(R¹⁶)C(O)N(R¹)R¹⁶,—NR¹C(O)R² or —N(R¹)R²¹; and W is CH.

Of this subclass of compounds, a preferred set of compounds are thosecompounds wherein A is —C(O)N(R¹)R²; R¹ is hydrogen; R² is lower alkylor —[C₁-C₈ alkyl]—R⁹; R⁵ is hydrogen, halo, alkyl, or alkoxy; and n iszero or one.

Of this set of compounds, a preferred subset of compounds are thosecompounds having the R-configuration at C-2 of the pyrrolidinyl ring.

Of this set of compounds, preferred compounds are those compoundsselected from the group consisting of.

N-[(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-ethylpyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-(3,4-dimethoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-2-acetamide;

N-[(4-methoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-carboxamide;and

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-ethylpyrimidin-4-yl]pyrrolidine-2-acetamide.

Of the compounds of formula (III) as described above in the Summary ofthe Invention, a preferred group of compounds are those compounds havingthe formula (IIIa), formula (IIIb) or formula (IIIc):

Of this group of compounds, a preferred subgroup of compounds are thosecompounds wherein

is optionally substituted phenyl or optionally substituted naphthyl.

Of the compounds of formula (Ya), formula (Yb) and formula (Yc) asdescribed above in the Summary of the invention, a preferred group ofcompounds are those compounds having the formula (Yc) wherein n is 1; mis 2 or 3; A is —C(O)OR¹ or —C(O)N(R¹)R²; each W is CH; R¹ is hydrogenor alkyl; and R² is hydrogen, alkyl, —(CH)_(n)—N(R¹)₂, optionallysubstituted heterocyclylalkyl or optionally substituted aralkyl.

Of this subgroup of compounds, a preferred class of compounds are thosecompounds wherein R⁴ is —N(R¹)R² where R¹ is hydrogen or alkyl and R² isheterocyclylalkyl selected from the group consisting of(1,3-benzodioxol-5-yl)methyl or (1,4-benzodioxan-4-yl)methyl.

Of this class of compounds, preferred compounds are selected from thegroup consisting of:

2-[[3-[[(1,3-benzodioxol-5-yl)methyl](methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]aceticacid, ethyl ester;

2-[[3-[[(1,3-benzodioxol-5-yl)methyl](methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N,N-diethylacetamide;

2-[[3-[[(1,3-benzodioxol-5-yl)methyl](methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-(2-dimethylaminoethyl)acetamide;

2-[[3-[[(1,3-benzodioxol-5-yl)methyl](methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]acetamide;

2-[[3-[(1,3-benzodioxol-5-yl)methyl]aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N,N-diethylacetamide;

2-[[3-[(1,3-benzodioxol-5-yl)methyl]aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-methylacetamide;

2-[[3-[(1,4-benzodioxan-6-yl)methyl]aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-methylacetamide;

2-[[3-[(1,4-benzodioxan-6-yl)methyl]aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N,N-diethylacetamide;

2-[[3-[(1,4-benzodioxan-6-yl)methyl]aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]acetamide;and

2-[[3-[(1,3-benzodioxol-5-yl)methyl]aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]acetamide.

Of the preferred subgroup of compounds, a preferred class of compoundsare those compounds wherein R⁴ is heterocyclyl.

Of this class of compounds, preferred compounds are selected from thegroup consisting of:

2-[[pyridin-3-ylmethyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl][(1,3-benzodioxol-5-yl)methyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;and

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl][2-(morpholin-4-yl)ethyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide.

Of this subgroup of compounds, another preferred class of compounds arethose compounds wherein R⁴ is hydroxy, cyano, —N(R¹)R², —N(R¹)—C(O)—R¹,—N(R¹)—C(O)OR¹, —N(R¹)—S(O)_(t)R¹, or —N(R¹)—C(O)—N(R¹)₂, where each R¹and each R² is independently hydrogen, alkyl or aralkyl.

Of this class of compounds, preferred compounds are selected from thegroup consisting of:

2-[[3-hydroxypropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-cyanoethyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[3-(dimethylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[3-(acetylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[3-(methylsufonylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[3-(methoxycarbonylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[3-(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[3-aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[3-aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;

2-[[3-(methylsufonylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;

2-[[3-(methoxycarbonylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;

2-[[3-(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;

2-[3-(acetylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;

2-[[3-aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;

2-[[3-(methoxycarbonylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;

2-[[3-(di(phenylmethyl)amino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;

2-[[3-(acetylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxan-4-yl)ethyl]acetamide;

2-[[3-(methylsufonylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;

2-[[3-(dimethylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;

2-[[3-(dimethylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;

2-[[3-(ureido)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;

2-[[3-(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;

2-[[3-(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;

2-[[3-aminopropyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;

2-[[3-(dimethylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;

2-[[3-(acetylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;

2-[[3-(methoxycarbonylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;

2-[[3-(methylsufonylamino)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;

2-[[3-(ureido)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,4-benzodioxane-6-yl)ethyl]acetamide;and

2-[[3-(ureido)propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(2,3-benzofuran-5-yl)ethyl]acetamide.

Of the compounds of formula (IV) as described above in the Summary ofthe Invention, a preferred group of compounds are those compounds havingthe formula (IVa), formula (IVb) or formula (IVc):

Of this group of compounds, a preferred subgroup of compounds are thosecompounds wherein said amino acid is an α-aminoacid of the Lconfiguration at the carbon a to the acid.

Of this group of compounds, another preferred subgroup of compounds arethose compounds wherein said amino acid is an α-aminoacid of the Dconfiguration at the carbon a to the acid.

Of this group of compounds, another preferred subgroup of compounds arethose compounds wherein R¹ is hydrogen; R² is lower alkyl or —[C₁-C₈alkyl]—R⁹; and R⁵ is hydrogen, halo, alkyl, or alkoxy.

Of this subgroup of compounds, a preferred class of compounds are thosecompounds wherein R⁹ is phenyl, tolyl, anisyl, 1,4-benzodioxan-6-yl,1,3-benzodioxol-5-yl, chlorophenyl, carboxyphenyl, 2-thienyl,dimethoxyphenyl or morpholinyl.

Of the compounds of formula (Va), formula (Vb) and formula (Vc) asdescribed above in the Summary of the Invention, a preferred group ofcompounds are those compounds wherein each X and each Y is N; each W isCH; and B is a fused optionally substituted heterocyclyl Of this groupof compounds, a preferred subgroup of compounds are those compoundshaving the formula (Vba):

where A is —OR¹, —C(O)N(R¹)R², —N(R¹⁶)C(O)N(R¹)R¹⁶, —NR¹C(O)R² or—N(R¹)R²¹; and

is an N-heterocyclyl selected from group consisting of piperidinyl,piperazinyl, pyrrolidinyl or morpholinyl.

Of this subgroup of compounds, a preferred compound isN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)purin-6-yl]piperidine-2-acetamide.

Of the compounds of formula (VIIa), formula (VIIb) and formula (VIIc) asdescribed above in the Summary of the Invention, a preferred compoundsisN-[(1,3-benzodioxol-5-yl)methyl]-1-[6-chloro-2-(pyridin-3-yl)pyrimidin-4-yl]piperidine-2-acetamide.

Of the compounds of formula (VIII) as described above in the Summary ofthe Invention, preferred compounds are4,6-dichloro-2-(1H-imidazol-1-yl)pyrimidine and2,4-dichloro-6-(1H-imidazol-1-yl)pyrimidine.

Of the compounds of formula (Ixa), formula (Ixb) and formula (Ixc), apreferred group of compounds are those compounds wherein L is aphotolytically cleavable linkage of formula (X):

wherein the unsatisfied valence on the-right of the formula representsthe point of attachment to the solid substrate and the unsatisfiedvalence on the left of the formula represents the point of attachment tothe ligand.

In addition to the preferred embodiments described above, othercompounds of the invention of interest-are those compounds of formula(I), formula (II) or formula (III) wherein each X, Y or Z is C(R¹⁹), andeach U is C(R⁵) where each R¹⁹ and R⁵ is as described above in claim 1.Also of interest are those compounds of formula (I), formula (II) orformula (III) wherein each X, Y or Z is N, and each U is C(R⁵) whereeach R⁵ is as described above in claim 1. Also of interest are thosecompounds of formula (I), formula (II) or formula (II) wherein each X isN, each Z or Y is C(R¹⁹), and each U is N where each R¹⁹ is as describedabove in claim 1. Also of interest are those compounds of formula (I),formula (II) or formula (II) wherein in each formula, one of X, Y, and Zis N and the others are C(R¹⁹), and U is C(R⁵) where each R¹⁹ and eachR⁵ is as described above in claim 1.

Preparation of the Compounds of the Invention

The compounds of the invention may be synthesized by two generalapproaches, one of which solid phase) could be thought of as a variantof the other (solution phase). The solution phase generic synthesis isshown in the following Reaction Scheme 1 which, for illustrationpurposes only, illustrates the synthesis of a compound of formula (I)where A is —C(O)N(R¹)R². It is understood that other compounds of theinvention may be prepared in a similar manner. In the following ReactionScheme 1, PG is a suitable protecting group; m, n, q, r, Q, U, W, X, Yand Z are as described above in the Summary of the Invention; V isN(R⁴), S or O (where R⁴ is as described in the Summary of theInvention); and R¹, R², R³, R¹², R¹³, R¹⁴, R¹⁵, R¹⁷, and R²⁰ are asdescribed above in the Summary of the Invention for compounds of formula(I):

In general, the compounds of formula (I) are prepared by first addingone equivalent of a compound of formula (XI) in one portion to asolution of one equivalent of a compound of formula (XII) having atleast two substituents displaceable by a nucleophile and 1.1 equivalentsof a trialkyl amine base (such as triethylamine) in a polar, nonproticsolvent such as THF or methylene chloride to provide the compound offormula (XIII). Upon completion of the reaction, the mixture is purifiedby conventional methods.

The compounds of formula (XIVcc) are synthesized by methods well knownin the amino acid and peptide synthetic art from the appropriatecompound of formula (XIVaa), wherein PG is a standard protecting groupfor the V subsituent. Compounds of formula (XIVaa) are commerciallyavailable, usually in protected form, or are readily synthesized byprocedures well-known in the art. Preferred protecting groups are Boc(t-butoxycarbonyl) and Fmoc (fluorenylmethoxy-carbonyl), althoughothers, such as CBZ (benzyloxycarbonyl), and Troc(trichloroethoxycarbonyl), could be used for particular circumstances.Side chain functionalities may be protected, as is well known in thepeptide art, by Trt (triphenylmethyl), tBu (t-butyl), Acm(acetamidomethyl) etc. The protected compounds of formula (XIVaa) arereacted with the appropriate amine to produce the compounds of formula(XIVbb) and deprotected to produce the compound of formula (XIVcc), onceagain by methods well known in the peptide art.

One equivalent of the compound of formula (XIVcc) is added to a solutionof one equivalent of the compound of formula (XIII) and one equivalentof base in a polar, aprotic solvent such as THF. The reaction is heatedto a temperature at which the reaction proceeds cleanly to completion inless than 16 hours. Upon completion of the reaction, the compound offormula (I) is purified and characterized by conventional methods.

Compounds of formula (I) having the so-called “reverse amide”, i.e.,where A is —N(R¹)C(O)R² can be made from the appropriate acid of formula(XIVaa) by Hofmann rearrangement of the acid to an amine, followed byacylation with an appropriate acid under the conditions described above.In many cases, the desired diamine can be obtained commercially.

The compounds of formula (I) in which A is a urea may be prepared byreacting a compound of formula (I) where A is —N(R¹)R²¹ (where R¹ ishydrogen and R²¹ is hydrogen, alkyl, aryl or aralkyl) with anisocyanate. Similarly, the compounds of formula (I) in which A is acarbamate may be prepared by reacting a compound of formula (I) (where Ais —N(R¹)R²¹ where R¹ is hydrogen and R²¹ is hydrogen, alkyl, aryl oraralkyl) with an alkyl chloroformate or by Curtius rearrangement of thecarboxylic acid azide of the compound of formula (XIVaa) in the presenceof the appropriate alcohol.

A specific embodiment of the generic synthesis of a compound of theinvention is shown below in Reaction Scheme 2 as applied to a6-chloro-2-(1-imidazolyl)-4-pyrimidinamine that incorporates the residueof D-β-thienylalanine piperonylamide:

One equivalent of isobutyl chloroformate is added to a solution ofN-Boc-D-β-thienylalanine and one equivalent of a base such as N-methylmorpholine in THF. After two minutes, one equivalent of piperonylamineis added and the mixture allowed to warm to room temperature. Afterthirty minutes, the reaction mixture is passed through a bed of Celiteand all volatiles are removed under reduced pressure to yieldN-Boc-D-β-thienylalanine piperonylamide.

The N-Boc-D-β-thienylalanine piperonylamide in methanol is treated withacetyl chloride. After 45 minutes, all volatiles are removed underreduced pressure to yield D-β-thienylalanine piperonylamidehydrochloride.

One equivalent of imidazole is added in one portion to a solution of oneequivalent of trichloropyrimidine and 1.5 equivs of triethylamine inTHF. After reaction is complete, the reaction mixture is poured intosaturated, aqueous ammonium chloride and extracted three times withethyl acetate. The combined organic layers are washed with brine anddried. The reaction mixture is filtered and all volatiles removed underreduced pressure. The product, 2-imidazolyl-4,6-dichloropyrimidine (thecompound of formula (VIIIa)) is isolated by flash chromatography (20%ethyl acetate in hexane) as an off-white solid.

Two equivalents of D-β-thienylalanine piperonylamide hydrochloride areadded to a solution of one equivalent of2-imidazolyl-4,6-dichloropyrimidine (the compound of formula (VIIIa))and three equivalents of Hünig's base (diisopropylethylamine) in THF.After reaction is complete, all volatiles are removed and the product(the compound of formula (Iaa)) is isolated.

A specific example of the synthesis as applied to sarcosinepiperonylamide hydrochloride is provided:

Isobutyl chloroformate (226 μL, 1.73 mmol) was added to a solution ofN-Boc sarcosine (1.73 mmol) and N-methylmorpholine (192 μL, 1.73 mmol)in THF. After two minutes, piperonylamine (216 mL, 1.73 mmol) was addedand the mixture allowed to warm to room temperature. After thirtyminutes, the reaction mixture was passed through a bed of Celite and allvolatiles were removed under reduced pressure to yield N-Boc sarcosinepiperonyl amide (531 mg, 95%) as a white solid. ¹H NMR: (CDCl₃)δ 2.41(s,3), 3.28 (s,2), 4.39 (d,2), 5.95 (s,2), 6.80 (m,3), 7.43 (bs,1), 9.04(bs,1).

N-Boc sarcosine piperonylamide (500 mg, 1.54 mmol) in methanol (10 mL)was treated with acetyl chloride (1 mL). After 45 minutes, all volatileswere removed under reduced pressure to yield sarcosine piperonyl amidehydrochloride (395 mg, quant.) as a sticky solid.

Imidazole (9.5 g, 140 mmol) was added in one portion to a solution oftrichloropyrimidine (24.7 g, 135 mmol) and triethylamine (30 mL, 216mmol) in THF (500 mL). After 16 hrs, the reaction mixture was pouredinto saturated, aqueous ammonium chloride and extracted three times withethyl acetate. The combined organic layers were washed with brine anddried over MgSO₄. The reaction mixture was filtered and all volatileswere removed under reduced pressure. 2-Imidazolyl-4,6-dichloropyrimidine(the compound of formula (VIIIa)) (9.61 g, 33%) was isolated by flashchromatography (20% ethyl acetate in hexane) as an off-white solid. ¹HNMR: (CDCl₃) δ 7.13 (s,1), 7.25 (s,1), 7.76 (s,1), 8.50 (s, 1).

Sarcosine piperonyl amide hydrochloride (50 mg, 0.19 mmol) was added toa solution of 2-imidazolyl-4,6-dichloropyrimidine (VIIIa) (20 mg, 0.093mmol) and Hünig's base (50 μL, 0.29 mmol) in THF (1 mL). After 16 hrs,all volatiles were removed and the product was isolated as a waxy solid(29 mg, 78%). ¹H NMR (CDCl₃) δ 3.2 (s,3), 4.25 (s,2), 4.38 (s,2), 5.88(s,2), 6.30 (bs,1), 6.42 (bs,2), 6.65 (m,3), 7.05 (s,1), 8.40 (s,1).

Another specific example of the synthesis of a compound of (XIc) isprovided:

Boc-pyrrolidine (3.0 g, 17.5 mmol) was dissolved in ether (35 ml) andtetramethylethylenediamine (TMEDA) (2.03 g, 17.5 mmol), cooled to −78°C. and s-butyllithium (1.3 M, 13.5 mL, 18 mmol) was added. Afterstirring for 1 hour, allyl bromide was added in ether (5 mL). Afterwarming to room temperature, the reaction was quenched with water andthe organic layer was separated. The organic layer was washed with 1 Msolution of NaH₂PO₄ and water, then dried over MgSO₄. The solvent wasremoved in vacuo and the residue was purified by chromatography onsilica gel (hexanes/ethyl acetate (9:1) to give the olefin (0.50 g, 14%,¹H NMR (CDCl₃) δ 5.65-5.85 (m, 1), 5.00-5.20 (m, 2), 3.70-3.90 (m, 1),3.20-3.45 (m, 2), 2.35-2.60 (M, 1), 2.00-2.20 (m, 1), 1.60-2.00 (m, 4),1.45 (s, 9)). The olefin (500 mg, 2.37 mmol), 5-bromo-1,3-benzodioxolane(476 mg, 2.37 mmol), triethylamine (478 mg, 4.74 mmol),tri-o-tolylphosphine (96 mg. 0.31 mmol) and Pd(OAc)₂ (26 mg, 0.12 mmol)was dissolved in CH₃CN and refluxed overnight under argon. An additional1 equivalent (476 mg) of the bromide and Pd(OAC)₂ (52 mg, 0.24 mmol) wasadded and refluxing continued for 4.5 hours. The reaction was filteredand the solvent was evaporated. The residue was taken up in ether andwashed successively with water, 1 M NaH₂PO₄, water, and brine. Afterdrying, the solvent was removed and the product was purified bychromatography (silica gel. hexane:ethyl acetate, 4:1) to yield 152 mg(19%) of the Boc-protected [(1,3-benzodiox-5-yl)prop-2-enyl]pyrrolidine(¹H NMR (CDCl₃) δ 6.90 (s, 1), 6.70-6.80 (m, 2), 6.35 (d, 1). 3.80-3.95(m, 1), 3.25-3.50 (m. 2), 2.45-2.70 (m, 1), 2.20-2.35 (m, 1), 1.70-2.00(M, 4), 1.45 (s, 9)). The Boc group was removed under standardconditions.

Another specific embodiment of the generic syntheis as applied to acompound of the invention follows:

To butyl alchohol (3 ml) was added 2-fluoro-4-chloropurine (41 mg, 0.24mmol), N-[(1,3-benzodioxol-5-yl)methyl]piperidine-2-acetamide (66 mg,0.24 mmol), and Hünig's's base (diisopropylethylamine) (0.042 mL, 0.24mmol). After stirring at 90° C for 6 hours, the reaction was dilutedwith ethyl acetate. The organic material was washed with saturated NH₄Cland brine, dried (MgSO₄), and the solvent was removed in vacuo.Chromatography of the residue (CH₂Cl₂/MeOH, 10/1) gave 42 mg of thefluoropurine. The fluoropurine (18.9 mg, 0.046 mmol) was dissolved inDMSO and reacted with TMS-imidazole (0.10 g, 0.66 mmol) and CsF (61 mg,0.40 mmol). After stirring at 130° C for 72 hours, the reaction wasdiluted with ethyl acetate and washed with saturated NH₄Cl and brine.The organic layer was dried (MgSO₄), the solvent removed in vacuo, andthe residue chromatographed (CH₂Cl₂/MeOH, 19/1) to give 12 mg ofN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)purin-6-yl]piperidine-2-acetamide.

Another specific example of the synthesis is provided:

To THF (10 mL) was added cyanuric chloride (158 mg, 0.85 mmol),N-[(1,3-benzodioxol-5-yl)methyl]piperidine-2-acetamide (47 mg, 0.17mmol), and imidazole (58 mg, 0.85 mmol). After stirring for 12 hours,the reaction was diluted with ethyl acetate. The organic material waswashed with saturated NH₄Cl and brine, dried (MgSO₄), and the solventwas removed in vacuo. Chromatography of the residue (hexanes/ethylacetate, 4/1) gave 60 mg of the dichlorotriazine. The dichlorotriazine(20 mg, 0.047 mmol) was dissolved in THF and reacted with TMS-imidazole(0.009 mL, 0.06 mmol) and CsF (11 mg, 0.07 mmol) at 0° C. After warmingto room temperature and stirring for 4 hours, the reaction was dilutedwith ethyl acetate and washed with saturated NH₄Cl, water, and brine.The organic layer was dried (MgSO₄), the solvent removed in vacuo, andthe residue chromatographed (ethyl acetate/hexanes/MeOH, 4/4/1) to give6.5 mg ofN-[(1,3-benzodioxol-5-yl)methyl]-1-[3-chloro-5-(1H-imidazol-1-yl)triazin-2-yl]piperidine-2-acetamide.

Another specific example of the synthesis is provided:

To a solution of indole-5-carboxylic acid (0.50 g, 3.1 mmol) in MeOH (25mL) was added trimethylsilyidiazomethane until no gas evolution wasobserved. The solution was concentrated, dissolved in CH₂Cl₂, and washedwith saturated NaHCO₃ and brine. The organic layer was dried (MgSO₄) andthe solvent was removed in vacuo to give 0.54 g of the ester (¹H NMR(CDCl₃) δ 3.95 (s, 3), 6.63 (s, 1), 7.25 (m, 1), 7.40 (d, 1), 7.95 (d,1), 8.25-8.4 (br s, 1), 8.45 (s, 1)). The ester (100 mg, 0.58 mmol) wasdissolved in DMF (10 mL) and 4-chloro-2-imidazol-1-ylpyrimidine (113 mg,0.63 mmol) was added. After heating at 60° C for 18 hours, the solventwas removed in vacuo, the residue was dissolved in CH₂Cl₂, and washedwith saturated NaHCO₃ and brine. The organic layer was dried (MgSO₄),the solvent was removed in vacuo and the residue was chromatographed(CH₂Cl₂/MeOH, 19/1) to give 68 mg (37%) of the pyrimidine (¹H NMR(CDCl₃) δ 3.95 (s, 3), 6.90 (s, 1), 7.25 (m, 2), 7.80 (m, 1), 7.95 (s,1), 8.10 (d, 1), 8.4 (s, 1), 8.50 (d, 1), 8.70 (m, 2)). The pyrimidinewas dissolved in THF/water (1/1) and LiOH (6 mg, 0.21 mmol) was added.After heating at 60° C for 3 hours, the solvent was removed in vacuo andacidified with methanolic HCl. The solvent was removed in vacuo,dissolved in DMF and treated with HATU (42 mg, 0.11 mmol), DIEA (37 mg,0.21 mmol), and piperonylamine (26 mL, 0.21 mmol). After stirring for 18hours, the solvent was removed in vacuo, the residue was dissolved inCH₂Cl₂, and washed with saturated NaHCO₃ and brine. The organic layerwas dried (MgSO₄), the solvent was removed in vacuo, and the residue waschromatographed (CH₂Cl₂/MeOH, 19/1) to give 2 mg (4%) ofN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]indole-6-carboxamide;¹H NMR (CDCl₃) δ 3.75 (s, 2), 5.95 (s, 2), 6.80-6.90 (m, 2), 7.05-7.15(m, 2), 7.25 (m, 2), 7.75-7.85 (m, 2), 8.00 (s, 2), 8.50-8.60 (m, 2),8.70-8.80 (m, 1); MS: (439.2 M+H)⁺.

Another specific embodiment of the generic synthesis as applied to acompound of the invention isN-[(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrole-2-carboxamide[MS: (403.2 M+H)⁺, which was prepared in a similar manner describedabove forN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]indole-6-carboxamide.

The following Reaction Scheme 3 depicts a method of preparing thecompounds of the invention where U is CR⁵ (where R⁵ is hydrogen) and X,Y and Z are CR¹⁹ (where R¹⁹ is hydrogen):

The above synthesis may be carried out as follows: To benzene (20 mL)was added 1-(3-aminophenyl)imidazole (755 mg, 4.7 mmol),7-chloro-3-oxoheptanoic acid ethyl ester (982 mg, 4.7 mmol), Na₂HPO₄(667 mg, 4.7 mmol), I₂ (60 mg, 0.23 mmol), and 4 Å molecular sieves (500mg). After refluxing for 6 hours, more 12 (60 mg) was added. Afterstirring for 16 hours, the reaction was filtered, the solvent wasremoved in vacuo, and the residues chromatographed (CH₂Cl₂/MeOH, 98/2)to give 120 mg (8%) of1-[3-(1H-imidazol-1-yl)phenyl]piperidine-2-acrylic acid ethyl ester (¹HNMR (CDCl₃) δ 7.85 (s, 1), 7.05-7.50 (m, 6), 4.80 (s, 1), 4.15 (q, 2),3.45 (t, 2), 2.4 (t, 2), 1.5-1.8 (m, 6), 1.30 (t, 3)). This ester (120mg, 0.38 mmol) was dissolved in MeOH (20 mL) and reacted with 10% Pd/C(60 mg) and 1 atm of H₂. After reacting for 60 hours, the reaction wasfiltered, the solvent removed in vacuo, and the residue chromatographed(ethyl acetate/hexanes, 1/1) to give 24 mg of1-[3-(1H-imidazol-1-yl)phenyl]piperidine-2-acetic acid ethyl ester(compound of formula (XV)). This ester (24 mg, 0.076 mmol) was dissolvedin 5% methanolic NaOH. After stirring for 16 hours, the reaction wasacidified with methanolic HCl, the solvent removed in vacuo, and theresidue dissolved in DMF. Piperonylamine (1 eq), Hünig's base (2 eq) andHATU (1 eq) were added. After reaction completion the reaction mixturewas partitioned with water and ethyl acetate. The organic layer wasseparated, washed with water, and dried. The solvent was removed invacuo and the residue was chromatographed (ethyl acetate/MeOH, 98/2) togive 6 mg of the compound of formula (Ibb),N-[(1,3-benzodioxol-5-yl)methyl]-1-[3-(1H-imidazol-1-yl)phenyl]piperidine-2-acetamide:¹H NMR (CDCl₃) δ 7.80 (s, 1), 7.10-7.30 (m, 4), 6.50-6.70 (m, 5), 5.90(s, 2), 4.20-4.35 (m, 2), 3.85 (brs, 1), 3.50 (t, 2), 2.95 (d, 1),2.35-2.55 (m, 2), 1.4-1.9 (m, 6); MS: (419 M+H)⁺.

The following Reaction Scheme 4 depicts a method of preparing compoundsof the invention where A is —OR¹:

The above synthesis may be carried out as follows: To DMF (100 ml) wasadded 4-chloro-2-imidazol-1-ylpyrimidine (0.50 g, 2.77 mmol),2-piperidineethanol (0.359 g, 2.77 mmol), and Hünig's base (0.536 g,4.15 mmol). After heating at 80° C for 5 hours, the solvent was removedin vacuo and the residue was chromatographed (CH₂Cl₂/MeOH, 19/1) to give349 mg (46%) of 1-[(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanol(the compound of formula (XVI)), (¹H NMR (CDCl₃) δ 8.54 (s, 2), 8.11 (d,1), 7.82 (t, 1), 7.11 (d, 1), 6.44 (d, 1), 3.60 (m, 2), 3.03 (m, 1),1.77 (m); MS: 274 (M+H)⁺). To a solution of1-[(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanol (25 mg, 0.092mmol) dissolved in DMF (5 ml) was added NaH (60% dispersion in oil, 5.5mg, 0.14 mmol) followed by piperonyl chloride (17 mg, 0.10 mmol) andt-butyl ammonium chloride. After stirring for 16 hours at 80° C., thesolvent was removed in vacuo and the residue was partitioned withsaturated NH₄Cl and CH₂Cl₂. The organic layer was separated, dried(MgSO₄), the solvent removed in vacuo, and the residue chromatographed(CH₂Cl₂/MeOH, 19/1) to give 13 mg (35%) of4-[2-[[(1,3-benzodioxol-5-yl)methoxy]ethyl]piperidin-1-yl]-2-(1H-imidazol-1-yl)pyrimidine(the compound of formula (Icc)); ¹H NMR (CDCl₃) δ 8.52 (s, 1), 8.05 (d,1), 7.80 (s, 1), 7.09 (s, 1), 6.73 (m, 3), 6.45 (d, 1), 5.93 (s, 2),4.30 (s, 2), 3.45 (m, 2), 2.95 (m, 1), 1.55 (m); MS: 408.7 (M+H)⁺.

Compounds of formula (XVI) may be used to prepare other compounds of theinvention as depicted below in Reaction Scheme 5 where R^(1b) ishydrogen or —CH₃, Ms is mesyl and Ac is acetyl:

The above synthesis may be carried out as follows: To a solution of1-[(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanol (the compoundof formula (XVI)) (236 mg, 0.86 mmol) and methanesulfonyl chloride (99mg, 0.87 mmol) dissolved in CH₂Cl₂ (20 mL) was added TEA (87.5 mg, 0.87mmol). After stirring for 16 hours at 0° C, methanesulfonyl chloride (99mg, 0.87 mmol) and TEA (87.5 mg, 0.87 mmol) were added and the solutionwas warmed to ambient temperature. After stirring for 1 hour, thesolution was washed with saturated NH₄Cl and brine; dried (MgSO₄), andthe solvent removed in vacuo to give 276 mg (91%) of the compound offormula (XVII) (¹H NMR (CDCl₃) δ 8.72 (s, 1), 8.15 (d, 1), 7.89 (s, 1),7.18 (s, 1), 6.46 (d, 1), 4.24 (m, 3), 2.95 (s, 3), 2.18 (m, 6), 1.76(m). MS: 352.5 (M+H)⁺). A solution of the compound of formula (XVII)(100 mg, 028 mmol) and a compound of formula (XVIII) (429 mg, 2.84 mmol)dissolved in CH₂Cl₂ (7.5 ml) was stirred for 16 hours, and then DMF (7.5ml) was added. After stirring for 2 hours, the solvent was removed invacuo and the residue was partitioned with saturated NH₄Cl and CH₂Cl₂.The organic layer was separated, washed with brine, dried (MgSO₄), thesolvent removed in vacuo, and the residue chromatographed (CH₂Cl₂/MeOH,19/1) to give 6.6 mg (21%) ofN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanamine(the compound of formula (Iee)): ¹H NMR (CDCl₃) δ 8.50 (s, 1), 8.08 (d,1), 7.77 (s, 1), 7.08 (s, 1), 6.66 (m, 3), 6.43 (d, 1), 5.91 (s, 2),3.60 (d, 2), 3.00 (m, 1), 2.57 (m, 2), 2.02 (m, 1), 1.65 (m). MS: 407.8(M+H)⁺.

To THF (3 mL) was addedN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanamine(8 mg, 0.03 mmol), Hünig's base (8 mg, 0.06 mmol), and acetic anhydride(4 mg, 0.04 mmol). After stirring for 16 hours, the solvent was removedin vacuo and the residue was chromatographed (CH₂Cl₂/MeOH. 19/1) to give8 mg (60%) ofN-acetyl-N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-ethanamine(the compound of formula (Igg)): ¹H NMR (CDCl₃) δ 8.48 (s, 1), 8.08 (d,1), 7.76 (s, 1), 7.09 (s, 1), 6.66 (m, 3), 6.33 (m, 1), 5.94 (s, 1),5.91 (s, 1), 4.43 (m,3), 3.40 (m, 2), 2.11 (d, 3), 1.14 (m); MS: 450.0(M+H)⁺.

Alternatively, to THF (3 mL) was addedN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl)piperidine-2-ethanamine(8 mg, 0.03 mmol), Hünig's base (8 mg, 0.06 mmol), and methanesulfonylchloride (4.5 mg, 0.04 mmol). After stirring for 16 hours, the solventwas removed in vacuo and the residue was chromatographed (CH₂Cl₂/MeOH.19/1) to give 7 mg (51%) ofN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(methylsulfonyl)piperidine-2-ethanamine(the compound of formula (Iff)); ¹H NMR (CDCl₃) δ 8.10 (s, 1), 7.78 (d,1), 7.13 (s, 1), 6.82 (s, 1), 6.72 (s, 2), 6.30 (d, 1), 5.94 (s, 2),4.23 (m, 3), 3.20 (m, 2), 2.80 (s, 3), 1.14 (m); MS: 485.7 (M+H)⁺.

To DMF (5 ml) was added the compound of formula (XVII) (50 mg, 0.14mmol), Hünig's base (28 mg, 0.21 mmol), and N-methylpiperonylamine (28mg, 0.17 mmol). After stirring at 80° C for 16 hours, the solvent wasremoved in vacuo and the residue was partitioned with saturated NH₄Cland CH₂Cl₂. The organic layer was separated, washed with brine, dried(MgSO₄), the solvent removed in vacuo, and the residue was partitionedwith ethyl acetate and water. The organic layer was separated, washedwith brine, dried (MgSO₄), the solvent was removed in vacuo, and theresidue was chromatographed (ethyl acetate/MeOH, 19/1) to give 7 mg(12%) ofN-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-methylpiperidine-2-ethanamine(the compound of formula (Idd)); ¹H NMR (CDCl₃) δ 8.53 (s, 1), 8.07 (d,1), 7.80 (s, 1), 7.10 (s, 1), 6.78 (s, 1), 6.69 (m, 2), 6.43 (d, 1),5.92 (s, 2), 3.40 (m, 2), 2.97 (m, 1), 1.80 (m); MS: 422.0 (M+H)⁺.

Reaction Scheme 6 depicts another method of preparing compounds of theinvention where V is C(R⁴)H:

The above synthesis may be carried out as follows: To a solution of LDA(1.28 g, 12 mmol) in THF (30 mL) at −78° C. was added2,4-dichloro-6-methylpyrimidine (1.96 g, 12 mmol) in THF (15 mL). Afterstirring for 15 minutes, 3,3-dimethylallyl bromide (1.79 g, 12 mmol) inTHF (5 mL) was added dropwise. After the reaction warmed to ambienttemperature, water and ethyl acetate was added. The organic layer wasseparated, the solvent was removed in vacuo, and the residue waschromatographed (ethyl acetate/hexane, 1/19) to give 2.06 g (74%) of2,4-dichloro-6-(4-methyl-3-pentenyl)pyrimidine (¹H NMR (CDCl₃) δ 7.15(s, 1), 5.10 (t, 1), 2.80 (t, 2), 2.45 (m, 21, 1.70 (s, 3), 1.55 (s,3)). To a solution of NaIO₄ (17 g, 81 mmol) and KMnO₄ (251 mg, 1.59mmol) in water was added K₂CO₃ (1.29 g, 9.38 mmol) and2,4dichloro-6-(4-methyl-3-pentenyl)pyrimidine (2.06 g, 8.9 mmol) int-butanol. After stirring for 16 hours, the reaction was acidified to pH3 and extracted with ethyl acetate. The organic layer was extracted withaqueous NaHCO₃. The aqueous layer was acidified to pH 3 and extractedwith ethyl acetate. The organic layer was dried and the solvent removedin vacuo to give 980 mg of 3-(2,4-dichloropyrimidin-6-yl)propionic acid(the compound of formula (XIX)), ¹H NMR (CDCl₃) δ 7.30 (s, 1), 3.05 (t,2), 2.90 (t, 2). The acid was coupled to piperonylamine under standardconditions with isobutyl chloroformate and N-methylmorpholine to givethe compound of formula (XX). Imidazole was added under standardconditions (1-trimethylsilylimidazole and CsF in DMF at 60° C.) to giveN-[(1,3-benzodioxol-5-yl)ethyl]-6-chloro-2-(1H-:imidazol-1-yl)pyrimidine-4-propionamide(the compound of formula (Ihh)); MS: 386 (M+H)⁺.

Reaction Schemes 6a through 6d depict methods of preparing compounds offormula (Yc). Compounds of formula (Ya) and formula (Yc) may besimilarly prepared:

Compounds of formulae (Y₁), (Y₂), (Y₄) and (Y₅) are commerciallyavailable or may be prepared by methods disclosed herein or by methodsknown to those of ordinary skill in the art. Each R¹, R², m and n areindependently as described above in the Summary of the Invention forcompounds of formula (Ya), formula (Yb) and formula (Yc); and R⁵ and Ware also as described above in the Summary of the Invention forcompounds of formula (Ya), formula (Yb) and formula (Yc).

The above synthesis may be carried out as follows:

To N-cyanoethylglycine, ethyl ester (15.9 g, 102 mmol) (a compound offormula (Y₂)) dissolved in DMSO (70 mL) was added4-chloro-6-methyl-2-methylsulfonylpyrimidine (18.8 g, 91 mmol) (acompound of formula (Y₁)) and diisopropylethylamine (18 mL, 100 mmol).After stirring for 16 hours, the reaction temperature was raised to 70°C. and imidazole (26.5 g, 0.39 mol) was added. After stirring for 1 day,the reaction was cooled to ambient temperature and added to ice water.The solid that formed was suction filtered and collected on paper togive 9.9 g of2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]aceticacid, ethyl ester (a compound of formula (Yc1)).

To2-1(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]aceticacid, ethyl ester (4.51 g, 14.4 mmol) dissolved in THF (250 mL) wasadded LiOH (0.91 g, 21.7 mmol) and water (30 mL). After stirring for 18hours, most of the solvent was removed in vacuo and 1 N HCl (21.7 mL,21.7 mmol) was added. The solid that formed was suction filtered andcollected on paper to give 3.17 g of2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]aceticacid (a compound of formula (Yc2)).

To2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]aceticacid (1.53 g, 5.3 mmol) slurried in DMF (25 mL) was addedcarbonyldiimidazole (0.87 g, 5.4 mmol). After stirring for 2 hours,diethylamine (1.0 mL, 9.7 mmol) (a compound of formula Y₄)) was added.After stirring for 18 hours, the reaction was partitioned with ethylacetate and water. The organic layer was separated, dried (Na₂SO₄), andthe solvent was removed in vacuo to give 0.91 g of2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6methyl-4-pyrimidinyl]amino)-N,N-diethylacetamide(a compound of formula (Yc3)).

The following compounds of formula (Yc3) and derivatives thereof wereprepared in a similar manner with the appropriately substituted startingmaterials:

2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-methylacetamide;

2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,4-benzodioxan-4-yl)ethyl]acetamide.

Ammonia (g) was bubbled into2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N,N-diethylacetamide(0.22 g, 0.65 mmol) dissolved in MeOH (25 mL). Raney Nickel (0.8 g) wasadded and the mixture was placed under nitrogen at 50 psi. When thereaction was determined to be complete by TLC, the reaction mixture wassuction filtered through celite and the solvent was removed in vacuo. Tothe residue dissolved in MeOH (10 mL) was added piperonal (0.29 g, 1.9mmol) and NaBH(OAc)₃ (0.40 g, 1.9 mmol). After stirring for 18 hours,the solvent was evaporated and the residue was partitioned between ethylacetate and aqueous bicarbonate solution. The organic layer wasseparated, dried (Na₂SO₄), and the solvent was removed in vacuo.Chromatography on silica with acetonitrile/ammonium hydroxide (19/1)gave2-[3-[(1,3-benzodioxol-5-ylmethyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N,N-diethylacetamide,a compound of formula (Yc4); NMR (CDCl₃) 8.4 (s, 1), 7.65 (s, 1), 7.0(s, 1), 6.85 (s, 1), 6.75 (d, 1), 6.5 (d, 1), 6.05 (br, 1), 5.85 (s, 2),4.3 (s, 2), 3.85 (s, 2), 3.65 (br, 2), 3.4 (m, 4), 2.95 (t, 2), 2.3 (s,3), 2.2 (m, 2), 1.25 (t, 3), 1.1 (t, 3) ppm.

The following compounds of formula (Yc4) and derivatives thereof wereprepared in a similar manner with appropriately substituted startingmaterials:

2-[[3-[[1,4-benzodioxan-6-yl)methyl]amino]propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-methylacetamide;NMR (CDCl₃) 8.5 (s, 1), 7.8 (s, 1), 7.1 (s, 1), 6.75 (m, 3), 6.25 (br,1), 4.25 (s, 4), 4.15 (br, 2), 3.7 (s, 2), 3.6 (s, 2), 2.8 (d, 3), 2.75(m, 2), 2.4 (s, 3), 1.85 (m, 2) ppm;

2-[[3-[(1,3-benzodioxol-5-ylmethyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-methylacetamide;NMR (DMSO-d₆) 8.4 (s, 1), 8.0 (m, 1), 7.8 (s, 1), 7.05 (s, 1), 6.9 (s,1), 6.8 (m, 2), 6.65 (s, 1), 6.3 (br, 1), 5.95 (s, 2), 4.1 (br, 2), 3.6(s, 2), 3.55 (br, 2), 3.3 (br, 3), 2.6 (m, 2), 2.3 (s, 3), 1.75 (m, 2)ppm;

2-[[3-[[(1,4-benzodioxan-6-yl)methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N,N-diethylacetamide;NMR (CDCl₃) 8.4 (s, 1), 7.7 (s, 1), 7.05 (s, 1), 6.85 (s, 1), 6.6 (m,2), 6.3 (br, 1), 4.4 (s, 2), 4.25 (s, 4), 3.7 (s, 2), 3.6 (m, 2), 3.4(q, 4), 2.7 (t, 2), 2.35 (s, 3), 1.9 (m, 2), 1.35 (t, 3), 1.15 (t, 3)ppm;

2-[[3-[[(1,4-benzodioxan-6-yl)methyl]amino]propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]acetamide;NMR (CDCl₃) 8.5 (s, 1), 7.8 (s, 1), 7.1 (s, 1), 6.75 (m, 3), 6.3 (br,1), 6.0 (br, 1), 4.2 (s, 4), 4.15 (s, 2), 3.65 (m, 4), 2.75 (m, 2), 2.4(s, 3), 1.85 (m, 2) ppm;

2-[[3-[(1,3-benzodioxol-5-ylmethyl)amino]propyl](2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]acetamide;NMR (CDCl₃) 8.5 (s, 1), 7.75 (s, 1), 7.05 (s, 1), 6.75 (m, 3), 6.3 (br,1), 5.95 (s, 2), 5.4 (br, 1), 4.15 (s, 2), 3.7 (br, 2), 3.6 (s, 2), 2.75(t, 2), 2.4 (s, 3), 1.85 (m, 2) ppm.

Compounds of formula (Y₄) wherein R² is 2-(1,4-benzodioxan-6-yl)ethylmay be prepared as follows and reacted with the compound of formula(Yc2) to prepare compounds of formula (Yc3), which may be furtherreacted as described above to form compounds of formula (Yc4):

To 1,4-benzodioxane-6-carboxaldehyde (10.0 g, 60 mmol) in acetic acid(50 mL) was added nitromethane (6.3 mL, 1.9 eq.) and ammonium acetate(5.1 g, 1.1 eq.). After heating at 110° C for 4 hours the mixture wascooled to ambient temperature, water (150 mL) was added, and the solidprecipitate was collected by filtration. The solid was crystallized frommethylene chloride-hexane (1:1, 45 mL) to obtain 7.6 g (61%) of6(2-nitroethenyl)-1,4-benzodioxane. To a portion of the solid (3.58 g)dissolved in MeOH-EtOH-AcOEt (1:1:1, 450 mL) was added 10% Pd/C (1.7 g)and concentrated HCl (3.3 mL, 2.3 eq). After shaking on a Parrhydrogenator at 45 psi for 5 hours, the catalyst was removed byfiltration through Celite and washed with methanol. Evaporation of thefiltrate gave 3.59 g (96%) of 1,4-benzodioxan-6-ethanamine,hydrochloride.

Alternatively, compounds of formula (Y₃) may be reacted as follows toform compounds of formula (Yc3) wherein R¹ and R² are both hydrogen,which may be further reacted with a compound of formula (Y5) to formcompounds of formula (Yc4):

To2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]aceticacid, ethyl ester (2.3 g, 7.3 mmol) slurried in MeOH (50 mL) and cooledin a dry ice/acetone bath was bubbled NH₃. The bomb was sealed andheated in an oil bath at 65° C for 2 days. The reaction was cooled in adry ice/acetone bath and the seal was broken. The solid was suctionfiltered to give 1.7 g of24(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]acetamide.

Reaction Scheme 6b depicts another method of preparing compounds offormula (Yc). Compounds of formula (Ya) and formula (Yb) may besimilarly prepared:

Compounds of formulae (Y₁), (Y₆), (Y₇), (Y₉) and (Y₅) are commerciallyavailable or may be prepared by methods disclosed herein or by methodsknown to those of ordinary skill in the art. Each R¹ R², m and n areindependently as described above in the Summary of the Invention forcompounds of formula (Ya), formula (Yb) and formula (Yc); and R⁴, R⁵ andW are also as described above in the Summary of the Invention forcompounds of formula (Ya), formula (Yb) and formula (Yc).

The above synthesis may be carried out as follows:

To homopiperonylamine hydrochloride (2.14 g, 10.6 mmol) (a compound offormula (7)) in CH₂Cl₂ (20 mL) in an ice bath was added triethylamine(3.1 mL, 21 mmol) and chloroacetyl chloride (0.85 mL, 10 mmol) (acompound of formula Y₆)). After warming to ambient temperature andstirring for 16 hours, the reaction was partitioned with 1 N HCl. Theorganic layer was separated, washed with aqueous bicarbonate, dried(Na₂SO₄), and the solvent was removed in vacuo to give 1.8 g of2-chloro-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide, a compound offormula 8).

To 2-chloro-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide (0.45 g, 1.9mmol) in ethanol (10 mL) was added 3-aminopropanol (0.72 mL, 9.4 mmol)(a compound of formula (Y₉)). After heating the reaction in an oil bathat 60° C for 1 day, the reaction was partitioned with ethyl acetate andwater. The organic layer was separated, washed with brine, dried(Na₂SO₄), and the solvent was removed in vacuo to give 0.44 g of2-[(3-hydroxypropyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide, acompound of formula (Y₁₀).

The following compounds of formula (Y₁₀) were prepared in a similarmanner from the appropriately substituted starting materials:

2-[(3-pyridinylmethyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[[2-(4-morpholinyl)ethyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;

2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide.

To 2-[(3-hydroxypropyl)amino]-N-1,3-benzodioxol-5-ylmethyl)acetamide(0.44 g, 1.6 mmol) dissolved in DMSO (5 mL) was added4-chloro-6-methyl-2-methylsulfonylpyrimidine (0.31 g, 1.5 mmol) (acompound of formula (Y₁) and diisopropylethylamine (0.55 mL, 3.1 mmol).After stirring for 16 hours, the reaction temperature was raised to 70°C and imidazole (0.47 g, 6.9 mol) was added. After stirring for 1 day,the reaction was cooled to ambient temperature and partitioned withwater and ethyl acetate. The organic layer is separated, dried (Na₂SO₄),and the solvent was removed in vacuo. Chromatography on silica withCH₂Cl₂/MeOH gave2-[(3-hydroxypropyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino)-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide,a compound of formula (Yc5).

The following compounds of formula (Yc5) and derivatives thereof wereprepared in a similar manner with the appropriately substituted startingmaterials:

2-[(3-pyridinylmethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.6 (s, 1), 8.45 (s, 2), 8.15 (t, 1), 7.8 (s, 1), 7.7 (d,1), 7.35 (br, 1), 7.05 (s, 1), 6.8 (br, 2), 6.6 (br, 2), 6.0 (s, 2), 4.8(m, 2), 4.2 (m, 2), 3.3 (m, 2), 2.6 (m, 2), 2.3 (s, 3) ppm;

2-[(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;NMR(CDCl₃) 8.5 (s, 1), 7.8 (s, 1), 7.1 (s, 1), 6.6 (d, 1), 6.55 (d, 1),6.3 (t, 1), 6.2 (s, 1), 5.9 (s, 2), 4.2 (s, 2), 3.9 (t, 2), 3.55 (t, 2),2.8 (t, 2), 2.75 (t, 2), 2.45 (s, 3) ppm;

2-[[3-[[(1,3-benzodioxol-5-yl)methyl)(methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]aceticacid, ethyl ester; NMR (CDCl₃) 8.5 (s, 1), 7.8 (s, 1), 7.05 (s, 1), 6.85(s, 1), 6.75 (m, 2), 6.4 (br, 1), 5.9 (s, 2), 4.2 (m, 4), 3.6 (m, 2),3.4 (s, 2), 2.4 (t, 2), 2.35 (s, 3), 2.2 (s, 3), 1.9 (t, 3), 1.2 (t, 3)ppm;

2-[[2-(4-morpholinyl)ethyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.5 (s, 1), 7.8 (s, 1), 7.1 (s, 1), 6.5 (d, 1), 6.3 (br, 1),6.15 (s, 2), 5.7 (br, 2), 4.0 (m, 4), 3.45 (m, 8), 2.6 (m, 2), 2.4 (s,3), 2.35 (m, 4) ppm; and

2-[(1,3-benzodioxol-5-ylmethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.75 (s, 1), 8,15 (t, 1), 7.8 (s, 1), 7.15 (s, 1), 6.75 (d,1), 6.7 (m, 2), 6.55 (d, 1), 6.4 (m, 2), 6.2 (br, 1), 6.0 (s, 2), 5.9(s, 2), 4.65 (br, 2), 4.1 (br, 2), 3.4 (m, 2), 2.3 (s, 3) ppm.

Alternatively, compounds of formula (Y₁₀) and derivatives thereof areprepared as follows:

In a manner similar to the preparation of compounds of formula (Yc3)above, to 2-[(2-cyanoethyl)(dimethylethoxycarbonyl)amino]acetic acid(8.3 g, 39 mmol) dissolved in CH₂Cl₂ (100 mL) was addedcarbonyldiimidazole (6.2 g., 38 mmol). After stirring for 30 minutes,homopiperonylamine, hydrochloride (8.0 g, 41 mmol) anddiisopropylethylamine (7.5 mL, 43 mmol) were added. After stirring for18 hours, most of the solvent was removed in vacuo and the residue waspartitioned with ethyl acetate and 1 N HCl. The organic layer wasseparated, washed with aqueous bicarbonate and brine, dried (Na₂SO₄),and the solvent was removed in vacuo to give 13 g of2-[(2-cyanoethyl)(dimethylethoxycarbonyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide.

To2-[(2-cyanoethyl)(dimethylethoxycarbonyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide(14 g, 37 mmol) in CH₂Cl₂ (75 mL) cooled in an ice bath was addedtrifluoroacetic acid (50 mL). After stirring for 1 hour the ice bath wasremoved and the solvent was removed in vacuo. The residue was trituratedwith ether and a solid formed. The solid was collected by filtration togive 12 g of2-[(2-cyanoethyl)amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide,trifluoroacetic acid salt, a compound of formula (Y₁₀).

Alternatively, compounds of formula (Y₁₀) and derivatives thereof areprepared as follows:

To N-methyl-β-alaninenitrile (50 g, mmol in acetonitrile was addedpiperonyl chloride (50 g, mmol). After stirring for 18 h, the solventwas removed in vacuo. The residue was dissolved in CH₂Cl₂, washed withaqueous carbonate, dried (MgSO₄), and the solvent was removed in vacuo.The residue was dissolved in methanol saturated with ammonia (600 mL)and Raney nickel (10 g) was added. After shaking under an atmosphere ofhydrogen at 20 psi for 6 h, the reaction was filtered through celite andthe solvent was removed in vacuo to give 65 g ofN-(1,3-benzodioxol-5-ylmethyl)-N-methyl-1,3-propanediamine.

To N-(1,3-benzodioxol-5-ylmethyl)-N-methyl-1,3-propanediamine (33 g,0.15 mol) in CH₂Cl₂ (500 mL) was added ethyl glyoxalate (30 mL of a 50%toluene solution, 0.15 mol) and sodium triacetoxyborohydride (40 g, 0.19mol). After stirring for 4 hours, the reaction was washed with aqueouspotassium carbonate and the solvent removed in vacuo. Chromatography onsilica with CH₂Cl₂/MeOH/ammonium hydroxide gave 14 g of2-([3-[(1,3-benzodioxol-5-ylmethyl)amino]propyl]amino]acetic acid, ethylester, a compound of formula (Y₁₀)

Reaction Scheme 6c depicts another method of preparing compounds offormula (Yc). Compounds of formula (Ya) and formula (Yb) may besimilarly prepared with the appropriately substituted startingmaterials.

Compounds of formulae (Yc3) are prepared by methods disclosed herein.Each R¹, R², m and n are independently as described above in the Summaryof the Invention for compounds of formula (Ya), formula (Yb) and formula(Yc); and R⁵ and W are also as described above in the Summary of theInvention for compounds of formula (Ya), formula (Yb) and formula (Yc).

The above synthesis may be carried out as follows:

To2-1(2-cyanoethyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-1,3-benzodioxol-5-yl)ethyl]acetamide(2.5 g, 5.8 mmol) (a compound of formula (Yc3)) in MeOH (50 mL) wasbubbled ammonia. Raney nickel (1.0 g of a 50% slurry) was added and thereaction was placed on a Parr hydrogenator at 50 psi. After shaking for16 hours, the pressure was released and the reaction mixture was suctionfiltered through Celite. The solvent was removed in vacuo and theresidue was chromatographed on silica gel (9:1 CH₃CN/NH₄OH) to afford2-[(3-aminopropyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-1,3-benzodioxol-5-yl)ethyl]acetamide,a compound of formula (Yc6); as a white solid; NMR (DMSO-d₆, 90° C) 8.4(s, 1), 7.8 (s, 1), 7.0 (s, 1), 6.75 (d, 1), 6.7 (s, 1), 6.6 (d, 1), 5.9(s, 2), 4.1 (s, 2), 3.6 (br, 2), 3.3 (m, 2), 2.75 (t, 2), 2.6 (t, 2),2.3 (s, 3), 1.8 (m, 2) ppm.

The following compounds of formula (Yc6) and derivatives thereof wereprepared in a similar manner with appropriately substituted startingmaterials:

2-[(3-aminopropyl)[(2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;NMR (DMSO-d₆, 90° C.) 8.4 (s, 1), 7.8 (s, 1), 7.05 (m, 3), 6.75 (d, 2),6.45 (s, 1), 4.1 (s, 2), 3.7 (s, 3), 3.55 (t, 2), 3.3 (m, 2), 3.2 (s,2), 3.6 (m, 4), 2.3 (s, 3) ppm;

2-[(3-aminopropyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;NMR (DMSO-d₆) 8.42 (br, 1), 8.08 (br, 1), 7.80 (br, 1), 7.02 (s, 1),6.65 (m, 4), 4.16 (m, 6), 4.05 (br, 1), 3.65 (br, 1), 3.45 (br, 2), 3.15(br, 2), 2.59 (m, 4), 2.35 (s, 3), 1.62 (m, 2) ppm; and

2-[(3-aminopropyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.46 (s, 1), 7.75 (s, 1), 7.06 (s, 1), 6.80 (s, 1), 6.70 (d,1), 6.52 (d, 1), 6.18 (br, 1), 4.46 (t, 2), 4.06 (br, 2), 3.60 (br, 2),3.45 (m, 2), 3.05 (m, 2), 2.78 (br, 2), 2.65 (m, 2), 2.39 (s, 3), 1.70(br, 4) ppm.

Compounds of formula (Yc6) may be used to prepare compounds of formula(Yc7), (Yc8) and (Yc9) as set forth below:

To2-[(3-aminopropyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide(0.3 g, 0.7 mmol) (a compound of formula (Yc6)) dissolved in MeOH (10mL) was added formalin (0.15 mL, 2.0 mmol) and sodiumtriacetoxyborohydride (0.37 g, 1.7 mmol). After stirring for 16 hours,the solvent was removed in vacuo. The residue was partitioned with ethylacetate and aqueous bicarbonate. The organic layer was separated, washedwith brine, dried (Na₂SO₄), and the solvent was removed in vacuo.Chromatography on silica with acetonitrile/ammonium hydroxide gave 0.14g of2-[[3-(dimethylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide,a compound of formula (Yc8); NMR (CDCl₃) 8.5 (s, 1), 7.8 (s, 1), 7.1 (s,1), 6.5 (d, 1), 6.45 (s, 2), 6.4 (d, 1), 6.2 (m, 1), 5.9 (s, 2), 4.15(s, 2), 3.55 (m, 2), 3.5 (q, 2), 2.6 (t, 2), 2.4 (s, 3), 2.3 (t, 2),2.25 (s, 6), 1.7 (m, 2) ppm.

To2-[(3-aminopropyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-1,3-benzodioxol-5-yl)ethyl]acetamide(50 mg, 0.11 mmol) (a compound of formula (Yc6)) in methanol (2 mL) wasadded benzaldehyde (0.2 M in methanol, 68 μL, 0.14 mmol). After stirringfor 15 minutes, borane-pyridine complex (0.2 M in methanol, 0.14 mmol)was added. After 2 hours, the solution was evaporated. The residue waspartitioned into water and ethyl acetate. The aqueous layer wasextracted twice with ethyl acetate. The combined ethyl acetate fractionswere washed with brine, dried over sodium sulfate and concentrated. Theresidue was purified by chromatography on silica gel (2:1 ethylacetate/hexanes) to provide2-[[3-(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide,a compound of formula (Yc8); as a white solid; NMR (CDCl₃) 8.65 (s, 1),7.7 (s, 1), 7.2 (br, 5), 7.1 (s, 1), 6.6 (d, 1), 6.55 (s, 1), 6.5 (d,1), 6.1 (br, 2), 5.9 (s, 2), 3.95 (br, 2), 3.5 (br, 6), 2.7 (m, 3), 2.35(s, 6) ppm.

The following compounds of formula (Yc8) and derivatives thereof wereprepared in a similar manner with appropriately substituted startingmaterials:

2-[[3(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.75 (s, 1), 7.2 (br, 5), 7.05 (s, 1), 6.9 (d,2), 6.65 (d, 2), 6.4 (br, 1), 4.1 (s, 2), 3.75 (s, 2), 3.7 (s, 3), 3.6(br, 2), 3.45 (dd, 2), 2.7 (m, 4), 2.35 (s, 3), 1.8 (s, 2) ppm;

2-[[3-(dimethylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-4-methoxyphenyl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.75 (s, 1), 7.05 (s, 1), 6.85 (d, 2), 6.6 (d,2), 6.3 (br, 1), 6.25 (br, 1), 4.1 (s, 2), 3.7 (s, 3), 3.5(m, 4), 2.7(t, 2), 2.4 (s, 3), 2.3 (t, 2), 2.2 (s, 6), 1.75 (m, 2) ppm;

2-[[3-bis(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.70 (s, 1), 7.35 (m, 10), 7.04 (s, 1), 6.62(d, 1), 6.45 (s, 1), 6.40 (d, 1), 6.06 (br, 1), 5.96 (br, 1), 4.15 (br,4), 3.92 (br, 2), 3.60 (s, 4), 3.45 (m, 4), 2.62 (t, 2), 2.50 (t, 2),2.30 (s, 3),1.72 (m, 2) ppm;

2-[[3-(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.75 (s, 1), 7.25 (m, 6), 7.05 (s, 1), 6.60 (d,1), 6.45 (s, 1), 6.40 (d, 1), 6.20 (br, 1), 4.10 (m, 6), 3.70 (br, 4),3.40 (m, 2), 2.65 (t, 2), 2.60 (t, 2), 2.40 (s, 3), 1.90 (br, 1), 1.76(m, 2) ppm;

2-[[3-(dimethylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-1,4-benzodioxan-6-yl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.75 (s, 1), 7.05 (s, 1), 6.65 (d, 1), 6.50 (s,1), 6.42 (s, 1), 6.30 (t, 1), 6.16 (br, 1), 4.12 (m, 6), 3.50 (m, 4),2.75 (m, 2), 2.62 (t, 2), 2.56 (s, 6), 2.40 (s, 3), 2.10 (m, 2) ppm;

2-[[3-(phenylmethylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.46 (s, 1), 7.75 (s, 1), 7.30 (m, 6), 7.10 (s, 1), 6.82 (s,1), 6.68 (d, 1), 6.54 (d, 1), 6.25 (br, 1), 4.46 (t, 2), 4.10 (br, 2),3.70 (br, 2), 3.62 (br, 2), 3.45 (m, 2), 3.05 (t, 2), 2.65 (m, 4), 2.40(s, 3), 1.78 (m, 2) ppm; and

2-[[3-(dimethylamino)propyl][2(1H-1-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.76 (s, 1), 7.06 (s, 1), 6.85 (s, 1), 6.70 (d,1), 6.50 (d, 1), 6.16 (br, 2), 4.50 (t, 2), 4.10 (s, 2), 3.52 (m, 4),3.05 (t, 2), 2.76 (m, 2), 2.68 (m, 2), 2.62 (s, 6), 2.42 (s, 3), 2.10(m, 2) ppm.

To2-[(3-aminopropyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide(0.3 g, 0.7 mmol) (a compound of formula (Yc6)) dissolved in pyridine (5mL) was added acetic anhydride (0.10 mL, 1.0 mmol). After stirring for16 hours, the reaction was partitioned with ethyl acetate and water. Theorganic layer was separated, washed with water and brine, dried(Na₂SO₄), and the solvent was removed in vacuo. Chromatography on silicawith CH₂Cl₂ gave 0.14 g of2-[[3-(acetylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide,a compound of formula (Yc7); NMR (DMSO-d₆) 8.4 (s, 1), 8.05 (t, 2), 7.85(t, 1), 7.8 (s, 1), 7.05 (s, 1), 6.7 (m, 2), 6.6 (m, 1), 6.2 (s, 1), 5.9(s, 2), 4.1 (m, 2), 3-3.6 (m, 6), 2.6 (m, 2), 2.3 (m, 3), 1.8 (s, 3),1.65 (m, 2) ppm.

The following compounds of formula (Yc7) and derivatives thereof wereprepared in a similar manner with appropriately substituted startingmaterials:

2-[[3-(methylsulfonylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.65 (s, 1), 7.0 (s, 1), 6.55 (m, 2), 6.5 (s,1), 6.45 (d, 1), 6.15 (br, 1), 5.95 (br, 1), 5.85 (s, 2), 4.1 (s, 2),3.65 (br, 2), 3.45 (m, 2), 3.2 (dd,2), 2.9 (s, 3), 2.65 (t, 2), 2.35 (s,3), 1.9 (m, 2) ppm;

2-[[3-(methoxycarbonylamino)propyl)[241H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-1,3-benzodioxol-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.7 (s, 1), 7.1(s, 1), 6.55 (d, 1), 6.5 (s, 1),6.45 (d, 1), 6.3 (br, 1), 6.1 (br, 1), 5.9 (s, 2), 4.1 (s, 2), 3.7 (s,3), 3.5 (m, 2), 3.2 (dd, 2), 2.7 (t, 2), 2.4 (s, 3), 1.85 (m, 4) ppm;

2-[[3-methylsulfonylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-4-methoxyphenyl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.75 (s, 1), 7.1 (s, 1), 6.95 (d, 2), 6.7 (d,2), 6.25 (br, 1), 6.15 (br, 1), 4.1 (s, 2), 3.75 (s, 3), 3.6 (br, 2),3.5 (m, 2), 3.2 (dd, 2), 2.95 (s, 3), 2.7 (t, 2), 2.4 (s, 3), 1.85 (m,2) ppm;

2-[[3-(methoxycarbonylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.75 (s, 1), 7.1 (s, 1), 6.9 (d, 2), 6.7 (d,2), 6.2 (br, 1), 6.1 (br, 1), 4.05 (s, 2), 3.75 (s, 3), 3.65 (s, 2), 3.5(s, 3), 3.2 (m, 2), 2.7 (t, 2), 2.4 (s, 3), 1.8 (m, 4) ppm;

2-[[3-(acetylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide;NMR (CDCl₃) 8.45 (s, 1), 7.7 (s, 1), 7.05 (s, 1), 6.9 (d, 2), 6.65 (d,2), 6.4 (br, 1), 6.1 (s, 1), 4.05 (s, 2), 3.7 (s, 3), 3.5 (m, 4), 3.25(dd, 2), 2.7 (t, 2), 2.4 (s, 3), 1.9 (s, 3), 1.8 (m, 2) ppm;

2-[[3-(methoxycarbonylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;NMR (CDCl₃) 8.60 (s, 1), 7.78 (s, 1), 7.08 (s, 1), 6.64 (d, 1), 6.45 (s,1), 6.44 (d, 1),=6.25 (br, 1), 6.15 (s, 1), 5.05 (br, 1), 4.12 (m, 6),3.65 (s, 3), 3.45 (m, 4), 3.20 (m, 2), 2.65 (t, 2), 2.40 (s, 3), 1.80(m, 2) ppm;

2-[3-(acetylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;NMR (CDCl₃) 8.50 (s, 1), 7.75 (s, 1), 7.06 (s, 1), 6.62 (d, 1), 6.58(br, 1), 6.45 (s,1), 6.42 (d, 1), 6.15 (s, 1), 4.10 (m, 6), 3.55 (m, 4),3.30 (m, 2), 2.64 (t, 2), 2.40 (s, 3), 1.92 (s, 3), 1.82 (m, 2) ppm;

2-[[3-methylsulfonylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,4-benzodioxan-6-yl)ethyl]acetamide;NMR (CDCl₃) 8.46 (s, 1), 7.76 (s, 1), 7.03 (s, 1), 6.65 (d, 1), 6.50 (s,1), 6.42 (d, 1), 6.18 (br, 1), 5.80 (br, 1), 4.20 (m, 6), 3.65 (br, 2),3.48 (m, 2), 3.20 (m, 2), 2.92 (s, 3), 2.65 (m, 2), 2.40 (s, 3), 1.90(m, 2) ppm;

2-[[3-(acetylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.46 (s, 1), 7.76 (s, 1), 7.05 (s, 1), 6.86 (s, 1), 6.72 (d,1), 6.55 (d, 1), 6.45 (br, 2), 6.13 (s, 1), 4.50 (t, 2), 4.08 (s, 2),3.55 (m, 4), 3.30 (q, 2), 3.06 (t, 2), 2.66 (t, 2), 2.40 (s, 3), 1.93(s, 3), 1.85 (m, 2) ppm;

2-[[3-(methoxycarbonylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.46 (s, 1), 7.76 (s, 1), 7.05 (s, 1), 6.84 (s, 1), 6.70 (d,1), 6.54 (d, 1), 6.26 (br, 2), 6.10 (s, 1), 5.08 (br, 1), 4.50 (t, 2),4.06 (s, 2), 3.65 (s, 3), 3.50 (m, 4), 3.22 (q, 2), 3.04 (t, 2), 2.66(t, 2), 2.42 (s, 3), 1.80 (m, 2) ppm; and

2-[[3-(methylsulfonylamino)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;NMR (CDCl₃) 8.44 (s, 1), 7.74 (s, 1), 7.02 (s, 1), 6.86 (s, 1), 6.72 (d,1), 6.52 (m, 2), 6.19 (s, 2), 5.80 (br, 1), 4.50 (t, 2), 4.10 (s, 2),3.62 (br, 2), 3.46 (q, 2), 3.20 (q, 2), 3.06 (t, 2), 2.95 (s, 3), 2.66(t, 2), 2.38 (s, 3), 1.86 (m, 2) ppm.

To2-[(3-aminopropyl)[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide(135 mg, 0.32 mmol) (a compound of formula (Yc6)) in pyridine (1.5 mL)was added water (1.5 mL) solution of potassium cyanate (64 mg, 0.76mmol). The mixture was stirred and heated in an oil bath at 80° Covernight. The mixture was poured into water and extracted with ethylacetate (3×20 mL). The combined ethyl acetate fractions were washed withbrine, dried over sodium sulfate and concentrated. The residue waspurified by chromatography on silica gel (9:1 CH₃CN/NH₄OH) to afford2-[[3-ureido)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(4-methoxyphenyl)ethyl]acetamide,a compound of formula (Yc9); as a white solid; NMR (DMSO-d₆, 90° C.) 8.4(s, 1), 7.8 (s, 1), 7.05 (d, 2), 7.0 (s, 1), 6.75 (d, 2), 6.4 (s, 1),4.1 (s, 2), 3.7 (s, 3), 3.5 (m, 2), 3.25 (m, 2), 3.05 (m, 2), 2.65 (t,2), 2.3 (s, 3), 1.7 (m, 2) ppm.

The following compounds of formula (Yc9) and derivatives thereof wereprepared in a similar manner with the appropriately substituted startingmaterials:

2-[[3-(ureido)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(1,4-benzodioxan-4-yl)ethyl]acetamide;NMR (DMSO-d₆) 8.42 (br, 1), 8.08 (t, 1), 7.80 (br, 1), 7.05 (s, 1), 6.60(m, 3), 6.03 (br, 1), 5.45 (br, 1), 4.18 (br, 6), 3.40 (m, 6), 3.00 (m,2), 2.55 (m, 2), 2.35 (br, 3), 1.70 (m, 2) ppm; and

2-[[3-(ureido)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]-N-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]acetamide;NMR (DMSO-d₆) 8.45 (br, 1), 8.12 (br, 1), 7.80 (br, 1), 7.00 (m, 2),6.82 (m, 1), 6.60 (br, 1), 6.10 (br, 1), 5.42 (br, 1), 4.42 (t, 2), 4.14(m, 2), 3.00-3.60 (m, 10), 2.60 (m, 2), 2.30 (s, 3), 1.68 (m, 2) ppm.

Reaction Scheme 6d depicts another method of preparing compounds offormula (Yc). Compounds of formula (Ya) and formula (Yb) may besimilarly prepared.

Compounds of formulae (Yc10) are prepared by methods disclosed herein.Each R¹, R², m and n are independently as described above in the Summaryof the Invention for compounds of formula (Ya), formula (Yb) and formula(Yc); and R⁵ and W are also as described above in the Summary of theInvention for compounds of formula (Ya), formula (Yb) and formula (Yc).

The above synthesis may be carried out as follows:

To2-[[3-[(1,3-benzodioxol-5-ylmethyl)amino](methyl)propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]aceticacid, ethyl ester (2.2 g, 4.6 mmol) (a compound of formula (Yc10))dissolved in THF (50 mL) was added LiOH (0.34 g, 8.1 mmol) and water (10mL). After stirring for 16 hours, the solvent was removed in vacuo and 1N HCl (8.1 mL, 8.1 mmol) was added. The solvent was removed in vacuo togive2-[[3-[(1,3-benzodioxol-5-ylmethyl)(methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]aceticacid, a compound of formula (Yc11).

To2-[[3-[(1,3-benzodioxol-5-ylmethyl)(methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]amino]aceticacid (0.35 g, 0.8 mmol) (a compound of formula (Yc11)) slurried in DMF(5 mL) was added carbonyldiimidazole (0.14 g, 0.8 mmol). After stirringfor 20 minutes, diethylamine (0.25 mL, 2.4 mmol) was added. Afterstirring for 18 hours, the reaction was partitioned with ethyl acetateand water. The organic layer was separated, washed with water, dried(Na₂SO₄), and the solvent was removed in vacuo to give 0.91 g of thedesired product Chromatography on silica with CH₂Cl₂/MeOH gave2-[[3-[[(1,3-benzodioxol-5-yl)methyl)(methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N,N-diethylacetamide;NMR (CDCl₃) 8.4 (s, 1), 7.85 (s, 1), 7.1 (m, 1), 6.85 (s, 1), 6.75 (m,2), 6.4 (br, 1)i 5.95 (s, 2), 4.4 (br, 2), 3.6 (br, 2), 3.4 (m, 6), 2.45(t, 2), 2.35 (s, 3), 2.2 (s, 3), 1.9 (m, 2), 1.3 (t, 3), 1.15 (t, 3)ppm.

The following compounds of formula (Yc12) and derivatives thereof wereprepared in a similar manner:

2-[[3-[[(1,3-benzodioxol-5-yl)methyl](methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-(2-dimethylaminoethyl)acetamide;NMR (CDCl₃) 8.5 (s, 1), 7.8 (s, 1), 7.1 (s, 1), 6.8 (5, 1), 6.75 (m, 2),6.25 (br, 1), 5.95 (s, 2), 4.15 (br, 2), 3.6 (br, 2), 3.4 (s, 2), 3.35(m, 2), 2.4 (t, 2), 2.4 (s, 3), 2.35 (t, 2), 2.2 (s, 3), 2.0 (br, 6),1.8 (m, 2), 1.6 (m, 2) ppm; and

2-[[3-[(1,3-benzodioxol-5-yl)methyl](methyl)amino]propyl][2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]acetamide;NMR (DMSO-d₆) 8.4 (s, 1), 7.8 (s, 1), 7.5 (s, 1), 7.1 (m, 2), 6.8 (m,3), 6.3 (br, 1), 6.0 (s, 2), 5.4 (br, 1), 4.1 (m, 2), 3.4 (m, 4), 2.4(t, 2), 2.3 (s, 3), 2.1 (s, 3), 1.75 (m, 2) ppm.

The solid phase generic synthesis of the compounds of the invention maybe conceptualized as the generic synthesis of Reaction Scheme 1 in whichR¹ has been replaced by a cleavable attachment to a derivatized polymerresin. At the end of the synthetic scheme, the resin is cleaved and R¹becomes hydrogen. The solid phase synthetic scheme is illustrated inReaction Scheme 7 as applied to the specific example, as before, of apiperonylamide, but in this case the amino acid is piperazine-2-aceticacid:

In the solid phase synthesis, the group which is to become R¹ isattached to the resin through a cleavable linkage, such as the2-nitrobenzyl residue, which can be photolytically cleaved. In theexample shown, the piperonylamine (see above) has been protected withBoc and reacted with 4-(bromomethyl)-3-nitrobenzoic acid to produce theBoc-protected compound of formula (XXI), which is then attached to afree amine of the lysine-derivatized, amino-functionalized syntheticsupport. In this case, a polyethyleneglycol-grafted crosslikedpolystyrene, 1% DVB crosslinked polystyrene or crosslinkedpolydimethylacrylamide is suspended in a polar aprotic solvent such asmethylene chloride, DMF or THF. An excess of the suitably protectedlinker-synthon is added to the suspended support followed by a couplingreagent such as diisopropylcarbodiimide (DIC), dicyclohexylcarbodiimide(DCC), bis(2-oxo-3-oxazolidinyl) phosphinic chloride (BOP), orO-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium-hexafluorophosphate(HATU) and optionally an acylation catalyst such asdimethylaminopyridine (DMAP) or hydroxybenzotriazole (HOBT). The mixtureis agitated at ambient temperature for 1 to 24 hours or until thereaction is complete as judged by a ninhydrin test The resin is washedwith an appropriate solvent or solvents multiple times to remove excessreagents and by-products to give the resin-compound of formula (XXII).

The resin-compound of formula (XXII) is deprotected to liberate thecompound of formula (XXIII), which is then suspended in a polar aproticsolvent such as methylene chloride or DMF. An excess of an appropriatelyprotected compound of formula (XXIV) is added followed by a couplingagent such as HATU, BOP or DIC with the optional addition of anacylation catalyst such as DMAP or HOBT. Alternatively an excess of anactivated form of the compound of formula (XXIV), such as thesymmetrical anhydride or acyl fluoride may be added to the resin. Themixture is shaken for 1 to 24 hours at ambient temperature and thenwashed multiple times with an appropriate solvent or solvents to removeexcess reagents and by-products to give the resin-compound of formula(XXV).

Resin-compound of formula (XXV) is deprotected to liberate the compoundof formula (XXVI), which is then suspended in a polar aprotic solventsuch as DMF or THF. An excess of the appropriate compound of formula(VIIIb) is added followed by an excess of a base such as triethylamineor diisopropylethylamine. The mixture is agitated and heated to 50-100°C for 1 to 24 hours, then cooled and washed multiple times with anappropriate solvent to remove excess reagents and by products to giveresin-compound of formula (IXaa). The resin-compound of formula (IXaa)is optionally treated to liberate protected functionality incorporatedas part of a synthon to produce the compound of formula (Iii).

For those compounds in which the substitution pattern of the piperazineis reversed (e.g., examples 95-102 below), the procedure of thepreceding paragraph may be slightly modified. Resin-compound of formula(XXV) is deprotected with piperidine to liberate an amine and thendissolved or suspended in an inert solvent, such as methylenedichloride. An excess of an appropriately protected acid that willfurnish R⁶ is added followed by a coupling agent such as HATU, BOP orDIC with the optional addition of an acylation catalyst such as DMAP orHOBT. Alternatively an excess of an activated form of the acid, such asthe symmetrical anhydride or acyl fluoride may be added to the resin.The mixture is shaken for 1 to 24 hours at ambient temperature and thenwashed multiple times with an appropriate solvent or solvents to removeexcess reagents. The product is suspended in a polar aprotic solvent,such as DMF or THF. An excess of the appropriate compound of formula(VIIIb) is added followed by an excess of a base such as triethylamineor diisopropylethylamine. The mixture is agitated and heated to 50-100°C for 1 to 24 hours, then cooled and washed multiple times with anappropriate solvent to remove excess reagents and by products to giveresin compounds analogous to the resin-compound of formula (IXaa), buthaving the pyrimidine attached to the piperazineacetic acid at the4-position.

This resin compound analogus to the resin-compound of formula (IXaa) isthen suspended in a protic solvent such as methanol oracetonitrile-water and stirred and photolyzed to cleave the product fromthe resin. Filtration, and evaporation of the filtrate gives the crudeproduct, which is then purified and characterized by standardtechniques.

In a specific example, 1.57 g of an amino-functionalized TentaGel resin(0.80 mmole) was suspended in 20 mL of methylene chloride and treatedwith 1.05 g of linker acid (2.4 mmole), 0.50 mL of DIC (3.2 mmole), and20 mg of DMAP (0.16 mmole). The mixture was shaken at room temperaturefor 20 hours and then washed with methylene chloride ten times to give aresin-compound of formula (XXII). The resin-compound of formula (XXII)was treated with 50% trifluoroacetic acid (TFA) in methylene chloride atroom temperature for 2 hours and then washed with methylene chloride tentimes, 15% triethylamine in methylene chloride for 10 minutes, and againmethylene chloride for 5 times. The deprotected resin-compound offormula (XXIII) was then suspended in 12 mL of methylene chloride andtreated with 1.444 g of the compound of of formula (XXIV) (3.2 mmole),1.216 g of HATU (3.2 mmole), and 1.3 mL of diisopropylethylamine (7.2mmole). The mixture was shaken for 16 hours at ambient temperature andthen washed 5 times to give resin-compound of formula (XXV). The Fmocwas removed by treatment with 30% piperidine in DMF and 777 mg of theresulting resin-bound compound of formula (XXVI) (0.35 mmole) was thenreacted with 320 mg of 2-imidazolyl-4-chloropyrimidine (the compound offormula (VIIIb)), in the presence of 0.61 mL of diisopropylethylamine(3.5 mmole) in 12 mL of DMF at 80° C for 15 hours and then cooled toroom temperature and washed with DMF and methylene chloride to give theresin-compound of formula (IXaa). The final product was cleaved from theresin by photolysis in methanol (MeOH) for 17 hours to give 54.6 mg ofproduct, a compound of formula (Iii) (31%). The crude product waspurified by flash chromatography (eluted with 4:4:1 ethylacetate:hexanes:MeOH). The Boc-protected amine product was treated with3 mL of 30% TFA-methylene chloride for 1 hour and was dried in vacuo togive quantitative amount of product.

The piperazineacetic acid compound of formula (XXIV) employed in thesynthesis above and many others in this application was synthesized asfollows: Twelve milliliters (50 mmol) of N,N′-dibenzylethylene-diamine,14 mL (100 mmol) of Et₃N and 250 mL toluene were combined at 0° C, and 7mL (50 mmol) of methyl 4-bromocrotonate (7 mL, 50 mmol) was added. Thereaction was slowly warmed to room temperature, stirred for 24 hours,filtered, concentrated in vacuo to a residue and treated with 10%aqueous HCl (300 mL). The mixture was filtered again and the filtratewashed with ethyl acetate (2×100 mL). The filtrate was made basic withK₂CO₃ and extracted with ethyl acetate (3×150 mL). The combined extractswere washed with brine, dried over MgSO₄ and concentrated in vacuo togive 13.7 g of methyl 1,4-4-dibenzylpiperazine-2-acetate. ¹H NMR (CDCl₃)δ 2.28-2.50 (m,4), 2.5-2.75 (m,4), 3.1 (bs, 1), 3.42 (d,2), 3.52 (d,1),3.6 (s,3), 3.75 (d,1), 7.15-7.35 (m,1).

The 13.7 g (40 mmol) of methyl 1,4-dibenzylpiperazine-2-acetate, 150 mLof MeOH, 50 mL of 1 N HCl (aqueous) and 3 g of 10% Pd/C were combinedand hydrogenated with H₂ (50 psi) for 24 hours. The reaction wasfiltered, the filtrate was concentrated in vacuo to remove most of theMeOH, and the residue was made basic with K₂CO₃ to pH=9-10, and 9.8 g(40 mmol) of BOC-ON was added slowly at 0° C. The reaction was stirredat 0° for 1 hour, allowed to warm up to room temperature, stirred for 2hours, and extracted with ethyl acetate (2×200 mL). The combinedextracts were treated with 50 mL of 10% HCl (aqueous). The aqueous layerwas washed with ethyl acetate, basified with K₂CO₃ and extracted threetimes with ethyl acetate. The combined organic layers were washed withbrine, dried over MgSO₄ and concentrated in vacuo to give 7.89 g ofmethyl 4-Boc-piperazine-2-acetate; ¹H NMR (CDCl₃) δ 1.4 (s,9), 2.31(dd,1), 2.37 (dd, 1), 2.55 (b, 1), 2.69-3.02 (m,4), 3.75 (s,3), 3.88(b,2).

A portion (5.2 g; 20 mmol) of the methyl 4-Boc-piperazine-2-acetateproduct from the previous step was combined with 60 mL of THF and 60 mLof 1 N NaOH (aqueous) and stirred at room temperature for 6 hours tosaponify the methyl ester. The reaction was cooled to 0° C., adjusted topH 9-10 with 10% HCl(aqueous), and 5.2 g (20 mmol) of FMOC-Cl was added.The reaction was stirred at room temperature for 6 hours, (adding 1 NNaOH (aqueous) to maintain pH=9-10) 1 hour, then acidified with 10% HClto pH=1. The reaction was extracted twice, the combined organic layerswere washed with brine, dried over MgSO₄ and concentrated in vacuo togive 8.56 g of the desired 4-Boc-1-Fmoc-piperazine-2-acetic acid (thecompound of formula (XXIV)); ¹H NMR (CDCl₃) δ 1.4 (s,9), 2.5-3.0 (m,5),3.94.2 (m,6), 4.5 (m,1), 7-25 (t,4), 7.32 (t,4), 7.48 (d,4), 7.75 (d,4).

In the cases in which 4-Boc-1-Fmoc-piperazine-2-acetic acid (thecompound of formula (XXIV)) was replaced by4-Boc-1-Fmoc-piperazine-2-carboxylic acid, the starting material wasprepared by dissolving 5.25 g (25.85 mmol) of 2-piperazine carboxylicacid-2HCl in 160 mL of 1:1 dioxane/H₂O, and adjusting the pH to 11 with50% NaOH (aq.). A solution of 7.21 g (29.28 mmol) of BOC-ON in 40 mL ofdioxane was slowly added (in portions) while maintaining the pH at 11with 50% NaOH (aq.) during the addition. The reaction was stirred atroom temperature for 5 hours, then cooled to 0° C and adjusted to pH 9.5with 50% NaOH (aq.). A solution of 7.34 g (28.37 mmol) of FMOC-CL in 40mL of dioxane was slowly added (in portions), maintaining a pH of 9.5during the addition with 50% NaOH (aq.). The mixture was warmed to roomtemperature, stirred for 20 hours, washed with ethyl ether (3×150 mL),adjusted to pH=2-3 with 6N HCl (aq.), and extracted with toluene (3×150mL). The combined extracts were dried over Na₂SO₄, concentrated in vacuoto a volume of 150 mL and chilled at −20° C overnight. The resultingsolids were filtered off, washed with hexane and dried in vacuo to give5.4 g of the desired 4-Boc-1-Fmoc-piperazine-2-carboxylic acid.

Alternatively, 4-Boc-morpholine-3-carboxylic acid, which can besubstituted for the compound of formula (XXIV) in Reaction Scheme 7above to prepare other compounds of the invention, can be prepared inthe following manner: To a solution of4-phenylmethylmorpholin-5-one-3-carboxylic acid methyl ester (5.1 g.20.5 mmol) in 100 mL of THF was added borane/DMS (10M, 2.6 mL) slowlywhile cooling at 0° C. The solution was allowed to warm to ambienttemperature and stirred for 18 hours. Water (100 mL) was then added andthe mixture extracted with ethyl acetate. The organic layers were driedover MgSO₄ and concentrated. The resulting oil was purified on a silicagel column eluted with 3:7 ethyl:hexanes to yield the morpholine (3.0 g,64%). The morpholine (3.0 g. 12.75 mmol) was dissolved in 50 mL MeOH and10% Pd/C (10 mg) was added. The mixture was stirred at-ambienttemperature under a H₂ atmosphere for 16 hours. The mixture was thenfiltered through celite and concentrated. The resulting oil wasdissolved in CH₂Cl₂ (25 mL) and di-t-butyldicarbonate (2.8 g, 12.75mmol) was added. After stirring for 4 hours, the mixture wasconcentrated and taken up in CH₂Cl₂ and washed with water, saturatedNaHCO₃, and brine. The organic layer was dried over MgSO₄ andconcentrated to yield 2.8 g (89%) of the ester. The ester was dissolvedin MeOH (30 mL) and NaOH (1.4 g, 35 mmol) was added. After stirring for4 hours at reflux, the solution was concentrated, acidified with 1 N HCland extracted with CH₂Cl₂. The organic layer was dried (MgSO₄) andconcentrated to yield 4-Boc-morpholine-3-carboxylic acid as a whitesolid (2.4 g, 90%). ¹H NMR (CDCl₃) δ 1.40 (m, 9). 3.20-350 (m, 2),3.70(m, 2), 3.90 (m, 1), 4.30-4.65 (m, 2).

1-Boc-perhydroazepine-2-acetic acid can also be substituted for thecompound of formula (XXIV) in Reaction Scheme 7 and can be prepared inthe following manner: N-Boc-perhydroazepine (1.06 g, 6.16 mmol) in etheris treated with TMEDA (715 mg, 6.16 mmol) followed by sec-butyllithium(1.3 M. 4.74 ml,

6.16 mmol) at −78° C. The reaction was slowly warmed to 40° C, stirredfor 1 hour, cooled to −78° C. and treated with a solution of3,3-dimethylallyl bromide (918 mg. 6.16 mmol) in ether. After warming toroom temperature and quenching with water, the organic layer is washedwith water, 1 M NaH₂PO₄, water, and brine. After drying (MgSO₄), thesolvent is removed and the product is purified by chromatography (silicagel, hexane:ethyl acetate 95:5), to yield the olefin (300 mg, 21%, ¹HNMR (CDCl₃) δ 5.05-5.20 (m, 1), 3.55-3.80 (m, 2), 2.60-2.75 (m, 1),1.90-2.20 (m, 3), 1.10-1.80 (m, 22). To a solution of NaIO₄ (2.17 g,10.2 mmol) and KMnO₄ (32 mg, 0.2 mmol) in 45 mL of water was added K₂CO₃(162 mg, 1.18 mmol) and the olefin (300 mg, 1.12 mmol) dissolved int-butanol (11 ml). After stirring for three days, the reaction wasacidified to pH 3 and extracted with ethyl acetate. The organic layerwas washed with water and brine, dried (MgSO₄), and the solvent wasremoved in vacuo to give 1-Boc-perhydroazepine-2-acetic acid (250 mg,87%): ¹H NMR (CDCl₃) δ 4.20-4.45 (m, 1), 3.55-3.80 (m, 1), 2.00-2.80 (m,4), 1.10-1.80 (m, 16).

4-Boc-morpholine-3-acetic acid can also be substituted for the compoundof formula (XXIV) in Reaction Scheme 7, and can be prepared in thefollowing manner from 4-benzylmorpholine-3-acetic acid ethyl ester(Brown, G. R; Foubister. A. J.; Stribling. D. J. Chem. Soc. PerkinTrans. 1 (1987), p. 547). After hydrogenolysis (Pd(OH)₂, H₂) of thebenzyl group, the N-Boc derivative is prepared by treatment withdi-t-butyldicarbonate and the ethyl ester is hydrolyzed by aqueous baseto provide 4-Boc-morpholine-3-acetic acid.

1-Boc-pyrrolidine-2-propionic acid can also be substituted for thecompound of formula (XXIV) in Reaction Scheme 7 and can be prepared inthe following manner: Boc-pyrrolidine (5.0 g, 29.2 mmol) was dissolvedin ether (35 ml) and TMEDA (3.0 g, 20 mmol), cooled to −78° C ands-butyllithium (1.3 M, 17 ml, 22 mmol) was added. After stirring for 1hour, allyl bromide (5.1 mL, 57 mmol) was added. After warming to roomtemperature, the reaction was quenched with water and the organic layerwas separated. The organic layer was dried (MgSO₄) and the solvent wasremoved in vacuo to give the olefin (2.9 g, 47%, ¹H NMR (CDCl₃) δ5.65-5.85 (m. 1), 5.00-5.20 (m, 2), 3.70-3.90 (m 1). 3.20-3.45 (m, 2).2.35-2.60 (M, 1). 2.00-2.20 (m, 1), 1.60-2.00 (m, 4), 1.45 (s, 9)). Tothe olefin (1.0 g, 4.7 mmol) in THF (20 mL) at 0° C was addedborane/THF. After warming to room temperature and stirring for 1 hour,H₂O₂ (30%, 14 mL) and 3N NaOH (3.2 mL) were added. The reaction waspartitioned with ethyl acetate and separated. The organic layer wasdried and concentrated in vacuo. The residue was added to NaIO₄ (1.2 g,5.4 mmol) and RuO₄ (10 mg, 0.08 mmol) in water (100 mL) and acetone (10mL). After stirring for 1 hour, the reaction was concentrated andextracted with CH₂Cl₂. The organic layer was extracted with 1 N NaOH.The aqueous layer was washed with CH₂Cl₂, made acidic with 1 N HCl, andextracted with CH₂Cl₂. The organic layer was dried (MgSO₄) andconcentrated to give 0.14 g (26%) of 1-Boc-pyrrolidine-2-propionic acid:¹H NMR (CDCl₃) δ 1.40 (m, 9), 1.60-2.00 (m, 6), 2.20 (m, 2). 2.40 (m,2), 3.30 (m. 2), 3.90 (m, 1).

4-Boc-thiomorpholine-3-carboxylic acid can also be substituted for thecompound of formula (XXIV) in Reaction Scheme 7 and can be prepared inthe following manner: To THF was added cysteine ethyl esterhydrochloride (1.15 g, 6.18 mmol), triethylamine (4.17 mL, 30 mmol) anddibromoethane (2.51 mL, 6.2 mmol). After stirring for 1 hour andrefluxing for 16 hours, the solids were removed by filtration. Thesolvent was removed in vacuo and the residue was chromatographed onsilica to give thiomorpholinecarboxylic acid ethyl ester (0.94 g, 87%).The ester (15.3 g, 95 mmol) was dissolved in dioxane/water (1/1) anddi-t-butyldicarbonate (24 g, 110 mmol) and LiOH were added. Afterstirring for 3 hours, the solvent was removed in vacuo and the pH wasadjusted to 3 with KHSO₃ and extracted with ethyl acetate. The organiclayer was separated, washed with brine, dried (MgSO₄), and the solventwas removed in vacuo to give 17.4 g (78%)4-Boc-thiomorpholine-3-carboxylic acid: ¹H NMR (CDCl₃) δ 1.45 (m, 9),2.45 (m, 1), 2.71 (m, 1). 2.93(m, 1), 3.10 (m. 1), 3.29 (m, 1), 4.11 (m,1), 4.19 (m, 1), 5.20 (m, 1). 4-Boc-thiomorpholine-3-acetic acid canalso be substituted for the compound of formula (XXIV) in ReactionScheme 7 and can be prepared in the following manner: To THF (50 mL) wasadded methyl bromocrotonate (1.0 mL, 8.6 mmol), Hünig's base (1.5 mL,8.6 mmol), and N-Boc-2-aminoethanethiol (1.5 g, 8.6 mmol). Afterstirring for 3 hours, the reaction was poured into saturated NH₄Cl andextracted with ethyl acetate. The organic layer was washed with brine,dried (MgSO₄), and the solvent was removed in vacuo. Chromatography(hexane/ethyl acetate, 6/1) gave N-Boc-2-aminoethanethiocrotonic acidmethyl ester. The ester was dissolved in CH₂Cl₂ (80 mL) and TFA (20 mL)was added. After stirring for 1 hour, the solvent was removed in vacuo.The residue was added to a solution of toluene and TEA (2.5 ml). Afterstirring for 16 hours, the solvent was removed in vacuo and the residuewas chromatographed to give the thiomorpholine. The ester (18.0 g, 95mmol) was dissolved in dioxane/water (1/1) and di-t-butyldicarbonate(19.6 g, 90 mmol) and LiOH were added. After stirring for 12 hours, thesolvent was removed in vacuo and the pH was adjusted to 3 with KHSO₃ andextracted with ethyl acetate. The organic layer was separated, washedwith brine, dried (MgSO₄), and the solvent was removed in vacuo to give20.3 g (86%) 4-Boc-thiomorpholine-3-acetic acid: ¹H NMR (CDCl₃) δ 1.45(m, 9), 2.45 (m, 1), 2.51 (m, 1), 2.68 (m, 1), 2.82 (m, 1), 3.05 (m. 4),4.24 (s, 1), 4.93 (s, 1).

4-Boc-thiomorpholine-2-acetic acid can also be substituted for thecompound of formula (XXIV) in Reaction Scheme 7 and can be prepared inthe following manner: To THF (100 mL) was added diethyl fumarate (3.27mL, 820 mmol), DBU (7.22 mL, 50 mmol), and aminoethanethiolhydrochloride (2.26 g, 20 mmol). After refluxing for 16 hours, thereaction was poured into saturated NaHCO₃, and extracted with ethylacetate. The organic layer was washed with brine, dried (MgSO₄), and thesolvent was removed in vacuo. Chromatography (ethyl acetate) gavethiomorpholinone (2.61 g, 70%). The ester was dissolved in THF (50 mL)and borane/DMS (3 mL, 30 mmol) was added. After stirring for 16 hours,ethanol was added to quench the reaction. HCl gas was bubbled into thereaction and the mixture was refluxed for 2 hours. The solvent wasremoved in vacuo and the residue was suspended in 0.5 M NaOH and CH₂Cl₂.The organic layer was separated, dried (Na₂SO₄), and the solvent wasremoved in vacuo. Chromatography on silica (MeOH/ethyl acetate) affordedstarting material (0.71 g, 29%) and the thiomorpholine (1.26 g, 56%).The ester (3.0 g, 11.4 mmol) was dissolved in dioxane/water (1/1) anddi-t-butyldicarbonate (2.29 g, 10.5 mmol) and LiOH were added. Afterstirring for 12 hours, the solvent was removed in vacuo and the pH wasadjusted to 3 with KHSO₄ and partitioned with ethyl acetate. The organiclayer was separated, washed with brine, dried (MgSO₄), and the solventwas removed in vacuo to give 2.20 g (81%) 4-Boc-thiomorpholine-2-aceticacid: ¹H NMR (CDCl₃) δ 1.44 (m, 9), 2.59 (m, 4), 3.17 (m, 1). 3.24.0 (m,4).

Reaction Scheme 7 depicts a synthesis in which a preformed, protectedcompound of formula (XXI) is coupled to the resin and deprotected toallow reaction with the protected compound of formula (XXIV). It will beapparent to the artisan that the sequence of this reaction series couldbe altered to provide the same deprotected piperonylamino-methyl benzoylresin. An example of such a sequence follows. This example alsoillustrates how one would reverse the substitution pattern in thepiperazineacetic acid ring.

4-Bromomethyl-3-nitrobenzoic acid (819 mg, 3.15 mmol) and HOBt (426 mg,3.15 mmol) were taken up in 15 mL of DMF, DIC (795 mg, 6.30 mmol) wasadded and the contents were stirred for 30 min at ambient temperature.The mixture was then added to the resin and shaken overnight. The resinwas filtered, washed and dried as before. The resin showed negativeninhydrin stain. The resin was taken in 15 mL of THF containingpiperonyl amine (1.51 g, 10 mmol), and shaken over the weekend. Theresin was filtered, washed and dried (1.507 g).N¹-Fmoc-N⁴-Boc-piperazine-2-acetic acid (978 mg, 2.1 mmol), HATU (798mg, 2.1 mmol) and DIEA (542 mg, 4.2 mmol) were mixed in 15 mL of DMF;and then added to the resin. After shaking for 24 hours, the resin wasfiltered, washed and dried as usual; the resin weighed 1.693 g. Theresin was taken in 15 mL of 30% v/v piperidine in DMF, and shaken for 2hours to cleave the Fmoc protecting group. After filtration, the resinwas subjected to the usual wash and dry cycle; the resin weighed 1.588g. The resin, acetic anhydride (591 mg, 5.8 mmol) and DIEA (748 mg, 5.8mmol) were taken in 15 mL of methylene chloride and shaken overnight toacetylate at N¹. After filtration, the resin was washed with methylenechloride and dried in a vacuum desiccator for 5 hours. The resin wasshaken with 15 mL of 1:1 TFA:methylene chloride for 1 hour to cleave thetBoc protecting group at N⁴. After filtration, the resin was washed withmethylene chloride (5×15 mL), followed by 20% triethyl amine inmethylene chloride (5×15 mL) and then again with methylene chloride (5×5mL). After drying, the resin weighed 1.294 g. 669 Mg of the resin fromthe previous step, DIEA (116 mg., 0.9 mmol) and4-chloro-2-(1-imidazolyl)-6-iso-propylpyrimidine (200 mg, 0.9 mmol) weretaken up in 6 mL of DMF and heated to 80° C for 24 hours. Afterfiltration the resin was washed (DMF, methanol and methylene chloride)and dried. A portion (377 mg) of the resin from the previous step wassuspended in methanol and photolyzed at 50° C for 6 hours. The solutionwas filtered, the solvent was removed and the residue was purified bychromatography (silica, methylene chloride:methanol, 95.5), yield 14 mg.¹H NMR and MS were consistent with the proposed structure.

The following compounds, shown in Table 1 through Table 7 arerepresentative of the compounds of the inventions and were synthesizedby the foregoing methods. All exhibited iNOS inhibitory activity atconcentrations less than 25 μM.

TABLE 1

Ex. # R²

R⁵ R⁶ R⁹ 1 —CH₂R⁹

H H

2 —CH₂R⁹

Cl Ac

3 —CH₂R⁹

H Boc

4 —CH₂R⁹

Cl Boc

5 —CH₂R⁹

F Boc

6 —CH₂R⁹

Cl H

7 —CH₂R⁹

Cl H

8 —CH₂R⁹

Cl H

9 —CH₂R⁹

Cl H

10 —(CH₂)₂—R⁹

Cl H

11 —CH₃

Cl H 12 —(CH₂)₃—R⁹

Cl H

13 —CH₃

Cl 29 —CH₂R⁹

H H

30 —CH₂R⁹

H H

34 —CH₂R⁹

Cl H

35 —(CH₂)₂—R⁹

Cl H

36 —CH₂R⁹

Cl H

52 —CH₂R⁹

H H

58 —CH₂R⁹

Cl Boc

59 —CH₃

Cl Boc 60 —CH₂R⁹

Cl Boc

76 —(CH₂)₂—R⁹

Cl —C(O)CH₂OCH₃

77 —(CH₂)₂—R⁹

H —C(O)O(CH₂)₃CH₃

78 —(CH₂)₂—R⁹

iPr

79 —(CH₂)₂—R⁹

H

80 —(CH₂)₂—R⁹

Cl Boc

81 —(CH₂)₂—R⁹

CH₃ Boc

82 —(CH₂)₂—R⁹

Cl Ac

83 —(CH₂)₂—R⁹

Cl —C(O)CH₂CH(CH₃)₂

84 —(CH₂)₂—R⁹

Cl H

85 —(CH₂)₂—R⁹

CH₃ H

86 —(CH₂)₂—R⁹

Cl Ac

87 —(CH₂)₂—R⁹

Cl —C(O)CH₂CH(CH₃)₂

88 —(CH₂)₂—R⁹

CH₃ Ac

89 —(CH₂)₂—R⁹

CH₃ —C(O)CH₂CH(CH₃)₂

90 —CH₂R⁹

Cl —C(O)OCH₃

91 —CH₂R⁹

Cl

92 —CH₂R⁹

Cl

93 —CH₂R⁹

Cl —S(O)₂NH(CH₃)

94 —CH₂R⁹

Cl

95 —CH₂R⁹

iPr —C(O)OCH₃

96 —CH₂R⁹

CH₃ —C(O)OCH₃

97 —CH₂R⁹

Cl —C(O)OCH₃

98 —CH₂R⁹

H —C(O)OCH₃

99 —CH₂R⁹

Cl —C(O)OCH₃

100 —CH₂R⁹

H —C(O)OCH₃

101 —CH₂R⁹

CF₃ Ac

102 —CH₂R⁹

iPr Ac

103 —CH₂R⁹

CH₃ —C(O)OC(CH₃)₃

104 —CH₂R⁹

iPr —C(O)OC(CH₃)₃

105 —CH₂R⁹

CF₃ Ac

106 —CH₂R⁹

iPr Ac

107 —CH₂R⁹

Et Ac

108 —CH₂R⁹

Cl

109 —CH₂R⁹

CH₃

110 —CH₂R⁹

iPr

111 —CH₂R⁹

Cl

112 —CH₂R⁹

CH₃

113 —CH₂R⁹

iPr

114 —(CH₂)₂—R⁹

Cl

115 —(CH₂)₂—R⁹

CH₃

116 —(CH₂)₂—R⁹

iPr

117 —CH₂R⁹

Cl

118 —CH₂R⁹

CH₃

119 —CH₂R⁹

iPr

120 —(CH₂)₂—R⁹

Cl

121 —(CH₂)₂—R⁹

CH₃

122 —(CH₂)₂—R⁹

iPr

TABLE 2

Ex. # R²

R⁵ R⁶ R⁹ 19 —CH₂—R⁹

Cl

42 —(CH₂)₂—R⁹

Cl

123 —(CH₂)₂—R⁹

Cl —C(O)CH₂CH(CH₃)₂

124 —(CH₂)₂—R⁹

Cl Boc

125 —(CH₂)₂—R⁹

Cl H

126 —(CH₂)₂—R⁹

Cl Ac

127 —(CH₂)₂—R⁹

Cl Ac

128 —(CH₂)₂—R⁹

Cl

129 —(CH₂)₂—R⁹

iPr

130 —(CH₂)₂—R⁹

Cl

131 —(CH₂)₂—R⁹

iPr

132 —(CH₂)₂—R⁹

Cl

133 —(CH₂)₂—R⁹

iPr

134 —(CH₂)₂—R⁹

Cl

135 —(CH₂)₂—R⁹

iPr

136 —CH₂—R⁹

CH₃

137 —CH₂—R⁹

iPr

138 —CH₂—R⁹

Cl

139 —CH₂—R⁹

CH₃

140 —CH₂—R⁹

Et

141 —CH₂—R⁹

iPr

142 —CH₂—R⁹

Cl

143 —(CH₂)₂—R⁹

CH₃

144 —(CH₂)₂—R⁹

Et

145 —(CH₂)₂—R⁹

iPr

146 —(CH₂)₂—R⁹

Cl

TABLE 3

Ex. # R² R⁴ R⁵ Q—R³ R⁹ or R¹⁰ (from R²) m n p AA 14 —CH₂R⁹ H Cl —SCH₃

2 0 0 D-Met 15 —CH₂R⁹ H Cl —SCH₃

2 0 0 D-Met 16 —(CH₂)₂R⁹ H Cl

1 0 0 [D] 17 —(CH₂)₃CH₃ H Cl

1 0 0 [D] 18 —CH₂R⁹ H Cl H

0 2 2 Acp 20 —(CH₂)₂R⁹ H Cl H

0 0 0 Gly 21 —CH₂R⁹ H Cl —OH

1 0 0 D,L-Ser 22 —CH₂R⁹ CH₃ Cl H

0 0 0 Sar 23 —CH₂R⁹ H Cl —CONH₂

2 0 0 L-Gln 24 —(CH₂)₂R⁹ H Cl H

1 0 0 D,L-Ala 25 —CH₂R⁹ H Cl —CONH₂

2 0 0 D-Gln 26 —CH₂R⁹ H Cl

3 0 0 L-Arg (NO₂) 27 —(CH₂)₂R⁹ H Cl —CONH₂

2 0 0 D-Gln 28 —CH₂R⁹ H Cl —NH₂

3 0 0 D,L-Orn 31 —(CH₂)₃R⁹ H H

1 0 0 [D] 32 —CH₂R⁹ H H —CONH₂

2 0 0 L-Gln 37 —CH₂R⁹ H Cl —SCH₃

2 0 0 D-Met 38 —CH₃ H Cl —SCH₃ 2 0 0 D-Met 39 —(CH₂)₃R¹⁰ H Cl —StBu—SCH₃ 1 0 0 L-Cys 40 —(CH₂)₃R⁹ H Cl —StBu phenyl 1 0 0 D-Cys 41 —CH₂R⁹ HCl

1 0 0 [D] 43 —CH₂R⁹ H Cl —CONH₂

2 0 0 D-Gln 44 —CH₂R⁹ H Cl —CONH₂

2 0 0 L-Gln 45 —CH₂R⁹ H Cl

3 0 0 L-Arg (NO₂) 46 —CH₂R⁹ H Cl

3 0 0 D-Arg 48 —(CH₂)₃CH₃ H Cl —NH₂ 3 0 0 D,L-Orn 49 —(CH₂)₂R¹⁰ H Cl—COOH —COOH 1 0 0 D,L-Asp 50 —(CH₂)₃R⁹ H Cl phenyl —S(O)₂CH₃ 1 0 0D,L-Phe 51 —CH₂R⁹ CH₃ Cl H

0 0 0 Sar 53 —CH₂R⁹ H H —OH

1 0 0 D,L-Ser 54 —CH₂R⁹ H H

3 0 0 L-Arg (NO₂) 56 —(CH₂)₂R⁹ H Cl

1 0 0 [L] 57 —CH₂R⁹ H Cl

1 0 0 [L] 61 —(CH₂)₂R⁹ CH₃ Cl H

0 0 0 Sar 62 —(CH₂)₂R⁹ H Cl H

1 0 0 D-Ala 64 —(CH₂)₃R⁹ H Cl

1 0 0 [D] 65 —(CH₂)₄R⁹ H Cl

1 0 0 [D] 66 —(CH₂)₂R⁹ H H

1 0 0 [D] 67 —(CH₂)₃R⁹ H H

1 0 0 [D] 68 —CH₂R⁹ H Cl —SCH₃

2 0 0 L-Met 69 —CH₂R⁹ H Cl —NHTrt

2 0 0 N^(γ)-trityl L-Gln 70 —CH₂R⁹ H Cl —NHTrt

2 0 0 N^(γ)-trityl D-Gln

TABLE 4

R⁹ or R¹⁰ Ex # R² R⁴ R⁵ Q-R³ (from R²) m n p AA 71 —(CH₂)₂R⁹ H Cl H

1 0 0 D-Ala 72 —(CH₂)₃R⁹ H Cl

1 0 0 [D] 73 —(CH₂)₄R⁹ H Cl

1 0 0 [D] 74 —CH₂R⁹ CH₃ Cl H

0 0 0 Sar

TABLE 5

Ex. # R² R⁴ R⁵ Q—R³ R⁹ or R¹⁰ (from R²) m n p AA 75 —(CH₂)₂R⁹ H Cl H

1 0 0 D-Ala 63 —(CH₂)₂R⁹ H H H

1 0 0 D-Ala

TABLE 6 Physical Data for Compounds of the Invention Ex.# Formula FABMSDefinitive ¹H NMR (ppm) 1 C₂₁H₂₄N₇O 392 9.6(1H), 8.3(1H), 8.2(1H)6.9-7.5(6H), 2.2(3H) 2 C₂₃H₂₆ClN₇O 468 8.5(1H), 7.6- 7.8(1H)6.9- 7.2 (6H),2.3(3H), 2.1(3H) 3 C₂₆H₃₂N₇O₃ 492 8.5(1H), 8.2(1H), 7.8(1H), 7.0- 7.2(5H), 6.6(1H), 2.3(3H), 1.5(9H) 4 C₂₆H₃₂ClN₇O₃ 526 8.5(1H), 7.8(1H),7.0- 7.2(6H), 2.3 (3H), 1.5(9H) 5 C₂₆H₃₂FN₇O₃ 510 8.5(1H), 7.8(1H), 7.0-7.2 (6H), 2.3(3H), 1.5(9H) 6 C₂₁H₂₂ClN₇O₃ 456 ND 7 C₂₁H₂₄ClN₇O ND9.6(1H), 8.3(1H), 8.2(1H), 6.9- 7.5 (6H) 9 C₂₀H₂₁Cl₂N₇O 446 9.6(1H),8.1(1H), 7.4(1H), 7.0(4H), 6.9(1H) 11 C₁₄H₁₈ClN₇O 336 9.7(1H), 8.2(1H),7.5(1H), 6.9 (1H), 2.6(3H) 14 C₂₀H₂₁ClN₆O₃S 461 2.0(SCH₃) 16C₂₃H₂₃ClN₆O₃S ND 2.65(m,2H), 3.36(m,2H), 3.55(m, 2H), 3.79(s,3H),3.80(m,2H), 3.83 (s,3H), 4.77(m,1H), 6:30(s,1H), 6.32 (bs,1H), 6.55-6.95(m,5H), 7.08(s, 1H), 7.18(d,1H), 7.78(s,1H), 8.45(s, 1H). 18C₂₁H₂₃ClN₆O₃ 443 8.4(1H), 7.8(1H), 7.2(1H), 7.0(1H), 6.7(2H),5.9(1H)4.2(2H), 2.2(2H) 22 C₁₈H₁₇ClN₆O₃ ND 3.2(s,3H), 4.25(s,2H),4.38(s,2H), 5.88(s,2H), 6.30(brs,1H), 6.42(bs, 2H), 6.65(m,3H),7.05(s,1H), 8.40 (s,1H). 56 C₂₄H₂₅ClN₆O₃S ND 8.5(1H), 7.8(1H), 7.2(1H),7.1(1H), 3.9(6H) 57 C₂₂H₁₉ClN₆O₃S ND 8.5(1H), 7.8(1H), 7.2(1H), 7.1(1H),4.3(2H) 58 C₂₅H₂₉Cl₂N₇O₃ 546 8.5(1H), 7.8(1H), 7.2- 7.4(5H), 6.6(1H),1.4(9H) 59 C₁₉H₂₆ClN₇O₃ 436 8.5(1H), 7.8(1H), 7.1(1H), 6.6 (2H), 1.5(9H)60 C₂₆H₃₀ClN₇O₅ 556 8.5(1H), 7.8(1H), 7.1(1H), 6.7(4H), 5.9(2H), 1.5(9H)61 C₁₉H₂₀N₆O₃ ND 3.22(s,3H), 4.24(bs,2H), 4.32(d,2H), 5.92(s,2H),6.30(bs,1H), 6.47(d, 1H), 6.65(m,3H), 7.04(s,1H), 7.68 (s,1H),7.95(d,1H), 8.41(s,1H). 62 C₂₀H₂₃ClN₆O₃ ND 1.48(d,3H), 2.78(m,2H),3.58(2H,m), 3.80(6H,s), 4.60(1H,m), 5.9- 6.25 (3H,m), 6.55- 6.8(3H,m),7.12 (1H,s), 7.78(1H,s), 8.44(1H,s). 63 C₂₀H₂₄N₆O₃ ND 1.40(d,3H) 64C₂₄H₂₅ClN₆O₃S ND 1.75(m,2H), 2.50(m,2H), 3.2- 3.5(m, 4H), 3.82(s,6H),4.78(m,1H), 6.21 (m,1H), 6.36(m,2H), 6.60- 6.95(m, 5H), 7.10(s,1H),7.21(d,1H), 7.80(s, 1H), 8.53(s,1H). 65 C₂₅H₂₇ClN₆O₃S ND 1.47(m,4H),2.52(m,2H), 3.2- 3.45 (m,4H), 3.83(s,6H), 4.78(m,1H),6.08(m,1H)6.17(m,2H), 6.64(m,2H), 6.77(m,3H), 7.13(s,1H), 7.19(d,1H),7.80(s,1H), 8.51(s,1H). 66 C₂₃H₂₄N₆O₃S ND 3.35- 3.6(m), 3.83(s,6H),4.62(m, 1H), 5.75(m,1H), 6.18(m,1H), 6.50- 6.95(m,7H), 7.17(s,1H),7.19(s,1H), 7.57(s,1H), 8.27(s,1H). 67 C₂₄H₂₆N₆O₃S ND 1.70(m,2H),2.48(m,2H), 3.1- 3.5 (m,4H), 3.82(s,6H), 4.77(s,1H), 5.90 (d,1H),6.03(m,1H), 6.29(d,1H), 6.60 (m,1H), 6.61(s,1H), 6.75- 6.95(m, 3H),7.12(s,1H), 7.20(d,1H), 7.82(s, 1H), 8.14(d,1H), 8.57(s,1H). 68C₂₀H₂₁ClN₆O₃S 461 2.0(SCH₃) 69 C₃₉H₃₄ClN₇O₄ 700 8.4(1H), 7.6(1H), 6.8-7.5(16H), 6.5 (3H), 5.8- 5.9(3H) 70 C₃₉H₃₄ClN₇O₄ 700 8.4(1H), 7.6(1H),6.8- 7.5 (16H), 6.5(3H), 5.8- 5.9(3H) 71 C₂₀H₂₃ClN₆O₃ ND 1.43(d,3H),2.79(m,2H), 3.57(m,2H), 3.80(s,3H), 3.82(s,3H), 4.60(m,1H), 5.95-6.20(m,3H), 6.60- 6.80(m, 3H), 7.18(s,1H), 7.51(s,1H), 8.28 (s,1H). 72C₂₄H₂₅ClN₆O₃S ND 1.75(m,2H), 2.50(m,2H), 3.2- 3.5 (4H), 3.82(s,6H),4.78(m,1H), 5.85 (m,1H), 6.10- 6.25(m,2H), 6.6- 7.0 (m,3H), 6.8-7.0(m,2H), 7.57(s,1H), 8.38(s,1H). 73 C₂₅H₂₇ClN₆O₃S ND 1.47(m,4H),2.52(m,2H), 3.2- 3.45 (m,4H), 3.83 (s,6H), 4.78(m,1H), 5.80(m,1H),6.22(m,2H), 6.63- 6.95 (m,5H), 7.20(m,2H), 7.50(s,1H), 8.33(m,1H). 74C₁₈H₁₇ClN₆O₃ ND 3.22(s,3H), 4.24(s,2H), 4.37(d,2H), 5.96(s,2H),6.29(s,1H), 6.76(s,2H), 7.17(s,1H), 7.56(s,1H), 8.37(s,1H). 75C₂₀H₂₃ClN₆O₃ ND 1.43(d,3H), 2.80(m,2H), 3.57(m,2H), 3.80(s,3H),3.82(s,3H), 4.60(m,1H), 6.20(m,1H), 6.4- 6.5(m,2H), 6.60- 6.80(m,3H),7.18(s,1H), 7.51(s,1H), 8.28(s,1H). 76 C₂₅H₂₈ClN₇O₅ 542 8.5(1H),7.8(1H), 7.1(1H), 6.4- 6.8 (3H), 5.9(2H), 3.4(3H) 77 C₂₇H₃₃N₇O₅ 5368.5(1H), 8.2(1H), 7.8(1H), 7.1(1H), 5.9(2H) 78 C₃₀H₃₇N₇O₅ 576 8.5(1H),7.8(1H), 7.1(1H), 6.4(3H), 5.9(2H), 1.3(6H) 79 C₂₉H₃₆N₈O₄ 561 8.5(1H),8.2(1H), 7.8(1H), 7.1(1H), 5.9(2H) 80 C₂₈H₃₆ClN₇O₅ 586 8.5(1H), 7.8(1H),6.7- 6.8(4H), 3.8 (6H), 1.5(9H) 81 C₂₉H₃₉N₇O₅ 566 8.5(1H), 7.8(1H),7.1(1H), 6.6- 6.8 (4H), 3.8(6H), 2.4(3H), 1.4(9H) 82 C₂₅H₃₀ClN₇O₄ 5288.5(1H), 7.8(1H), 7.1(1H), 6.6- 6.8 (4H), 3.8(6H), 2.2(3H) 83C₂₈H₃₆ClN₇O₄ 570 ND 84 C₂₃H₂₈ClN₇O₃ 486 9.5(1H), 8.0(1H), 3.9(6H) 85C₂₄H₃₁N₇O₃ 466 9.6(1H), 8.1(1H), 2.4(3H) 86 C₂₅H₃₀ClN₇O₄ 528 8.5(1H),7.8(1H), 7.1(1H), 3.9(6H), 2.2(3H) 87 C₂₈H₃₆ClN₇O₄ 570 8.5(1H), 7.8(1H),7.1(1H), 3.9(6H), 1.0(6H) 88 C₂₆H₃₃N₇₄ 508 8.5(1H), 7.8(1H), 7.1(1H),3.9(6H), 2.4(3H), 2.2(3H) 89 C₂₉H₃₉N₇O₄ 550 8.5(1H), 7.8(1H), 7.1(1H),3.9(6H), 2.4(3H), 1.0(6H) 90 C₂₃H₂₄ClN₇O₅ 514 8.5(1HO,7.8(1H), 7.1(1H),6.4- 6.8 (4H), 5.9(2H), 3.7(3H) 91 C₂₉H₂₉ClN₈O₅ 605 8.4(1H), 7.6(1H),7.2(1H), 6.9(1H), 6.5- 6.8(5H), 5.8(2H), 3.7(3H) 92 C₂₉H₃₀ClN₇)₄ 5768.4(1H), 7.7(1H), 7.0(1H), 5.8(2H), 3.7(3H) 93 C₂₃H₃₇ClN₈O₅S 5638.5(1H), 7.8(1H), 7.5(3H), 7.1(1H), 5.9(2H), 2.8(6H) 94 C₂₈H₂₅Cl₂N₁₁O₃634 8.5(1H), 8.3(1H), 7.8(1H), 7.5(1H), 7.0(2H), 6.6- 6.8(3H), 6.4(2H),5.9(2H) 95 C₂₆H₃₁N₇O₅ 522 8.6(1H), 7.8(1H), 7.1(1H), 6.6- 6.8 (2-3H),5.9(2H), 3.7(3H), 1.2(6H) 96 C₂₆H₃₁N₇O₅ 494 8.6(1H), 7.8(1H), 7.1(1H),5.9(2H), 3.7(3H), 2.4(3H) 97 C₂₃H₂₄ClN₇O₅ 514 8.5(1H), 7.8(1H), 5.9(2H),3.8(3H) 98 C₂₃H₂₅N₇O₅ 480 8.6(1H), 8.2(1H), 7.8(1H), 5.9(2H), 3.7(3H) 99C₂₂H₂₃Cl₂N₇O₃ 504 8.4(1H), 7.7(1H), 7.0- 7.3(6H), 3.7(3H) 100C₂₂H₂₄ClNO₃ 470 8.5(1H), 8.1(1H), 7.8(1H), 7.1- 7.3 (6H), 3.8(3H) 101C₂₄H₂₄F₃N₇04 532 8.4(1H), 7.6(1H), 7.2(1H), 5.9(2H), 2.3(3H) 102C₂₆H₃₁N₇O₄ 506 8.5(1H), 7.8(1H), 7.1(1HO,5.9(2H), 2.3(3H), 1.3(6H) 103C₂₇H₃₃N₇O₅ 536 8.45(1H), 7.85(1H), 7.1(1H), 5.9 (2H), 2.4(3H), 1.4(9H)104 C₂₉H₃₇N₇O₅ 564 8.35(1H), 7.7(1H), 7.1(1H), 5.9(2H), 1.4(9H),1.25(6H) 105 C₂₄H₂₄F₃N₇O₄ 532 8.4(1H), 7.6(1H), 7.1(1H), 5.9(2H),2.2(3H) 106 C₂₆H₃₁N₇O₄ 506 8.5(1H), 7.8(1H), 7.05(1H), 5.9(2H), 1.25(6H)107 C₂₅H₂₉N₇O₄ 492 8.5(1H), 7.8(1H), 5.9(2H), 2.65(2H), 1.3(3H) 108C₂₁H₂₁ClN₆O₄ 457 8.5(1H), 7.8(1H), 7.1(1H), 6.8(3H), 6.4(1H), 5.9(2H),4.4(2H) 109 C₂₂H₂₄N₆O₄ 8.5(1H), 7.8(1H), 7.1(1H), 6.8(3H), 6.2(1H),5.9(2H), 4.4(2H), 2.4(3H) 110 C₂₄H₂₈N₆O₄ 465 8.5(1H), 7.8(1H), 7.1(1H),6.8(3H), 6.2(1H), 5.9(2H), 4.4(2H), 1.2(6H) 111 C₂₁H₂₁ClN₆O₃S 473.38.48(s,1H), 7.76(s,1H), 7.10(s,1H), 6.60(m,3H), 5.88(m,3H), 4.32(m, 2H),2.6- 3.1(m,6H). 112 C₂₂H₂₄N₆O₃S 453.3 8.45(s,1H), 7.79(s,1H),7.07(s,1H), 6.60(m,3H), 6.40(bs,1H), 6.10(m, 1H), 5.90(s,2H),4.30(d,2H), 2.5- 3.1(m,6H), 3.40(s,3H). 113 C₂₄H₂₈N₆O₃S 8.5(s,1H),7.8(s,1H), 7.03(s,1H), 6.60(m,3H), 6.37(bs,1H), 6.10(bs, 1H),5.83(s,2H), 4.28(m,2H), 2.45- 3.1(7H),1.24(d,6H). 114 C₂₂H₂₃ClN₅O₃S487.3 8.40(s,1H), 7.68(s,1H), 7.03(s,1H), 6.76(s,1H), 6.70(s,2H),6.53(bs,1H), 6.45(bs,1H), 5.93(s,2H), 4.40(m,4H), 3.6(m,2H), 3.35(m,2H),3.00(m,2H), 2.6- 2.9(m,4H). 115 C₂₃H₂₆N₆O₃S 467.5 8.44(s,1H), 7.7(s,1H),7.05(s,1H), 6.77(s,1H), 6.77(s,1H), 6.71(s,H), 6.50(bs,1H), 6.28(s,1H),5.95(s,1H), 5.92(s,2H), 4.40(m,4H), 3.58(m,2H), 3.30(m,2H), 2.6-3.05(m,6H), 2.40(s, 3H). 116 C₂₅H₃₀N₆O₃S 495.4 8.45(s,1H), 7.77(s,1H),7.06(s,1H), 6.86(s,1H), 6.70(s,2H), 6.55(bs,1H), 6.28(s,1H), 5.90(s,2H),4.41(d,2H), 3.58(m,2H), 3.38(m,2H), 2.6- 3.0 (m,7H), 1.25(d,6H). 117C₂₁H₂₁ClN₆O₃S 473.4 8.41(s,1H), 7.78(s,1H), 7.03(s,1H), 6.75(m,2H),6.43(s,1H), 6.30(bs,1H), 4.2- 4.5(bs,4H), 3.76(m,2H), 3.4(m, 1H), 2.4-2.8(m;4H). 118 C₂₂H₂₄N₆O₃S 453.4 8.58(1H), 7.82(s,1H), 7.10(s,1H), 6.6-6.8(m,4H), 6.30(s,1H), 5.92(m, 2H), 6.76(m,1H), 4.25- 4.45(m,4H),3.76(m,3H), 3.4(m,1H), 2.4- 2.8(7H), 2.4(s,3H). 119 C₂₄H₂₈N₆O₃S 481.48.47(s,1H), 7.82(s,1H), 7.08(s,1H), 6.71(m,2H), 6.30(s,1H), 6.03(m,1H),5.90(s,2H), 4.22- 4.44(m,4H), 3.75 (m,2H), 3.4(m,1H). 120 C₂₂H₂₃ClN₆O₃S487.4 8.42(s,1H), 7.77(s,1H), 7.03(s,1H), 6.6- 6.75(m,3H), 6.42(s,1H),6.02(bs, 1H), 5.90(s,2H), 3.30- 3.9(m,6H), 2.75(m,4H), 2.40(m,2H). 121C₂₃H₂₆N₆O₃S 467.5 8.57(s,1H), 7.81(s,1H), 7.10(s,1H), 6.57- 6.75(m,3H),6.30(s,1H), 5.95(s, 2H), 5.47(m,1H), 4.37(m,4H), 3.25- 3.8(m,5H),2.77(m,4H), 2.40(s,3H). 122 C₂₃H₃₀N₆O₃S 495.5 8.55(s,1H), 7.82(s,1H),7.08(s,1H), 6.58- 6.76(m,3H), 6.30(s,1H), 5.90 (s,2H), 5.60(m,1H),4.37(m,2H), 3.28- 3.8(m,5H), 2.6- 2.9(m,5H), 2.40(m,2H), 1.23(d,6H). 123C₂₇H₃₄ClN₇O₄ 556 ND 124 C₂₇H₃₄ClN₇O₅ 572 8.4(1H), 7.7(1H), 7.1(1H),6.4(1H), 6.5- 6.8(3H), 3.9(6H), 1.5(9H) 125 C₂₂H₂₆ClN₇O₃ 472 9.0(1H),7.9(1H), 7.2(1H), 6.4- 6.8(4H) 126 C₂₄H₂₈ClN₇O₄ 514 8.4(1H), 7.7(1H),7.1(1H), 6.4- 6.8(4H), 2.1(3H) 127 C₄H₂₈ClN₇O₄ 514 8.5(1H), 7.8(1H),7.1(1H), 6.4- 6.8(4H), 3.8(6H) 128 C₂₂H₂₅ClN₆O₄ 473.13 8.5(1H), 7.7(1H),7.1(1H), 6.4(1H), 3.8(6H) 129 C₂₅H₃₂N₆O₄ 481.26 8.5(1H), 7.8(1H),7.1(1H), 6.2(1H), 1.3(6H) 130 C₂₁H₂₁ClN₆O₄ 457.17 8.4(1H), 7.7(1H),7.1(1H), 6.4(1H), 5.9(1H) 131 C₂₄H₂₈N₆O₄ 465 8.5(1H), 7.8(1H), 7.1(1H),6.2(1H), 5.9(2H), 1.2(6H) 132 C₂₂H₂₅ClN₆O₄ 473.13 8.5(1H), 7.8(1H),7.1(1H), 6.5(1H), 3.8(6H) 133 C₂₅H₃₂N₆O₄ 480.63 8.5(1H), 7.8(1H),7.1(1H), 6.3(1H), 3.9(6H), 1.2(6H) 134 C₂₁H₂₁ClN₆O₄ 457.17 8.5(1H),7.8(1H), 7.1(1H), 6.5(1H), 5.9(2H) 135 C₂₄H₂₈N₆O₄ 465 8.6(1H), 7.8(1H),7.1(1H), 6.3(1H), 5.9(2H), 1.2(6H) 136 C₂₃H₂₅N₇O₄ 464 8.4(1H), 7.6(1H),6.95(1H), 5.9(2H), 2.35(3H), 2.0(3H) 137 C₂₅H₂₉N₇O₄ 492 8.4(1H),7.6(1H), 6.95(1H), 5.9(2H), 2.0(3H), 1.25(6H) 138 C₂₂H₂₂ClN₇O₄ 4848.4(1H), 7.6(1H), 7.0(1H), 5.9(2H), 2.0(3H) 139 C₂₁H₂₂N₆O₃ 407 8.4(1H),7.7(1H), 7.05(1H), 5.9(2H) 140 C₂₂H₂₄N₆O₃ 421 8.4(1H), 7.7(1H),7.05(1H), 5.9(2H), 2.6(2H), 1.3(3H) 141 C₂₃H₂₆N₆O₃ 435 8.4(1H), 7.7(1H),7.05(1H), 5.9(2H), 1.3(6H) 142 C₂₀H₁₉ClN₆O₃ 427 8.4(1H), 7.6(1H),6.6(2H), 5.9(2H) 143 C₂₂H₂₄N₆O₃ 421 8.45(1H), 7.7(1H), 7.05(1H), 5.9(2H)144 C₂₃H₂₆N₆O₃ 435 8.45(1H), 7.7(1H), 7.05(1H), 5.9 (2H), 2.65(2H),1.3(3H) 145 C₂₄H₂₈N₆O₃ 449 8.45(1H), 7.7(1H), 7.05(1H), 5.9(2H), 1.3(6H)146 C₂₁H₂₁ClN₆O₃ 441 8.45(1H), 7.7(1H), 7.05(1H), 5.9(2H)

TABLE 7 Linker Groups (L) Linker Group (-L-) Cleavage Reagent

Light

Light

Light

Ce(NH₄)₂(NO₃)₆

Li, Mg, or BuLi

H₃O⁺

H₃O⁺

1) O₂ or Br₂, MeOH 2) H₃O⁺

O₃, OsO₄/IO₄ ⁻, or KMnO₄

O₃, OsO₄/IO₄ ⁻, or KMnO₄

O₃, OsO₄/IO₄ ⁻, or KMnO₄

(Ph₃)PRhCl (H)

Hg⁺²

Zn or Mg

Oxidation, e.g., Pb(OAc)₄ or H₅IO₆

In addition to the compounds specifically named in the PreferredEmbodiments, the following compounds were made by the methods disclosedherein:

2-[[2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-hydroxy-N-[(1,3-benzodioxol-5-yl)methyl]propanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-carboxy-N-(2-carboxyethyl)propanamide;

2-[[2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-(thiophen-2-yl)-N-[3-(morpholin-4-yl)propyl]propanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-[(1,1-dimethylethyl)thio]-N-[3-(methylthio)propyl]propanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-[(1,1-dimethylethyl)thio]-N-[3-(phenyl)propyl]propanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-[(1,1-dimethylethyl)thio]-N-[2-(3,4-dimethoxyphenyl)ethyl]propanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[2-(3,4-dimethoxyphenyl)ethyl-propanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-hydroxy-N-[(1,3-benzodioxol-5-yl)methyl]propanamide;

2-[[6-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-hydroxy-N-[(1,3-benzodioxol-5-yl)methyl]propanamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-3-[(3,4-dimethylphenyl)methylthio]-N-[(cyclopropyl)methyl]propanamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-3-[(3,4-dimethylphenyl)methylthio]-N-[(cyclopropyl)methyl]propanamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-3-(thiophen-2-yl)-N-[(4-chlorophenyl)methyl]propanamide;

3-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]propanamide;

3-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(4-trifluoromethylphenyl)methyl]propanamide;

3-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]propanamide;

3-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino]-N-[(6-methoxypyridin-2-yl)methyl]propanamide;

3-[[2-(1H-imidazol-1-yl)-4-methylpyrimidin-4-yl](methyl)amino]-N-[(3,5-dimethoxyphenyl)methyl]propanamide;

3-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino]-N-[(pyridin-2-yl)methyl]propanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-3-(methylthio)-N-[(1,3-benzodioxol-5-yl)methyl]butanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-4-(methylthio)-N-[(4-methoxyphenyl)methyl]butanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-4-(methylthio)-N-[2-(3,4-dimethoxyphenyl)ethyl]butanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-4-methylthio)-N-(methyl)butanamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-methylthiobutanamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(4-methoxyphenyl)methyl]-4-methylsulfonylbutanamide;

2-[[2-(1H-imidazol-1-yl)-4-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(butylthio)butanamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]-4-methylthiobutanamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(2,5-dimethoxyphenyl)methyl]-3-methyl-3-[(phenylmethyl)thio]butanamide;

4-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[2-(1,3-benzodioxol-5-yl)ethyl]butanamide;

4-[[2-(1H-imidazol-1-yl)-methylpyrimidin-4-yl](methyl)amino]-N-[(1,3-benzodioxol-5-yl)methyl]butanamide;

4-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl](methyl)amino]-N-[(phenoxy)carbonylmethyl]butanamide;

2-[[2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]pentane-1,5-diamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-(4-methoxyphenyl)methyl]pentane-1,5-diamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[2-(3,4-dimethoxyphenyl)ethyl]pentane-1,5-diamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]pentane-1,5-diamide;

2-[[6-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]pentane-1,5-diamide;

2-[[2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-5-[[amino(nitroimino)methyl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]pentanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-5-[[amino(nitroimino)methyl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]pentanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(4-methoxyphenyl)methyl]-5-[[imino(amino)methyl]amino]pentanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(4-methoxyphenyl)methyl]-5-[[imino(nitroamino)methyl]amino]pentanamide;

2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-5-[[amino(imino)methyl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]pentanamide;

6-amino-2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[2-(3,4-dimethoxyphenyl)ethyl]hexanamide;

6-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]hexanamide;

5-amino-2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]pentanamide;

5-amino-2-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-butyl-pentanamide;

2-[[6-(1H-imidazol-1-yl)pyrimidin-1-yl]amino]-4-methyl-N-[(1,3-benzodioxol-5-yl)methyl]pentanamide;

2-[[6-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-4-methyl-N-[2-(3,4-dimethoxyphenyl)ethyl]pentanamide;

5-[[amino(imino)methyl]amino]-6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(phenylmethyl)pentanamide;

5-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]pentanamide;

5-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(1,4-benzodioxan-6-yl)ethyl]pentanamide;and

7-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-(2-phenylcyclopropyl)heptanamide;

α-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-thiophenepropanamide;

α-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-(butyl)-2-thiophenepropanamide;

α-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[(1,3-benzodioxol-5-yl)methyl]-2-thiophenepropanamide;

N-[(1,3-benzodioxol-5-yl)methyl]-α-[[6-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]benzenepropanamide;

α-[[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-N-[3-(methylsulfonyl)propyl]benzene-propanamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-α-[[6-(1H-imidazol-1-yl)pyrimidin-4-yl]amino]-2-thiophenepropanamide;

N-[(1,3-benzodioxol-5-oxy)ethyl]-2-(1H-imidazol-1-yl)pyrimidine-4-amine;

2-(1H-imidazol-1-yl)-6-fluoro-4-[[(3,4-dimethoxyphenyl)ethyl]amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-fluoro-4-[[(phenyl)ethyl]amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(1,3-benzodioxol-5-yl)methylcarbonyl]-aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[2-(1,3-benzodioxol-5-yl)ethylcarbonyl]-aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(1,3-benzodioxol-5-yl)methyl]aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(1,4-benzodioxan-4-yl)methyl]aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(6-methoxynaphthyl)methyl]aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(3,5-dimethylphenyl)methyl]aminopropyl]methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(3,5-dimethoxyphenyl)methyl-aminopropyl]-methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[[3-(dimethylamino)phenyl]methyl]aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(3-methoxyphenyl)methyl]aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(n-undecanyl)amino]propyl](methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-(1-methylethyl)-4-[[3-[2-(3-ethoxyphenyl)ethyl]aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-4-[[3-[(pyridin-1-yl)methyl]aminopropyl](methyl)amino]pyrimidine;10997

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(6-methoxypyridin-1-yl)methyl]aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-(1-methylethyl)-4-[[3-[(pyridin-2-yl)methyl]aminopropyl]-(methyl)amino]pyrimidine;

2-(1H-imidazol-1-yl)-6-methyl-4-[[3-[(6-methylpyridin-2-yl)methyl]aminopropyl]-(methyl)amino]pyrimidine;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-6-chloro-2-(1H-imidazol-1-yl)pyrimidine-4-propionamide;

N-[(1,3-benzodioxol-5-yl)methyl]-2-(1H-imidazol-1-yl)pyrimidine-4-propionamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-2-(1H-imidazol-1-yl)pyrimidine-4-propionamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-2-[(2-(1H-imidazol-1-yl)pyrimidin-4-yl)oxy]acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-2-[(2-(1H-imidazol-1-yl)pyrimidin-4-yl)thio]acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)-methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[phenylmethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[3-phenylpropyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-phenylethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(thiophene-2-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(methyl)piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1,4-bis[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-[[(phenyl)amino]carbonyl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-[(methoxy)carbonyl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-1-methylpiperazine-2-acetamide;

4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-1-methylpiperazine-2-acetamide;

N-[(3-chloro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-1-methylpiperazine-2-acetamide;

4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-1-methylpiperazine-2-acetamide;

4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(3,4,5-trimethoxyphenyl)methyl]-1-methylpiperazine-2-acetamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl-1-methylpiperazine-2-acetamide;

1-butyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(furan-2-yl)methyl]piperazine-2-carboxamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-butyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-butyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(2,3-dimethoxyphenyl)methyl]-1-butyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-1-[(4-methyoxyphenyl)methyl]lpiperazine-2-acetamide;

4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-1-[(4-methyoxyphenyl)methyl]piperazine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-1-[(4-methyoxyphenyl)ethyl]lpiperazine-2-acetamide;

4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-1-[(4-methyoxyphenyl)methyl]lpiperazine-2-carboxamide;

4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl-1-[(4-methyoxyphenyl)methyl]piperazine-2-acetamide;

4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-1-[(4-methyoxyphenyl)methyl]piperazine-2-acetamide;

4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-1-[(4-methyoxyphenyl)methyl]piperazine-2-acetamide;

4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-1-[(4-methyoxyphenyl)methyl]piperazine-2-acetamide;

4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(indan-5-yl)methyl]-1-[(4-methyoxyphenyl)methyl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(2,3-dichlorophenyl)methyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(3,4-dichlorophenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(3,4-dichlorophenyl)methyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[(3,4-dichlorophenyl)methyl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-4-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxan-6-yl)ethyl-1-[(1,3-benzodioxol-5-yl)methyl-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[(4-methoxyphenyl)methyl]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(4-methoxyphenyl)ethyl-1-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[[2-(phenyl)cyclopropyl]amino]-1-[(1,3-benzodioxol-5-yl)methyl]-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[(4-ethoxyphenyl)methyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[(4-methoxyphenyl)methyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[(3,4-dimethoxyphenyl)methyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(3,4-dimethoxyphenyl)methyl]-1-[(1,3-benzodioxan-6-yl)methyl]-4-[2-(1H-imidazol-1-yl)-4-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[(pyridin-3-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-[(pyridin-3-yl)methyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-[(pyridin-3-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-[(pyridin-3-yl)methyl]-4-[2-(1H-imidazol-1-yl)-4-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[(3,4-dimethoxyphenyl)methyl]-1-[(pyridin-3-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[3-(3,4-dimethoxyphenyl)propyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-ethoxyphenyl)methyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(4-methylphenoxy)ethyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methylphenyl)methyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-chlorophenyl)methyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-chlorophenyl)methyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4yl]piperazine-2-acetamide;

N-[2-(4-methoxyphenyl)ethyl]-1-[(3-fluoro-4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-acetyl-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-ethoxyphenyl)methyl]-1-acetyl-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(4-methylphenoxy)ethyl]-1-acetyl-4-[2-(1H-imidazol-1-yl)-4-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2(3-chloro-4-methoxyphenyl)ethyl]-1-acetyl-4-[2-(1H-imidazol-1-yl)-6-chloroylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-acetyl-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-acetyl-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[(4-methoxyphenyl)methyl]-1-acetyl-4-[2-(1H-imidazol-1-yl)chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-4-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(3-chloro-4-methoxyphenyl)ethyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(3-chloro-4-methoxyphenyl)ethyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-(1,3-benzodioxol-5-yl)methyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(2,6-dimethoxyphenyl)methyl]-1-(3-methyl-1-oxobutyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-(methoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(methoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(methoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(methoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(3,4-dimethylphenyl)methyl]-1-(methoxyacetyl)-4-[6-(1H-imidazol-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-(methoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-(methoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-(methoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-(methoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[2-3,4-dimethoxyphenyl)ethyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[(4-methylphenyl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl-]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(4-chlorophenyl)ethyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(3-chloro-4-methoxyphenyl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-4-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(tetrahydrofuran-2-yl)carbonyl-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-[4-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[(4-methoxyphenyl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(4-methoxyphenyl)ethyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(3-methoxyphenyl)ethyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,4-benzodioxan-2-yl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-iso-propyl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[(3,4-dimethoxyphenyl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-(iso-propyl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(3,5-dimethoxyphenyl)methyl]-1-[(tetrahydrofuran-2-yl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-ethoxyphenyl)methyl]-1-[(2-hydroxy-2-oxoethoxy)acetyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[(3-chloro-4-methoxyphenyl)methyl]-1-[(2-hydroxy-2-oxoethoxy)acetyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[(2-hydroxy-2-oxoethoxy)acetyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-3,4-dimethoxyphenyl)ethyl]-1-phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[3-(3,4-dimethoxyphenyl)propyl]-1-(phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methylphenyl)methyl]-1-phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-(phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-phenoxyacetyl)-4-[6(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-(phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-(phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-carboxamide;

N-[2-(4-methoxyphenyl)ethyl]-1-(phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(4-methoxyphenyl)ethyl]-1-phenoxyacetyl)-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[(4-methoxyphenyl)carbonyl]-4-[2-(1H-imidazol-1-yl)-6-chloropyrimidin-4-yl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-4-(6-fluoropyridin-2-yl)-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

1-(acetyl)-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylsulfonylphenyl)methyl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-4-[[2-(ethoxycarbonyl)methyl-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

4-[amino(imino)methyl]-N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-2-acetamide;

1-methylsulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-methylsulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-methylsulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-methylsulfonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl]methyl]piperazine-2-acetamide;

1-(n-octyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(n-octyl)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-(n-octyl)sulfonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(n-octyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(n-octyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(n-octyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]piperazine-2-acetamide;

1-(n-octyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-fluorophenyl)sulfonyl]piperazine-2-acetamide;

1-(4-methylphenyl)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(pyridin-3-yl)methyl]piperazine-2-carboxamide;

1-(4-methylphenyl)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-methylphenyl)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-fluorophenyl)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(4-fluorophenyl)sulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-chloro-4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(dimethylamino)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[6-trifluoromethyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(dimethylamino)sulfonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-acetamide;

1-n-propyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(n-propyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methylphenoxy)ethyl]piperazine-2-carboxamide;

1-(n-propyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-chlorophenyl)ethyl]piperazine-2-carboxamide;

1-n-propyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1n-propyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-chloro-4-methoxyphenyl)ethyl]piperazine-2-carboxamide;

1-(n-propyl)aminocarbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(n-propyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(n-propyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(n-propyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-(n-propyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(n-propyl)aminocarbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-(n-propyl)aminocarbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(n-propyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-carboxamide;

1-(n-propyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-acetamide;

1-(cyclohexyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(cyclohexyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(cyclohexyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-chloro-4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(cyclohexyl)aminocarbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-chloro-4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(cyclohexyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(cyclohexyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-cyclohexyl)aminocarbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-(cyclohexyl)aminocarbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-cyclohexyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(cyclohexyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(cyclohexyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-(cyclohexyl)aminocarbonyl-4-[6-trifluoromethyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(cyclohexyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-carboxamide;

1-(cyclohexyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]piperazine-2-carboxamide;

1-(cyclohexyl)aminocarbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]piperazine-2-carboxamide;

1-(cyclohexyl)aminocarbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,3-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(cyclohexyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,3-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methylpiperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methylphenoxy)ethyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-chloro-4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-phenylsulfonyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-(phenylsulfonyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(thien-2-yl)ethyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-[2-(thien-2-yl)ethyl]-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-[2-(thien-2-yl)ethyl]-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[2-(thien-2-yl)ethyl]-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-4-yl)methyl]piperazine-2-carboxamide;

1-[2-(thien-2-yl)ethyl]-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,3-dimethoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(thien-2-yl)ethyl]-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(cyclopropyl)methyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(2,4-dimethoxyphenyl)ethyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-4-methoxyphenyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-(3,4-dichlorophenyl)aminocarbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(3,4-dichlorophenyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(3,4-dichlorophenyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1,4-benzodioxan-6-yl)methyl)piperazine-2-acetamide;

1-(3,4-dichlorophenyl)aminocarbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-(3,4-dichlorophenyl)aminocarbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(methoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-carboxamide;

1-(methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-(methoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-chloro-4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(methoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(methoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-carboxamide;

1-(methoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-carboxamide;

1-(methoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-(methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(cyclopropyl)methyl]piperazine-2-carboxamide;

1-(iso-propoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methylphenoxy)ethyl]piperazine-2-carboxamide;

1-(iso-propoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]piperazine-2-carboxamide;

1-(iso-propoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(iso-propoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(isopropoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxane-yl)ethyl]piperazine-2-carboxamide;

1-(iso-propoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(iso-propoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(iso-propoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(cyclopropyl)piperazine-2-acetamide;

1-(n-butoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(n-butoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(n-butoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(n-butoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-(n-butoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-(n-butoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-4-yl)ethyl]piperazine-2-acetamide;

1-(n-butoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methylpiperazine-2-acetamide;

1-(n-butoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(2-(methoxy)ethoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-[3-(,4-dimethoxyphenyl)propyl]piperazine-2-carboxamide;

1-(2-(methoxy)ethoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-(2-methoxy)ethoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(2-(methoxy)ethoxy)carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(2-(methoxy)ethoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(2-(methoxy)ethoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(2-(methoxy)ethoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-methoxyphenyl)ethyl]piperazine-2-carboxamide;

1-(1-methylpropoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methylphenoxy)ethyl]piperazine-2-acetamide;

1-(1-methylpropoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(1-methylpropoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-(1-methylpropoxy)carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(1-methylpropoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-(1-methylpropoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(1-methylpropoxy)carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(1-methylpropoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(1-methylpropoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1(1-methylpropoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-acetamide;

1-(phenoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(phenoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(phenoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(phenoxy)carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(phenoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(furan-2-yl)methyl]piperazine-2-acetamide;

1-(phenoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(phenoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(phenoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxanyl)ethyl]piperazine-2-carboxamide;

1-(phenoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-(phenoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-(4-methoxyphenoxy)carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6yl)ethyl]piperazine-2-carboxamide;

1-(4-methoxyphenoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methylphenoxy)ethyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methylphenoxy)ethyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-((phenyl)methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-((phenyl)methoxy)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-acetamide;

1-((phenyl)methoxy)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-((phenyl)methoxy)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-(4-methoxyphenyl)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-(4-methoxyphenyl)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]piperazine-2-carboxamide;

1-(pyridin-3-yl)carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-(pyridin-3-yl)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-(pyridin-3-yl)carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(pyridin-3-yl)carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-(pyridin-3-yl)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-(pyridin-3-yl)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

1-(pyridin-3-yl)carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-carboxamide;

1-[2-(4-methoxyphenyl)ethyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-3-chloro-4-methoxyphenyl)ethyl]piperazine-2-carboxamide;

1-[2-4-methoxyphenyl)ethyl]-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-[2-4-methoxyphenyl)ethyl]-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(4-methoxyphenyl)ethyl]-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(4-methoxyphenyl)ethyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-[2-(4-methoxyphenyl)ethyl]-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[2-(4-methoxyphenyl)ethyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-[2-(4-methoxyphenyl)ethyl]-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-[2-(4-methoxyphenyl)ethyl]-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperazine-2-carboxamide;

1-[2-(4-methoxyphenyl)ethyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-[(3,4-dichlorophenyl)methyl]carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-acetamide;

1-[(3,4-dichlorophenyl)methyl]carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]piperazine-2-carboxamide;

1-[(3,4-dichlorophenyl)methyl]carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-[(3,4-dichlorophenyl)methyl]carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]piperazine-2carboxamide;

1-[(3,4-dichlorophenyl)methyl]carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[3-(3,4-dimethoxyphenyl)propyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[3-(3,4-dimethoxyphenyl)propyl]piperazine-2-acetamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-5-yl)methyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-methyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-iso-propyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-carboxamide;

1-[(1,3-benzodioxol-5-yl)methyl]carbonyl-4-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-phenylcyclopropyl)piperazine-2-carboxamide;

1-methylsulfonyl-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-carboxamide;

N-[(4-methoxyphenyl)ethyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-1-(2-methyl-1-oxopropyl)piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl-4-(1-oxopropyl)piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-2-(1H-imidazol-1-yl)-5-methylpyrimidin-4-yl]-4-(phenylmethyl)piperazine-3-acetamide;

4-[(dimethylethoxy)carbonyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

4-[(dimethylethoxy)carbonyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

4-[(dimethylethoxy)carbonyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperazine-2-acetamide;

4-[(dimethylethoxy)carbonyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

4-[(dimethylethoxy)carbonyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-1,4-benzodioxan-6-yl)ethyl]piperazine-2-acetamide;

4-[(dimethylethoxy)carbonyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

4-[(dimethylethoxy)carbonyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)ethyl]-4-methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)ethyl]-4-methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-methylpiperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-methylpiperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)ethyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl))methyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl))methyl]-4-methylpiperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-methoxyphenyl))methyl-4-methylpiperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[[4-(2-methoxyethoxy)phenyl))methyl]-4-methylpiperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-methylpiperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(cyclopropyl)methyl]-4-methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(indan-5-yl)methyl]-4-methylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(4-ethoxyphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-butylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-butylpiperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-butylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[1,4-benzodioxan-6-yl)ethyl]-4-butylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-1,4-benzodioxan-6-yl)ethyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-(4-methoxyphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-butylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-yl)methyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-(2-phenylcyclopropyl)-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-[(3,4-dichlorphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(3,4-dichlorphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-1,3-benzodioxol-5-yl)ethyl]-4-[(3,4-dichlorphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(3,4-dichlorphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(3,4-dichlorphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(3,4-dichlorphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-[(3,4-dichlorphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chloroxyphenyl)methyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(-[(1,3-benzodioxol-5-yl)methyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(-[(1,3-benzodioxol-5-yl)methyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(1,3-benzodioxol-5-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(1,4-benzodioxan-6-yl)methylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,-benzodioxan-6-yl)methyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(1,4-benzodioxan-4-yl)methyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-thiophenyl)ethyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1-adamantyl)methyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(5-indanyl)methyl]-4-[(1,4-benzodioxan-6-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)propyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(4-ethoxyphenyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4benzodioxan-6-yl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-[(pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(2,6-dimethoxyphenyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[-pyridin-3-yl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(cyclopropyl)methyl]-4-[(pyridin-3-yl)methyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1-adamantyl)methyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(cyclopropyl)methyl]-4-[(3-fluoro-4-methoxyphenyl)methyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-[(4-methylphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)ethyl]-4-acetylpiperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4,5-trimethoxyphenyl)methyl)-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-yl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxanyl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-difluoroxyphenyl)ethyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-phenylcyclopropyl)-4-acetylpiperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(cyclopropyl)-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(indan-5-yl)methyl]-4-acetylpiperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-(3methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-carboxamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(3-methyl-1oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(3methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-yl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-thienyl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[[4-(2-methoxyethoxy)phenyl]ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)ethyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[6(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-phenylcyclopropyl)4-(3-methyl-1-oxobutyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(indan-2-yl)-4-(3-methyl-1-oxobutyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(indan-5-yl)-4-(3-methyl-1-oxobutyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-(methylethyl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-ethoxyphenyl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(indan-5-yl)-4-(2-methoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]N-[(3,4-dimethoxyphenyl)propyl]-4-tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethylphenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-difluorophenyl)ethyl]-4-(tetrahydro-3-furanoyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]-4-(tetrahydro-3-furanoyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)butyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl)-N-[(2,4-dimethoxyphenyl)methyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(2,6-dimethoxyphenyl)methyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,6-dimethoxyphenyl)methyl]-4-(2-carboxymethoxy-1-oxoethyl)piperazine-2-carboxamide;

1-[4-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(2-phenoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)propyl]-4-(2-phenoxy-1-oxoethyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(2-phenoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2-phenoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(3,4-dimethylphenyl)methyl]-4-(2-phenoxy-1-oxoethyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(2-phenoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(2-phenoxy-1-oxoethyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)propyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)butyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,5-dimethylphenyl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-methoxyphenyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-thienyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-thienyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-carboxamide;

1-6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-difluorophenyl)ethyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(5-indanyl)methyl]-4-(pyridin-3-ylcarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-[2-4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)ethyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethylphenyl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[3,4-dimethylphenyl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethylphenyl)ethyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(3-pyridinyl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-carboxamide;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[2-(4methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-thienyl)ethyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1H-methylpyrrol-2-yl)ethyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenylmethyl-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[2-(4-methoxyphenyl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-carboxamide;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(4-chlorophenyl)methyl-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxy-3-chlorophenyl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethylphenyl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(2-thienyl)ethyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(2-indanyl)-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(5-indanyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(5-indanyl)methyl]-4-[2-(1,3-benzodioxol-5-yl)-1-oxoethyl]piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-yl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(methylsulfonyl)piperazine-2acetamide;

1-[2(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2-methoxyphenyl)ethyl]-4-(methylsulfonyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(methylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl-4-(octylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-octylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[4-methoxyphenyl)methyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(octylsulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,6-dimethoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-adamantyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-carboxamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,3-dimethoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)propyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)butyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(4-ethoxyphenyl)methyl-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-(propylaminocarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-yl]-N-[(4-methylphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chorophenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(propylaminocarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethylphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-methoxyphenylmethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-methoxyphenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-thienyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-thienyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-difluorophenyl)ethyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]-4-(propylaminocarbonyl)-piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-(cyclopropyl)-4(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-indanyl)-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(5-indanyl)methyl]-4-(propylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-4-yl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-methoxyphenyl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-thienyl)ethyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-difluorophenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-indanyl)-4-(cyclohexylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(phenylsulfonylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-[N-(1,3-benzodioxol-5-yl)methyl]-4-(phenylsulfonylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(phenylsulfonylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl-4-(phenylsulfonylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(2,3-dimethoxyphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)propyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)ethyl]-4-(phenylaminocarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(phenylaminocarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)ethyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl-4-phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl-4-phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-thienyl)ethyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-difluorophenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(cyclopropyl)methyl]-4-(phenylaminocarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(5-indanyl)methyl]-4-phenylaminocarbonyl)piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,3-dimethoxyphenyl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(2,3-dimethoxyphenyl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethylphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethylphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-furyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-1(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)ethyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,3-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(cyclopropyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-indanyl)-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(5-indanyl)methyl]-4-[(4-methoxyphenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)propyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)butyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)ethyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4dimethylphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[-3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(3,4dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-[1(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,5-dimethoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(3,4-dichlorophenyl)aminocarbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-3,4-dimethoxyphenyl)ethyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methylphenyl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-yl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)ethyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-2-yl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-(methoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-(methylethoxycarbonyl)piperazine-2-acetamide;

1-2-(1H-imidazol-1-yl)-pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-methylethoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(butoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-(butoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]N-[(4-methoxyphenyl)methyl]-4-(butoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-(butoxycarbonyl)piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4-difluorophenyl)methyl]-4-(butoxycarbonyl)piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl)-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]-4-[(2-methoxyethoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-yl)methyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-thienyl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]-4-[(1-methylpropoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(1-methylpropoxy)carbonyl]piperazine-2-acetamide;

1-6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-4-[(1-methylpropoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-trifluoromethylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-acetamide;

1-[6-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1-methylpyrrol-2-yl)ethyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylethyl)pyrimidin-4-yl]-N-[(2,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,6-dimethoxyphenyl)methyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-4-[(4-methoxyphenoxy)carbonyl]piperazine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-4-[6-[bis(ethoxycarbonyl)methyl]-2-(1H-imidazol-1-yl)lpyrimidin-4-yl]-1-](methoxy)carbonyl]piperazine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-4-[6-(aminocarbonyl)-2-(1H-imidazol-1-yl)lpyrimidin-4-yl]-1-[(methoxy)carbonyl]piperazine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-methylpiperidine-2-carboxamide;

N-[(2-methoxypyridin-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-carboxamide;

N-[(2-methylpyridin-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-carboxamide;

N-[(4-nitrophenyl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-acetamide;

N-[[4-(acetylamino)phenyl]methyl]-1-[2(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-acetamide;

N-[[4-(methylsulfonylamino)phenyl]methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-acetamide;

N-[(2,3-dihydrobenzofuran-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-acetamide;

N-[(indan-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-acetamide;

N-[(3-chloro-4-methoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetamide;

N-[(4-methoxyphenyl)aminocarbonyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-methaneamine;

N-[(1,3-benzodioxol-5-yl)methylcarbonyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-methaneamine;

N-[(4-methoxyphenoxy)carbonyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-methaneamine;

N-[(4-methoxyphenyl)methylcarbonyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-methaneamine;

N-[[(1,3-benzodioxol-5-yl)methyl]aminocarbonyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-methaneamine;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-methaneamine;

N-[(1,3-benzodioxol-5-yl)carbonyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]piperidine-2-ethaneamine;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-ethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenoxy)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,4-dimethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperidine-3-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperidine-3-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperidine-3-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperidine-3-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperidine-3-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chloro-4-methoxyphenyl)methyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)methyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,4-dimethoxyphenyl)methyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperidine-3-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[1-(phenylmethyl)piperidin-4-yl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1-cyanocyclohexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(2,2-dimethoxyethyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-tridecylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-hydroxy-4-methylthiobutyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N,N-[bis(2-cyanoethyl)]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N,N-[bis(2-cyanomethyl)]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(4,4-diethoxybutyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,3-dihydrobenzofuran-5-yl)methyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(indan-5-yl)methyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(cyclohexyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(naphthalen-1-yl)methyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(4-chlorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(2-ethylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-ethylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(2-ethylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(1-methylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1-methylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-methylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(cyclooctyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1-ethyl-3-hydroxy-1-hydroxyethylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[3-(morpholin-4-yl)propyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(1-methyl-3-phenylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1-methyl-3-phenylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1-methyl-3-phenylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(1-methylheptyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1-methylheptyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1-methylheptyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-fluorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-fluorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(4-methylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1-phenylethyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-phenylmethylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(3,4-dichlorophenyl)methyl]piperidine-2-acetamide;piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(2-phenylethyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(2-phenylethyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[3-(pyrrolidinon-1-yl)propyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1,5-dimethylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1,5-dimethylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(1,5-dimethylhexyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2-fluorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2-fluorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-methylpyrimidin-4-yl]-N-[2-(2-chlorophenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(furan-2-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(furan-2-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin4-yl]-N-[(furan-2-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(pyridin-2-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(pyridin-2-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[pyridin-2-yl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-trifluoromethylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-trifluoromethylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(2-phenylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(2-phenylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(2-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-pyrimidin-4-yl]-N-[2-(2-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(2-hydroxy-4-methylthiobutyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(2-hydroxy-4-methylthiobutyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl-N-[(2,4-dichlorophenyl)methylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(3-methylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-yl]-N-[(3-methylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[2-(3-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]N-[2-(3,4-dimethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(phenylbutyl)piperidine-2-acetamide

1-[2-(1H-imidazol-1-yl)-pyrimidin-4-yl)-N-(phenylbutyl)piperidin-6-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1-hydroxymethylpentyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1-hydroxymethylpentyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl]pyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3,5-dimethoxyphenyl)methyl-piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[2-(4-ethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-ethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(4-ethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[2-(4-bromophenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-4-bromophenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(4-bromophenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-pentylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-pentylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-pentylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[3-(1H-imidazol-1-yl)propyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[3-(1H-imidazol-1-yl)propyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-chlorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-chlorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(2,4-dichlorophenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(2,4-dichlorophenyl)methyl]piperidin-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-2-(1-phenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[1-(phenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3-fluorophenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl-)methylethylpyrimidin-4-yl]-N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl-N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-chlorophenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(4-chlorophenyl)ethyl]piperidine-2-acetamide;

1-2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(5-hydroxypentyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-butylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-fluorophenyl)(methyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-fluorophenyl)(methyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(2,5-dimethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl-N-[2-(2,5-dimethoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-2-(4-ethoxy-3-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(3-methylethoxy)propyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-hexylpipenidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-hexylpipenidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-hexylpiperidin-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-cyclohexen-1-yl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-cyclohexen-1-yl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(3-fluoro-5-trifluoromethylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-fluoro-5-trifluoromethylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-pyrimidin-4-yl]-N-[2-(4-methylphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(4-methylphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-methylethylpyrimidin-4-yl)-N-3-ethoxypropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(3-ethoxypropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-heptylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-heptylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-heptylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(3-methoxypropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(1-cyclohexylethyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1-cyclohexylethyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(4-trifluoromethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-trifluoromethoxyphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-flurophenyl)ethyl]piperidine-2-acetamide;

1-2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(4-flurophenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[2-(3-bromo-4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-bromo-4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3-bromo-4-methoxyphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(3-phenylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-(3-phenylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(3-phenylpropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-octylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-octylpiperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(1-hydroxy-3-methylbutyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[1-(4-methylphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[1-(4-methylphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[1-(4-methylphenyl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-(4,4-diethoxybutyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(4-trifluoromethylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-pyrimidin-4-yl]-N-](4-trifluoromethylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-trifluoromethylphenyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-(3-butoxypropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-4-methylpyrimidin-4-yl]-N-(3-butoxypropyl)piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[2-(thiophen-2-yl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(thiophen-2-yl)ethyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[3-(pyrrolidin-1-yl)propyl]piperidine-2-acetamide;

1-2-(1H-imidazol-1-yl)-6-methylethylpyrimidin-4-yl]-N-[(cyclohexyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(cyclohexyl)methyl]piperidine-2-acetamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-fluorophenyl)methyl]piperidine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[3-(1H-imidazol-1-yl)phenyl]piperidine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-chloro-5-(1H-imidazol-1-yl)triazin-1-yl]piperidine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[6-(1H-imidazol-1-yl)pyrazin-2-yl]piperidine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[6-(morpholin-4-yl)-2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperidine-2-acetamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-hydroxy-N-[4-(hydroxycarbonyl)phenyl]methyl]pyrrolidine-2-carboxamide;

N-[(3,4-dimethoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-2-acetamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]pyrrolidine-2-acetamide;

N-[(3-chloro-4-methoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-2-acetamide;

N-[(3-chloro-4-methoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-ethylpyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-[(3,4-dihydroxyphenyl)ethyl-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-octyl-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-(phenylpropyl)-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-[(pyridin-3-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-carboxamide;

N-[(morpholin-4-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-1,4-benzodioxan-4-yl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]pyrrolidine-2-carboxamide;

1-2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-methoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-ethoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-bromophenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidinyl]-N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(2,5-dimethoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(4-methoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3-bromo-4-methoxyphenyl)ethyl]pyrrolidine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-2-propionamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-2-propionamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-3-carboxamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-3-carboxamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrolidine-3-acetamide;

4-[2-[[4-(methoxy)phenoxy]propyl]pyrrolidin-1-yl]-2-(1H-imidazol-1-yl)pyrimidine;

4-[2-[[4-(methoxy)phenoxy]propyl]pyrrolidin-1-yl]-2-(1H-imidazol-1-yl)-6-methylpyrimidine;

4-[2-[(1,3-benzodioxol-5-yl)propyl]pyrrolidin-1-yl]-2-(1H-imidazol-1-yl)pyrimidine;

4-[2-[(1,3-benzodioxol-5-yl)prop-2-enyl]pyrrolidin-1-yl]-2-(1H-imidazol-1-yl)pyrimidine;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]pyrrolidine-3-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-ethylpyrimidin-4-yl]pyrrolidine-3-acetamide;

4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)ethyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)-6-methylprimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]-thiomorpholine-2-acetamide;

N-[(1,3-dioxolan-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]azetidine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)ethyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]thiomorpholine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]indole-6-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]pyrrole-2-carboxamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;

4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,3-benzodioxol-5-yl)ethyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(1,4-benzodioxan-6-yl)ethyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)ethyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[2-(3,4-dimethoxyphenyl)ethyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]morpholine-2-carboxamide;

4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]morpholine-2-acetamide;

4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,3-benzodioxol-5-yl)methyl]morpholine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]morpholine-3-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]morpholine-3-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[6-ethyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl]morpholine-3-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]morpholine-3-carboxamide;

N-[(4-methoxyphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-methylpyrimidin-4-yl]morpholine-3-carboxamide;

N-[(4-chlorophenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]morpholine-3-carboxamide;

N-[(3,4-dichlorophenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]morpholine-3-carboxamide;

N-[(4-methylphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]morpholine-3-carboxamide;

N-[(3,4-dimethylphenyl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]morpholine-3-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(1,3-benzodioxol-6-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-ethylpyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(1,4-benzodioxan-6-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-ethylpyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[(3,4-dimethoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-carboxamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-ethylpyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(1,4-benzodioxan-6-yl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(3,4-dimethoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(3,4-dimethoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-(methylethyl)pyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(4-methoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(4-trifluoromethoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]perhydroazepine-2-acetamide;

N-[(4-trifluoromethoxyphenyl)methyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]perhydroazepine-2-acetamide;

2-[[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]amino]-N-[(4-chlorophenyl)ethyl]pyridine-3-propanamide;

4-chloro-2-(1H-imidazol-1-yl)-6-(perhydroazepin-1-yl)pyrimidine;

2,4-bis(1H-imidazol-1-yl)-6-methylpyrimidine;

N-[(3,4-dimethoxyphenyl)ethyl]-6-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-methyl-5,6,7,8,-tetrahydropyrido[5,6-c]pyrimidine-4-amine;

2-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-N-[(1,4-benzodioxan-6-yl)ethyl]isoquinoline-3carboxamide;and

4-chloro-2-(1H-imidazol-1-yl)-6-[(2-methoxyphenyl)amino]pyrimidine.

While the present invention has been described with reference to thespecific embodiments thereof, it should be understood by those skilledin the art that various changes may be made and equivalents may besubstituted without departing from the true spirit and scope of theinvention. In addition, many modifications may be made to adapt aparticular situation, material, composition of matter, process, processstep or steps, to the objective, spirit and scope of the presentinvention. All such modifications are intended to be within the scope ofthe claims appended hereto.

What is claimed is:
 1. A compound of formula (Vb):

wherein B is a fused imidazolyl; and wherein: A is —R¹, —OR¹,—C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R², —N(R¹⁶)C(O)OR², —N(R¹)R²¹,—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹, —SO₂NHC(O)R¹, —N(R¹)SO₂R²²,—SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹; each X and Y are N; each W is Nor CH; n is zero or an integer from 1 to 3; t is zero, one or two;

 is an optionally substituted N-heterocyclyl; each R¹ and R² areindependently chosen from the group consisting of hydrogen, optionallysubstituted C₁-C₂₀ alkyl, optionally substituted cycloalkyl, —[C₀-C₈alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹, —[C₂-C₈ alkyl]—R¹⁰(optionally substituted by hydroxy), —[C₁-C₈]—R¹¹ (optionallysubstituted by hydroxy), and optionally substituted heterocyclyl; or R¹and R² together with the nitrogen atom to which they are attached is anoptionally substituted N-heterocyclyl; R⁹ is chosen from the groupconsisting of haloalkyl, cycloalkyl (optionally substituted with halo,cyano, alkyl or alkoxy), carbocyclyl (optionally substituted with one ormore substituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy); each R¹⁰ is independently chosen from the group consisting ofhalo, alkoxy, optionally substituted aryloxy, optionally substitutedaralkoxy, optionally substituted —S(O)_(t)—R²², acylamino, amino,monoalkylamino, dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto,and alkylsulfonamido; each R¹¹ is independently chosen from the groupconsisting of cyano, di(alkoxy)alkyl, carboxy, alkoxycarbonyl,aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl; eachR¹⁴, and R²⁰ are independently hydrogen or alkyl; each R¹⁶ isindependently hydrogen, alkyl, optionally substituted aryl, optionallysubstituted aralkyl or cycloalkyl; each R²¹ is independently hydrogen,alkyl, cycloalkyl, optionally substituted aryl, optionally substitutedaralkyl, —C(O)R²² or —SO₂R²²; or R²¹ taken together with R¹ and thenitrogen to which they are attached is an optionally substitutedN-heterocyclyl; or R²¹ taken together with R¹⁶ and the nitrogen to whichthey are attached is an optionally substituted N-heterocyclyl; each R²²is independently alkyl, cycloalkyl, optionally substituted aryl oroptionally substituted aralkyl; and as a single stereoisomer or mixturethereof, or a pharmaceutically acceptable salt thereof.
 2. The compoundof claim 1 wherein each W is CH.
 3. The compound of claim 2 of theformula (Vba):

where A is —OR¹, —C(O)N(R¹)R², —N(R¹⁶)C(O)N(R¹)R¹⁶, —NR¹C(O)R² or—N(R¹)R²¹; and

 is an N-heterocyclyl selected from group consisting of piperidinyl,piperazinyl, pyrrolidinyl or morpholinyl.
 4. The compound of claim 3,i.e.,N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)purin-6-yl]piperidine-2-acetamide.5. A compound of formula (Va):

wherein B is a fused optionally substituted imidazolyl; and wherein: Ais —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹,—SO₂NHC(O)R¹, —N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹; eachX and Y are N; V is N(R⁴), S, O or C(R⁴)H; each W is N or OH; Q ischosen from the group consisting of a direct bond, —C(O)—, —O—,—C(═N-R¹)—, —S(O)_(t), and —N(R⁶)—; m is zero or an integer from 1 to 4;n is zero or an integer from 1 to 3; q is zero or one; r is zero or one,provided that when Q and V are heteroatoms, m, q, and r cannot all bezero; when A is —OR¹, —N(R¹)C(O)R², —N(R¹⁸)C(O)OR², —N(R¹)R²¹,—N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (where t is zero), or —N(R¹)SO₂R²², n,q, and r cannot all be zero; and when Q is a heteroatom and A is —OR¹,—N(R¹)C(O)R², —N(R¹⁸)C(O)OR², —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (when tis zero) or —N(R¹)SO₂R²², m and n cannot both be zero; t is zero, one ortwo; each R¹ and R² are independently chosen from the group consistingof hydrogen, optionally substituted C₁-C₂₀ alkyl, optionally substitutedcycloalkyl, —[C₀-C₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹,—[C₂-C₈ alkyl], R¹⁰ (optionally substituted by hydroxy), —[C₁ -C ₈]—R¹¹(optionally substituted by hydroxy), and optionally substitutedheterocyclyl; or R¹ and R² together with the nitrogen atom to which theyare attached is an optionally substituted N-heterocyclyl; R³ is chosenfrom the group consisting of hydrogen, alkyl, cycloalkyl, optionallysubstituted aryl, —[C₂-C₈ alkyl]—R¹⁰, —[C₁-C₈ alkyl]—R¹¹, andheterocyclyl (optionally substituted by one or more substituentsselected from the group consisting of halo, alkyl, alkoxy andimidazolyl); or when Q is —N(R⁶)—or a direct bond to R³, R³ mayadditionally be aminocarbonyl, alkoxycarbonyl, alkylsulfonyl,monoalkylaminocarbonyl, dialkylaminocarbonyl and —C(═NR¹⁸)—NH₂; or —Q—R³taken together represents —C(O)OH, —C(O)N(R¹)R², —C(═NH)—N(r¹)R² or

R⁴ is chosen from the group consisting of hydrogen, alkyl, aryl, aralkyland cycloalkyl; provided that when A is —R¹or —OR¹, R⁴ cannot behydrogen, and when V is CH, R⁴ may additionally be hydroxy; R⁶ is chosenfrom the group consisting of hydrogen, alkyl, cycloalkyl, —[C₁-C₈alkyl]-R⁸, alkoxycarbonyl, optionally substituted aryloxycarbonyl,optionally substituted aralkoxycarbonyl, alkylsulfonyl, optionallysubstituted aryl, optionally substituted heterocyclyl,alkoxycarbonylalkyl, carboxyalkyl, optionally substituted arylsulfonyl,aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, optionallysubstituted arylaminocarbonyl, aminosulfonyl, monoalkylaminosulfonyl,dialkylaminosulfonyl, arylaminosulfonyl, arylsulfonylaminocarbonyl,optionally substituted N-heterocyclyl, —C(═NH)—N(CN)R¹, —C(O)—R²³—N(R¹)R², —C(O)—R²³ —N(R¹)C(O)-R²³ —N(R¹)R², and —C(O)—N(R¹)—R²³—C(O)OR¹; each R⁸ and R⁹ are independently chosen from the groupconsisting of haloalkyl, cycloalkyl (optionally substituted with halo,cyano, alkyl or alkoxy), carbocyclyl (optionally substituted with one ormore substituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy); each R¹⁰ is independently chosen from the group consisting ofhalo, alkoxy, optionally substituted aryloxy, optionally substitutedaralkoxy, optionally substituted —S(O)_(t)—R²², acylamino, amino,monoalkylamino, dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto,and alkylsulfonamido; each R¹¹ is independently chosen from the groupconsisting of cyano, di(alkoxy)alkyl, carboxy, alkoxycarbonyl,aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl; eachR¹², R¹³, R¹⁴, R¹⁵, R¹⁷, and R²⁰ are independently hydrogen or alkyl;each R¹⁶ is independently hydrogen, alkyl, optionally substituted aryl,optionally substituted aralkyl or cycloalkyl; R¹⁸ is hydrogen, NO₂, ortoluenesulfonyl; each R²¹ is independently hydrogen, alkyl, cycloalkyl,optionally substituted aryl, optionally substituted aralkyl, —C(O)R²² or—SO₂R²²; or R²¹ taken together with R¹ and the nitrogen to which theyare attached is an optionally substituted N-heterocyclyl; or R²¹ takentogether with R¹⁶ and the nitrogen to which they are attached is anoptionally substituted N-heterocyclyl; each R²² is independently alkyl,cycloalkyl, optionally substituted aryl or optionally substitutedaralkyl; and R²³ is an amino acid residue; as a single stereoisomer ormixture thereof, or a pharmaceutically acceptable salt thereof.
 6. Acompound of formula (Vc):

wherein B is a fused optionally substituted imidazolyl; and wherein: Ais —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹,—SO₂NHC(O)R¹, —N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹; eachX and Y are N; V is S, O or C(R⁴)H; each W is N or CH; n is zero or aninteger from 1 to 3; q is zero or one; r is zero or one, provided thatwhen V is a heteroatom, q and r cannot both be zero; and when A is —OR¹,—N(R¹)C(O)R², —N(R¹⁸)C(O)OR², —N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶,—S(O)_(t)R¹(where t is zero), or —N(R¹)SO₂R²², n, q, and r cannot all bezero; t is zero, one or two;

 is an optionally substituted carbocyclyl or optionally substitutedN-heterocyclyl; each R¹ and R² are independently chosen from the groupconsisting of hydrogen, optionally substituted C₁-C₂₀ alkyl, optionallysubstituted cycloalkyl, —[C_(0-C) ₈ alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹,—[C₂-C₈ alkynyl]—R⁹, —[C₂-C₈ alkyl]—R¹⁰ (optionally substituted byhydroxy), -[C₁-C₈]-R¹¹ (optionally substituted by hydroxy), andoptionally substituted heterocyclyl; or R¹ and R² together with thenitrogen atom to which they are attached is an optionally substitutedN-heterocyclyl; R⁴ is chosen from the group consisting of hydrogen,alkyl, aryl, aralkyl and cycloalkyl; provided that when A is —R¹ or—OR¹, R⁴ cannot be hydrogen, and when V is OH, R⁴ may additionally behydroxy; R⁹ is chosen from the group consisting of haloalkyl, cycloalkyl(optionally substituted with halo, cyano, alkyl or alkoxy), carbocyclyl(optionally substituted with one or more substituents selected from thegroup consisting of halo, alkyl and alkoxy), and heterocyclyl(optionally substituted with alkyl, aralkyl or alkoxy); each R¹⁰ isindependently chosen from the group consisting of halo, alkoxy,optionally substituted aryloxy, optionally substituted aralkoxy,optionally substituted —S(O)_(t)—R²², acylamino, amino, monoalkylamino,dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto, andalkylsulfonamido; each R¹¹ is independently chosen from the groupconsisting of cyano, di(alkoxy)alkyl, carboxy, alkoxycarbonyl,aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl; eachR¹², R¹³, R¹⁴, and R²⁰ are independently hydrogen or alkyl; each R¹⁶ isindependently hydrogen, alkyl, optionally substituted aryl, optionallysubstituted aralkyl or cycloalkyl; each R²¹ is independently hydrogen,alkyl, cycloalkyl, optionally substituted aryl, optionally substitutedaralkyl, —C(O)R²² or —SO₂R²²; or R²¹ taken together with R¹and thenitrogen to which they are attached is an optionally substitutedN-heterocyclyl; or R²¹ taken together with R¹⁶ and the nitrogen to whichthey are attached is an optionally substituted N-heterocyclyl; and eachR²² is independently alkyl, cycloalkyl, optionally substituted aryl oroptionally substituted aralkyl; as a single stereoisomer or mixturethereof, or a pharmaceutically acceptable salt thereof.
 7. A compound offormula (Vc):

wherein B is a fused optionally substituted imidazolyl; and wherein: Ais —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹, —SO₂NHC(O)R¹,—N(R¹)SO₂R²², —SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹; each X and Y areN; V is N(R⁴); each W is N or CH; n is zero or an integer from 1 to 3; qis zero or one; r is zero or one, provided that when V is a heteroatom,q and r cannot both be zero; and when A is —OR¹, —N(R¹)C(O)R²,—N(R¹⁶)C(O)OR², —N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (where t iszero), or —N(R¹)SO₂R²², n, q, and r cannot all be zero; t is zero, oneor two;

 is an optionally substituted N-heterocyclyl; each R¹ and R² areindependently chosen from the group consisting of hydrogen, optionallysubstituted C₁-C₂₀ alkyl, optionally substituted cycloalkyl, —[C₀-C₈alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹, —[C₂-C₈ alkyl]—R¹⁰(optionally substituted by hydroxy), —[C₁-C₈]—R¹¹ (optionallysubstituted by hydroxy), and optionally substituted heterocyclyl; or R¹and R² together with the nitrogen atom to which they are attached is anoptionally substituted N-heterocyclyl; R⁴ is chosen from the groupconsisting of hydrogen, alkyl, aryl, aralkyl and cycloalkyl; providedthat when A is —R¹ or —-OR¹, R⁴ cannot be hydrogen, and when V is CH, R⁴may additionally be hydroxy; R⁹ is chosen from the group consisting ofhaloalkyl, cycloalkyl (optionally substituted with halo, cyano, alkyl oralkoxy), carbocyclyl (optionally substituted with one or moresubstituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy); each R¹⁰ is independently chosen from the group consisting ofhalo, alkoxy, optionally substituted aryloxy, optionally substitutedaralkoxy, optionally substituted —S(O)_(t)—R²², acylamino, amino,monoalkylamino, dialkylamino, (triphenylmethyl) amino, hydroxy,mercapto, and alkylsulfonamido; each R¹¹ is independently chosen fromthe group consisting of cyano, di(alkoxy)alkyl, carboxy, alkoxycarbonyl,aminocarbonyl, monoalkylaminocarbonyl and dialkylaminocarbonyl; eachR¹², R¹³, R¹⁴, and R²⁰ are independently hydrogen or alkyl; each R¹⁶ isindependently hydrogen, alkyl, optionally substituted aryl, optionallysubstituted aralkyl or cycloalkyl; each R²¹ is independently hydrogen,alkyl, cycloalkyl, optionally substituted aryl, optionally substitutedaralkyl, —C(O)R²² or or R²¹ taken together with R¹ and the nitrogen towhich they are attached is an optionally substituted N-heterocyclyl; orR²¹ taken together with R¹⁶ and the nitrogen to which they are attachedis an optionally substituted N-heterocyclyl; and each R²² isindependently alkyl, cycloalkyl, optionally substituted aryl oroptionally substituted aralkyl; as a single stereoisomer or mixturethereof, or a pharmaceutically acceptable salt thereof.
 8. A compound offormula (Vc):

wherein B is a fused optionally substituted imidazolyl; and wherein: Ais —R¹, —OR¹, —C(O)N(R¹)R², —P(O)[N(R¹)R²]₂—N(R¹)C(O)R², —N(R¹⁶)C(O)OR²,—N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)₂R¹, —SO₂NHC(O)R¹, —N(R¹)SO₂R²²,—SO₂N(R¹)H, —C(O)NHSO₂R²², or —CH═NOR¹; each X and Y are N; V is N(R⁴ );each W is N or CH; n is zero or an integer from 1 to 3; q is zero orone; r is zero or one, provided that when V is a heteroatom, q and rcannot both be zero; and when A is —OR¹, —N(R¹)C(O)R², —N(R¹⁸)C(O)OR²,—N(R¹)R²¹, —N(R¹⁶)C(O)N(R¹)R¹⁶, —S(O)_(t)R¹ (where t is zero), or—N(R¹)SO₂R²², n, q, and r cannot all be zero; t is zero, one or two;

 is an optionally substituted carbocyclyl; each R¹ and R² areindependently chosen from the group consisting of hydrogen, optionallysubstituted C₁-C₂₀ alkyl, optionally substituted cycloalkyl, —[C₀-C₈alkyl]—R⁹, —[C₂-C₈ alkenyl]—R⁹, —[C₂-C₈ alkynyl]—R⁹, —[C₂-C₈ alkyl]—R¹⁰(optionally substituted by hydroxy), —[C₁-C₈]—R¹¹ (optionallysubstituted by hydroxy), and optionally substituted heterocyclyl; or R¹and R² together with the nitrogen atom to which they are attached is anoptionally substituted N-heterocyclyl; R⁴ is chosen from the groupconsisting of hydrogen, alkyl, aryl, aralkyl and cycloalkyl; providedthat when A is —R¹ or —OR¹, R⁴ cannot be hydrogen, and when V is CH, R⁴may additionally be hydroxy; R⁹ is chosen from the group consisting ofhaloalkyl, cycloalkyl (optionally substituted with halo, cyano, alkyl oralkoxy), carbocyclyl (optionally substituted with one or moresubstituents selected from the group consisting of halo, alkyl andalkoxy), and heterocyclyl (optionally substituted with alkyl, aralkyl oralkoxy); each R¹⁰ is independently chosen from the group consisting ofhalo, alkoxy, optionally substituted aryloxy, optionally substitutedaralkoxy, optionally substituted —S(O)_(t)—R²², acylamino, amino,monoalkylamino, dialkylamino, (triphenylmethyl)amino, hydroxy, mercapto,and alkylsulfonamido; each R¹¹ is independently chosen from the groupconsisting of cyano, di(alkoxy)alkyl, carboxy, alkoxycarbonyl,aminocarbonyl, monoalkylaminocarbonyl and dialalxylaminocarbonyl; eachR¹², R¹³, R¹⁴, and R²⁰ are independently hydrogen or alkyl; each R¹⁶ isindependently hydrogen, alkyl, optionally substituted aryl, optionallysubstituted aralkyl or cycloalkyl; each R²¹ is independently hydrogen,alkyl, cycloalkyl, optionally substituted aryl, optionally substitutedaralkyl, —C(O)R²² or —SO₂R²²; or R²¹ taken together with R¹and thenitrogen to which they are attached is an optionally substitutedN-heterocyclyl; or R²¹ taken together with R¹⁶ and the nitrogen to whichthey are attached is an optionally substituted N-heterocyclyl; and eachR²² is independently alkyl, cycloalkyl, optionally substituted aryl oroptionally substituted aralkyl; and as a single stereoisomer or mixturethereof, or a pharmaceutically acceptable salt thereof.